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1
Introduction
A HISTORICAL PERSPECTIVE
At the beginning of the 19th 
century, the French scientist 
Théophile Laennec systematically 
documented the physical and 
pulmonary signs of tuberculosis 
for the first time3,4. He linked 
pulmonary lesions found on 
the lungs of autopsied patients 
with the symptoms in surviving 
tuberculosis patients. Following 
his work in 1865 Jean-Antoine 
Villemin demonstrated the 
transmissible nature of M. 
tuberculosis5. Villemin did this 
by infecting laboratory rabbits 
with tuberculous matter taken 
from an autopsy of an individual 
who had died of tuberculosis. 
The infected rabbits developed 
extensive tuberculosis three 
months after infection. Despite his 
findings, Villemin’s work was ignored by the scientific community at that time.  Nearly two 
decades later on 24 March in 1882 Robert Koch stumped his audience as he revealed that 
a bacterium, namely Mycobacterium tuberculosis, was the etiologic agent of tuberculosis 
(Figure 1)6. During his lecture he used a microscope to show miniscule rod-like structures 
or bacilli that could cause tuberculosis in infected guinea pigs5. His findings were made 
possible by the development of a new staining technique and a method for growing 
bacteria on slanted solid cultures. He received the Nobel Prize in physiology or medicine in 
1905 for “his investigations and discoveries in relation to tuberculosis”7.
Figure 1 | Tubercle bacilli (stained blue) in a section 
of tissue from consumptive lung, drawn by Koch 
and published with the expanded 1884 version of 
“The Etiology of Tuberculosis.” In: Koch R., Gessamelte 
Werke von Robert Koch, Georg Thieme, Leipzig, 1912, 
Table XXII. Reprinted from Historical perspectives on 
the etiology of tuberculosis, 2, Barnes, Pages No 432, 
Copyright (2000), with permission from Elsevier.
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Tuberculosis reached its peak in the 18th century when one in every four people died of 
tuberculosis in Great Britain8,9. After that, various factors stemmed the spread of tuberculosis 
and reduced overall mortality rates, including Koch’s identification of tuberculosis, the 
development of the tuberculin skin test, another legacy of Koch, and the understanding of 
the disease’s contagious nature. In particular, social factors such as improved sanitation, the 
introduction of vaccination with bacille Calmette–Guérin (BCG) and heavy public health 
campaigns (Figure 2) all converged to reduce morbidity and mortality due to tuberculosis 
even before the arrival of antibiotics. Between 1946 and 1949, the development of the 
antibiotic streptomycin made effective treatment and cure of TB a reality. Today, the control 
and decrease in tuberculosis-related deaths is an advancement that is still clouded by the 
fact that tuberculosis remains a formidable disease in developing countries, killing nearly 
1.8 million people in 2016 alone10. Likewise, nearly one third of the world is a latent reservoir 
of tuberculosis. Thus 135 years after Robert Koch’s discovery we are still fighting the battle 
of tuberculosis.
Figure 2 | Public health posters used to reduce the spread of tuberculosis issued in the 1900s 
in the US, UK and France (from left to right). Copyright Details:  Left1 (Courtesy of Library of 
Congress from where this image may be obtained at no cost https://www.loc.gov/item/98516354/), 
Middle (© IWM (Art.IWM PST 14135)) and Right2 (Retrieved from https://digital.library.illinois.edu/
items/7e64fa40-0b13-0134-1d55-0050569601ca-2).
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Introduction
STAGES OF TUBERCULOSIS INFECTION
After aerosol-dependent infection, approximately 5% of infected individuals develop 
primary or active pulmonary tuberculosis within two years of infection either with or without 
a short period of latency11 (Figure 3). Development of active tuberculosis is most common 
in children suffering from certain primary immune-deficiencies 12 or in adults suffering 
from HIV/AIDs13. However, most infected individuals develop latent TB, characterised by a 
positive diagnostic test such as the Mantoux test (TST) or interferon-gamma release assay 
(IGRA), but show no overt clinical symptoms14.
Another 5-10% of individuals with latent tuberculosis infection (LTBI) progress to active 
disease during their lifetime13.  Factors that influence the progression from LTBI to active 
disease are thought to be reflective of an impairment in host defence. Genetic factors are 
believed to contribute, whilst co-morbidities that promote the transition from latent to 
active disease include the depletion of CD4+ T cells during HIV infection 15,  smoking16,17, 
diabetes 18 or the use of  anti-TNF biological agents for treatment of rheumatoid arthritis 
(RA) 19.  Lastly, environmental factors such as age, malnutrition, the microbiome and low 
vitamin-D (VitD) levels 15  may also affect susceptibility to varying degrees. Once disease is 
established, host driven inflammation, bacterial burden and drug resistance influence the 
success rate of antibiotic therapy. 
14997-lachmandas-layout.indd   13 12/10/2017   12:17
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Figure 3 | Stages of Mycobacterium tuberculosis Infection. Transmission of M. tuberculosis 
takes place by aerosols. Infection establishes latent tuberculosis in most people except for a small 
group of people known as early clearers, who manage to clear the mycobacteria through yet-to-
be identified host defences. Progression to active tuberculosis depends on a multitude of factors 
including diabetes, smoking and HIV. Cure, death and transmissibility of the disease are affected by 
factors such as treatment availability, adherence to treatment and drug resistance. Data for annual 
deaths and active tuberculosis are as of 2015 published by the World Health Organisation (WHO). 
Images of people created by Gan Khoon Lay from the Noun Project. 
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PART I: Tuberculosis & Diabetes
Globally, 15% of tuberculosis cases are estimated to be attributable to diabetes20. Systematic 
reviews have shown that individuals with diabetes are twice as likely to die during 
tuberculosis treatment 21, thrice as likely to develop active tuberculosis18,22 and four times 
as likely to relapse following treatment21. Figure 4A highlights the specific relative risks 
associated with TB-DM. 
10.4 million
442  million 
Active TB Cases
Type 2 Diabetes Cases
0 1 2 3 4 5
Combined Treatment 
Failure/Death Risk15
Risk of Death15
Risk of Active TB12 
Risk of TB Relapse15
Relative Risk
Relative Risks associated with TB-DM
1.69
1.89
3.11
3.89
A B
Figure 4 | Diabetes increases the risk of active tuberculosis. (A) Relative risk values associated 
with TB-DM patients compared to TB-only patients. Data obtained from Baker et al, in which 5 
studies reported the risk of relapse, 23 reported deaths and 12 reported the combined outcome of 
failure and death. Relative risk value risk of TB in DM patients (13 studies) was taken from Jeon et al.  
(B) In red, number of people with active tuberculosis in 2015 (WHO statistics). In green, number of 
people with type 2 diabetes mellitus in 2014 (WHO statistics) at risk for active tuberculosis.
The number of people living with diabetes is predicted to rise from 415 million in 2015 
to 642 million in 2040, amounting to a staggering 55% increase in diabetes prevalence23. 
Figure 4B attempts to illustrate how diabetes stands to threaten the successful control 
of tuberculosis disease that we have thus far achieved. Importantly, the exact biological 
mechanisms underpinning the increase in susceptibility to tuberculosis are to date unclear. 
Apart from tuberculosis, diabetes patients are susceptible to a wide range of infections. For 
instance, certain relatively rare infections occur almost exclusively in patients with diabetes, 
namely rhinocerebral mucormycosis24,25, Fournier’s gangrene and Klebsiella pneumoniae liver 
abscess26. Likewise, bacterial pneumonia27, urinary tract infections (UTIs)28, skin infections29 
and invasive fungal infections by Candida species30,31 also occur more frequently in patients 
with diabetes. Several biological explanations for these infections exists. For instance, 
diabetic ketoacidosis32,33 accounts for a large number of mucormycosis cases, glycosuria 
accounts for the increase in UTI infections and diabetic neuropathy, macroangiopathy and 
14997-lachmandas-layout.indd   15 12/10/2017   12:17
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microangiopathy account for the increased skin lesions, poor wound healing and extreme 
cases of gangrene observed in diabetes patients30. Importantly, a general decrease in the 
functioning of cells of the immune system has also been widely reported in patients with 
diabetes31,34. In the case of tuberculosis and diabetes, the question therefore is whether 
a particular trait of diabetes, akin to CD4+ T cell depletion in HIV patients, or whether a 
general decrease in immune defence mechanisms is the cause for increased susceptibility 
to tuberculosis.
14997-lachmandas-layout.indd   16 12/10/2017   12:17
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Introduction
PART II: Cellular metabolism of immune cells and host defense to 
tuberculosis
Immuno-metabolism is a nascent field of research aiming to understand the role that cellular 
metabolism has in controlling the responses of our immune system. The way that immune 
cells use energy substrates such as glucose, fatty acids or amino acids can determine the 
function of these cells, and in turn these pathways may be perturbed in several disease 
states, including diabetes mellitus.  
During homeostasis, cells of the immune system transport glucose into the cytosol where 
it is metabolised by glycolysis into pyruvate, which is further oxidised in the mitochondria 
canonically by way of the tri-carboxylic cycle (TCA) and oxidative phosphorylation 
(OXPHOS) pathways35. During activation, such as stimulation or differentiation, reliance on 
these pathways for energy changes to accommodate the needs of the cell. In particular, the 
function, activation status, and nutrient availability dictates variations on these pathways 
to generate sufficient energy. A common example is that of LPS stimulation during which 
cells increase their reliance on glycolysis whilst decreasing OXPHOS based metabolism, a 
process known as the Warburg effect36,37. 
Each cell type has a unique metabolic profile. Neutrophils predominantly rely on glucose 
and glycolysis for energy to fuel functions such as ROS production and NET formation38,39. 
Activated myeloid cells or lymphocytes metabolise glucose, glutamine and other substrates 
predominantly through glycolysis and the TCA cycle35. Alternatively, cell types with roles in 
surveillance and maintenance such as M2 macrophages or regulatory T cells rely more on 
oxidative pathways such as fatty acid oxidation and OXPHOS 40,41. 
14997-lachmandas-layout.indd   17 12/10/2017   12:17
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Figure 5 | Metabolic Pathways that Influence Host Immune Responses. Immune cells need 
energy in the form of ATP to survive, grow, reproduce and perform specific functions.  During 
homeostasis glucose (Glc) entering the cytosol is converted into pyruvate (Pyr) in a series of steps 
known as glycolysis. Pyruvate is then transported into the mitochondria where it is metabolised 
into CO
2
 and 32 ATP via the tri-carboxylic (TCA) cycle and electron transport chain (ETC) in a process 
called oxidative phosphorylation (OXPHOS). Upon activation, glucose import into the cytosol is 
increased. This increases the glycolytic rates and thus availability of other glycolytic intermediates 
which serve as precursors for biosynthetic processes. The resulting excess pyruvate is converted 
into lactate (Lac) via aerobic glycolysis, which generates two molecules of ATP. Another product 
of glycolysis, glucose-6-phosphate (G6P), feeds into the pentose phosphate pathway (PPPW) 
which supports nucleotide biosynthesis and generates the co-factor NADPH. Pyruvate can also 
be converted to acetyl-CoA (Ac-CoA) which supports the synthesis of cholesterol and lipids, which 
in turn can be broken down by oxidation to re-enter the TCA cycle.  Alternative fuels such as 
glutamine (Gln) or other amino acids enter into the tricarboxylic cycle and supply intermediates 
for biosynthesis. α-ketoglutarate (α-KG), Citrate (Cit), Glutamate (Glu), Malonyl – CoA (Ma-CoA), 
Oxaloacetate (OAA). © Ekta Lachmandas, inspired by Ghesquiere et al 42.
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Introduction
Similar to the energy demands of different cell types, infection by pathogens modulate 
the metabolic landscape of immune cells. With regards to M. tuberculosis, studies in mice 
and isolated monocytes from humans have shown that mycobacteria induce glycolysis in 
immune cells and that inhibition of this pathway impairs mycobacterial clearance in human 
macrophages43. Further investigation into the molecular mechanisms behind these and 
other described pathways will expand our repertoire of knowledge on the relation between 
tuberculosis and metabolism. 
Last but not least, if metabolism is tightly linked with the immune response to tuberculosis, 
can cellular metabolism be clinically modulated to enhance anti-mycobacterial responses? 
This area of research is known as host-directed therapy and one such example would be 
that of metformin. Metformin is the most widely administered type II diabetes drug around 
the world. It functions by reducing blood glucose levels and improving insulin resistance. 
Metformin works through a multitude of mechanisms including mTOR inhibition, inhibition 
of complex I of the electron transport chain, and activation of AMPK44. As a result, metformin 
profoundly influences various cellular immune functions. Metformin has already been 
proposed as adjunctive therapy for tuberculosis45, but before confirming its suitability it 
must be thoroughly investigated in humans and controlled clinical studies.
14997-lachmandas-layout.indd   19 12/10/2017   12:17
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AIM AND OUTLINE OF THIS THESIS 
The previous paragraphs illustrate the susceptibility of patients with diabetes to tuberculosis 
and the role of metabolism in the immune response to tuberculosis. Both areas of research 
are in their infancy and hence many aspects of susceptibility and metabolism remain 
unknown. The aim of this thesis was to contribute to (1) uncovering the mechanisms behind 
the increased tuberculosis susceptibility in diabetes and (2) the investigation of changes in 
cellular metabolism that take place during tuberculosis infection. 
PART I: The impact of diabetes on susceptibility to tuberculosis. 
Hyperglycaemia is one of the hallmarks of type II diabetes and numerous studies have 
associated it with a compromised innate immune response46,47. In Chapter 2 I examined if 
culture-controlled hyperglycaemia influences cytokine production, phagocytosis and the 
clearance of M. tuberculosis from infected human macrophages. Type II diabetes is a complex 
disease in which insulin resistance and dysregulated glucose metabolism associates with 
other metabolic traits such as raised cholesterol and triglyceride levels, hyperuricemia and 
hypertension. This mixed clinical picture makes it difficult to discern the specific influence 
of hyperglycaemia on tuberculosis in patients with type II diabetes. Therefore, in Chapter 
3 we recruited a small cohort of type I diabetes patients with severely dysregulated 
hyperglycaemia and no other overt complications. Their cytokine and metabolic responses 
to tuberculosis were compared to matched healthy controls and the mechanisms that 
contributed to the observed differences were investigated. 
The microbiota of people with diabetes is significantly altered compared to that of healthy 
individuals48,49. Components of a healthy microbiota such as short chain fatty acids (SCFA) are 
known to modulate and control the immune response50. In particular, butyrate-producing 
bacteria have been associated with a state of health51,52. Butyrate is a small molecule 
that limits inflammation and thus disease associated pathology. To understand its role in 
tuberculosis, in Chapter 4 we examined the effects of SCFA and in particular butyrate on 
the immune response to tuberculosis and delineated the mechanisms behind their effects.
14997-lachmandas-layout.indd   20 12/10/2017   12:17
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PART II: Cellular metabolism of immune cells and host defence to 
tuberculosis
The Warburg effect, a metabolic switch from glycolysis to OXPHOS, is the first metabolic 
change to have been described in an immunological context, specifically during stimulation 
with LPS36. In Chapter 5 we investigated whether a similar switch to glycolysis takes place 
during tuberculosis. Specifically, transcriptional changes in glycolysis in patients with 
pulmonary tuberculosis were examined, validated and the molecular mechanisms behind 
them were elucidated. 
When investigating the metabolic changes induced by mycobacteria, to our surprise we 
discovered that OXPHOS was not decreased but instead upregulated. This was in contrast 
to TLR4 stimulation by LPS. To understand the significance of these differences, monocytes 
were stimulated with a range of stimuli and the subsequent changes in OXPHOS metabolism 
were investigated. Chapter 6 covers this study using primarily LPS/TLR4 and P3C/TLR2 as 
model stimuli and links changes in metabolism to functions such as cytokine production 
and phagocytosis. 
Having previously looked at individual pathways, in Chapter 7 we used a systems biology 
approach to identify global changes in metabolism in a TST skin model of tuberculosis 
infection. Genetic changes in a panel of relevant metabolic genes were analysed to 
determine if they could influence cytokine production to M. tuberculosis. 
Metformin has been proposed as adjunctive therapy for tuberculosis and diabetes and a 
murine study that emerged during the course of this thesis described results to support 
this proposition. To evaluate the applicability of these studies in humans in Chapter 8 
we examined the effect of metformin on several host defence mechanisms in healthy 
volunteers who were given metformin for five days.
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ABSTRACT 
Type 2 diabetes mellitus is an established risk factor for tuberculosis but the underlying 
mechanisms are largely unknown. We examined the effects of hyperglycaemia, a hallmark 
of diabetes, on the cytokine response to and macrophage infection with Mycobacterium 
tuberculosis. Increasing in vitro glucose concentrations from 5 to 25 mmol/L had marginal 
effects on cytokine production following stimulation of peripheral blood mononuclear 
cells (PBMCs) with M. tuberculosis lysate, LPS or Candida albicans, while 40 mmol/L glucose 
increased production of TNF-α, IL-1β, IL-6 and IL-10, but not of IFN-γ, IL-17A and IL-22. 
Macrophage differentiation under hyperglycaemic conditions of 25 mmol/L glucose was 
also associated with increased cytokine production upon stimulation with M. tuberculosis 
lysate and LPS but in infection experiments no differences in M. tuberculosis killing or 
outgrowth was observed. The phagocytic capacity of these hyperglycaemic macrophages 
also remained unaltered. The fact that only very high glucose concentrations were able to 
significantly influence cytokine production by macrophages suggests that hyperglycaemia 
alone cannot fully explain the increased susceptibility of diabetes mellitus patients to 
tuberculosis.
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INTRODUCTION
Type 2 diabetes mellitus (DM) has been increasingly recognized as an important risk factor 
for tuberculosis (TB). Epidemiological studies have demonstrated that adults with diabetes 
have a significantly increased risk of developing active TB [1] and it is estimated that globally 
15% of TB cases are attributable to DM [2]. The global prevalence of DM will rise by an 
estimated 55% over the next 20 years, with the largest increases in TB endemic regions of 
Africa and Asia [3]. As a result, DM will become an increasingly important factor contributing 
to the sustained TB epidemic [4,5].
The causative pathogen of TB, Mycobacterium tuberculosis (MTB), primarily infects 
phagocytic cells of the lung, such as alveolar macrophages. The early stage of infection is 
characterised by the recruitment and accumulation of various innate immune cells at the 
site of infection including neutrophils, dendritic cells and interstitial macrophages, the latter 
of which subsequently become infected by the growing population of mycobacteria and 
ultimately develop into bacteria-sequestering granulomas [6,7]. Effective immunity against 
MTB is dependent on the production of pro-inflammatory cytokines like interferon-γ (IFN-γ) 
and tumour necrosis factor-α (TNF-α) [8–11], whilst anti-inflammatory cytokines such as 
interleukin-(IL)-10 can attenuate the anti-bacterial immune response [10,12]. 
It has been hypothesised that alterations in the immune response of patients with diabetes 
give rise to either an enhanced susceptibility to infection or accelerated progression towards 
active TB disease [5]. A possible explanation for these immunological changes is chronic 
hyperglycaemia, a hallmark of DM. Various studies have demonstrated that diabetes and 
hyperglycaemia in particular is associated with a compromised innate immune response 
which includes impairments in phagocytosis, cytokine secretion and macrophage activation 
[13–18]. Other studies that have investigated the adaptive arm of the immune response 
have yielded conflicting results when comparing differences in cytokine production 
between diabetes patients with or without TB [19–21]. These inconsistent data illustrate 
both the complexity of the interaction between TB and DM and reveal limitations in the 
comparability of studies that use divergent methods, such as differences in cellular origins 
and patient populations. 
To better understand the effects of hyperglycaemia on the innate immune response during 
concurrent diabetes and tuberculosis, we investigated whether elevated concentrations of 
glucose could directly regulate the functional capacities of human macrophages in vitro. We 
initially determined the effects of hyperglycaemia on the cytokine response of PBMCs and 
macrophages after stimulation with bacterial lipopolysaccharide (LPS) or whole pathogen 
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lysates, and later in alternatively activated (M2) macrophages upon infection with the MTB 
strain H37Rv. Finally, we assessed the phagocytic ability of hyperglycaemic M2 macrophages 
and studied their capacity to support mycobacterial outgrowth.
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METHODS
Ethics Statement
PBMCs were isolated from buffy coats donated after written informed consent by healthy 
volunteers to the Sanquin Bloodbank (http://www.sanquin.nl/en/) in Nijmegen and Leiden. 
Blood was collected anonymously which, according to institutional ethical policy, does 
not require a separate review by the Ethical Committee. Experiments were conducted 
according to the principles expressed in the Declaration of Helsinki.
Healthy Volunteers
Since blood donations were anonymous no tuberculosis skin test or IFN-γ release assay 
could be performed but the incidence of TB in the indigenous Dutch population is 
extremely low (4/100,000) and Bacillus Calmette-Guérin (BCG) vaccination is not part of the 
routine vaccination program. The incidence of diabetes mellitus in the Dutch population 
for persons under 25 years of age is less than 1% and under 45 years of age is about 1.5%. 
Since the average age of blood donors in these experiments is approximately 45 years [22] 
we expect that almost none of them would have diabetes mellitus which would otherwise 
act as a confounding factor [23]. 
Cytokine Stimulation Experiments
Isolation of peripheral blood mononuclear cells (PBMCs) was performed by differential 
centrifugation over Ficoll-Paque (GE Healthcare) within 0-2 hours of collection. After 
counting (Casy Counter) cells were adjusted to 5 x 106 cells/mL were suspended in glucose 
free RPMI 1640 (Gibco) supplemented with 50 mg/mL gentamicin (Lonza) and 2 mM 
L-glutamine (Life Technologies). 100 μL of PBMCs was incubated in flat bottom 96-well 
plates (Greiner) with varying final glucose concentrations from 5 mmol/L to 40 mmol/L 
D-glucose (Sigma-Aldrich) in glucose-free RPMI, and stimulated with 1 μg/mL of H37Rv 
lysate, 1 x 106 microorganisms/mL of heat-killed Candida albicans (ATCC MYA-3573 (UC 820)) 
or 10 ng/mL LPS (Sigma-Aldrich, E. coli serotype 055:B5). The plates were incubated for 24 h, 
48 h or 7 days at 37°C in a 5% CO
2
 environment. Alternatively, 100 μL of PBMCs (5 x 106/mL) 
was incubated for 1 h at 37°C in 5% CO
2
 and adherent monocytes were selected by washing 
out non-adherent cells with warm PBS. Adherent monocytes were differentiated into M2 
macrophages (n=18) in 10% human pooled serum and 50 ng/mL M-CSF (R&D Systems) 
or M0 macrophages (n=23) in 10% human pooled serum for 6 days. Monocytes were 
differentiated in the presence of 5 mmol/L or 25 mmol/L glucose. In some cases monocytes 
were differentiated in 5 mmol/L glucose with 20 mmol/L mannitol (Sigma-Aldrich) to 
control for effects of osmolarity on cytokine production. Media containing M-CSF and/or 
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serum and glucose were refreshed on day 3 of differentiation. Differentiated macrophages 
were stimulated on day 6 with RPMI (negative control), 1 μg/mL H37Rv lysate or 10 ng/mL 
LPS (positive control). Cell culture supernatants were collected after 24 h. 
Cytokine Measurements
Cell culture supernatants were collected and stored at -20°C for cytokine measurements, 
which were performed by ELISA: IL-1β, TNF-α, IL-17A, IL-22 (R&D Systems); IL-6, IFN-γ and 
IL-10 (Sanquin). 
H37Rv Lysates and Culture
Cultures of H37Rv MTB were grown to mid-log phase in Middlebrook 7H9 liquid medium 
(Difco, Becton-Dickinson) supplemented with oleic acid/albumin/dextrose/catalase (OADC) 
(BBL, Becton-Dickinson), washed three times in sterile saline, heat killed and then disrupted 
using a bead beater, after which the concentration was measured using a bicinchoninic 
acid (BCA) assay (Pierce, Thermo Scientific). 
H37Rv Infection of M2 macrophages
CD14+ monocytes were isolated from PBMCs by magnetic cell sorting with anti-CD14-
coated beads (Miltenyi Biotec) and seeded in tissue culture-treated flasks (Corning). After 
6 days of differentiation in the presence of 50 ng/mL M-CSF, M2 macrophages were 
harvested using trypsin and transferred to tissue culture-treated 24-well plates (Corning) 
with 300,000 macrophages per well. Macrophages were incubated O/N at 37°C in 5% CO2 
and subsequently infected with the H37Rv strain of MTB. Mycobacterial cultures were 
diluted to pre-log phase density one day before infection to ensure that the bacteria were in 
the log phase of the growth curve. Bacterial density was determined by measuring optical 
density at 600 nm (OD-600) and the bacterial suspension was diluted to a concentration 
of 30 x 106 bacteria/mL (MOI 10:1). 100 µL of the bacterial suspension was added to 
the cell cultures, after which the plates were centrifuged for 3 minutes at 800 rpm and 
incubated at 37°C in 5% CO
2
. After 60 minutes the plates were washed with culture medium 
containing 30 µg/mL gentamicin and subsequently incubated O/N at 37°C in 5% CO
2
 in 
medium containing 5 µg/mL gentamicin. Supernatants were collected and filtered before 
cytokine measurements. M2 macrophages were lysed in water for 5 minutes and plated on 
Middlebrook 7H10 agar (Difco, Becton-Dickinson) supplemented with OADC. CFUs were 
determined after 2-3 weeks.
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Cell viability assay
Macrophage viability during prolonged H37Rv infection was assessed by using a LDH 
cytotoxicity kit according to the manufacturer’s instructions (Pierce, Thermo Scientific). For 
each experimental condition 50 µL of freshly harvested supernatant was incubated with 50 
µL LDH reaction mixture for 30 minutes at room temperature in a 96-well plate. The reaction 
was stopped by adding 50 µL of stop solution and the plate was subsequently measured 
on a Mithras LB 940 microplate reader (Berthold Technologies) at 485 nm. Spontaneous 
and maximum LDH release controls were included in order to calculate the percentage of 
cytotoxicity. Macrophages were additionally stained with Trypan Blue (Sigma-Aldrich) as a 
second measure of cell viability.
Phagocytosis Quantification Assay
To quantify phagocytic capacity, fluorescent polystyrene particles (Fluoresbrite YG 
carboxylate microspheres) were used as described by Leclerc et al [24]. In short, M2 
macrophages were incubated with P-beads in a ratio of 10 beads to 1 cell for 90 minutes at 
37°C. Subsequently cells were collected with a cell scraper and centrifuged at 1500 rpm for 10 
minutes. Following centrifugation supernatant was discarded and cells were re-suspended 
in 100 µL culture medium or 100 µL culture medium and Trypan Blue (1:1) (Sigma-Aldrich). 
Internalisation of the beads was quantified by flow cytometry. Non-internalised beads 
emitted a red fluorescent signal after Trypan Blue quenching which was detected in the 
FL-3 channel where as internalised beads were detected in the FL-1 channel.
Statistical Analysis
Differences were analysed using a Wilcoxon signed rank test (paired, non-parametric 
analysis) unless otherwise stated. Data was considered statistically significant at a p-value 
<0.05. Data are shown as cumulative results of levels obtained in all volunteers (means ± 
SEM).
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RESULTS
Hyperglycaemic culture conditions variably affect cytokine production from PBMCs. 
Little or no difference was seen in cytokine production following stimulation and culture of 
PBMCs in glucose concentrations ranging from 5 to 25 mmol/L, while culture in 40 mmol/L 
glucose mostly led to higher cytokine production (Figure 1). Production of pro-inflammatory 
cytokines IL-6 and IL-1β significantly increased in a dose dependent manner upon H37Rv 
stimulation whereas TNF-α production only increased at the highest glucose concentrations 
of 40 mmol/L. Production of the anti-inflammatory cytokine IL-10 also increased upon H37Rv 
lysate and Candida stimulations in the presence of 25 mmol/L or 40 mmol/L glucose. In 
comparison, induction of T-cell cytokines showed a high degree of variability in response to 
varying glucose concentrations. Overall, compared to normal glucose concentrations of 5 
mmol/L, 40 mmol/L glucose showed the most significant changes in cytokine production 
(all p-values <0.05). 
Macrophage differentiation in hyperglycaemic conditions leads to hyper-responsive 
cytokine production. The effect of hyperglycaemia on PBMC cytokine production was 
mild and mainly observed at the highest glucose concentrations (40 mmol/L). Both 25 
mmol/L and 40 mmol/L of glucose can be observed in diabetes patients although the 
latter is rarely seen and is thus unlikely to account for the increase in TB susceptibility. We 
therefore proceeded by differentiating monocytes into M0 (serum derived) and M2 (M-CSF 
and serum derived) macrophages in the presence of 5 mmol/L glucose or the more clinically 
relevant hyperglycaemic condition of 25 mmol/L glucose. M2 macrophage differentiation 
was verified by assessing cell surface marker expression (CD14+/CD163+; Supplementary 
Figure 1). Differentiated macrophages were stimulated with LPS or H37Rv lysate (Figure 
2A). Cytokine production was generally higher in macrophages differentiated under high 
glucose concentrations, although not all differences were statistically significant. Pro-
inflammatory cytokines (TNF-α and IL-6) and anti-inflammatory cytokines (IL-10 and IL-
1RA) from hyperglycaemic M2 macrophages were significantly increased after stimulation 
with H37Rv lysate and LPS. M0 macrophages displayed a similar pattern, except for TNF-α 
production.
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Figure 1 | Cytokine production by PBMCs in response to antigenic stimuli in varying 
concentrations of glucose. (A) PBMCs were stimulated in the presence of 5 mmol/L to 40 mmol/L 
glucose with RPMI, H37Rv lysate (1 μg/mL), LPS (10 ng/mL) or heat-killed Candida Albicans (1 × 106 
microorganisms/ mL). Cell culture supernatants were collected after 24 h, 48 h or 7 days. (B) Data are 
shown as mean ± SEM of supernatant TNF-α, IL-1β, IL-6, IFN-γ, IL-17, IL-22 and IL-10 levels obtained 
in ! 6 volunteers, *p<0.05, **p<0.01.
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Figure 2 | Cytokine production by M0 and M2 macrophages stimulated in varying 
concentrations of glucose. (A) Adherent monocytes were differentiated in either 5 or 25 mmol/L 
glucose into M0 macrophages (serum only) or M2 macrophages (M-CSF and serum) for 6 days and 
stimulated with RPMI, H37Rv lysate (1 μg/mL) or LPS (10 ng/mL). (B) Cell culture supernatants were 
collected and the pro-inflammatory cytokines TNF-α and IL-6 were measured along with the anti-
inflammatory cytokines IL-10 and IL-1RA (n = 23). Data are shown as mean ± SEM, *p<0.05, **p<0.01 
&, ***p<0.001. 
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Figure 3 | Effects of euglycaemic and hyperglycaemic culture conditions on H37RV infection 
and cytokine production in vitro. (A) CD14+ selected monocytes were differentiated into M2 
macrophages in the presence of 5 mmol/L glucose, 5 mmol/L glucose and 20 mmol/L mannitol 
or 25 mmol/L glucose. The macrophages were infected for 1 hour with H37Rv at an MOI of 10. 
After infection the macrophages were washed and fresh media containing the different glucose 
media was added. After 24 hours supernatants were collected and the cells were lysed by osmotic 
pressure. (B) Cell lysates were serially diluted and plated on Middlebrook 7H10 agar. CFUs were 
counted after 2–3 weeks of growth at 37°C. Data are shown as mean ± SEM of two independent 
experiments (n = 4). (C) Pro-inflammatory cytokines TNF-α and IL-6 were measured along with the 
anti-inflammatory cytokines IL-10 and IL-1RA. Data are shown as mean ± SEM. 
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Sub-maximal concentrations of LPS and H37Rv were used to provide room for the potential 
boosting effects of hyperglycaemia on cytokine production.
Given the nature of these experiments the observed increase in cytokine production may 
have simply been a consequence of increased osmolarity during cell culture. To control 
for this, mannitol was used to achieve similar osmolarity in the 5 mmol/L and 25 mmol/L 
culture conditions (Supplementary Figure 2). In most cases the elevated cytokine production 
from M0 and M2 hyperglycaemic macrophages, as seen in Figure 2B, was reproducible 
under osmolarity controlled conditions. Thus the effects of hyperglycaemia on cytokine 
production cannot simply be explained by a difference in osmolarity. 
Hyperglycaemia does not affect the cytokine response to and the survival of 
M. tuberculosis in human macrophages. After investigating the cytokine profiles of 
macrophages stimulated with either LPS or H37Rv lysate in the presence of varying glucose 
concentrations the effect of hyperglycaemia on the in vitro infection of M2 macrophages 
with the H37Rv strain of MTB was determined. M2 macrophages were used for the infection 
experiments as we have previously shown that this macrophage subtype is more adept 
in supporting mycobacterial survival and could therefore serve as the primary bacterial 
reservoir in the lungs during MTB infection [25]. After 24 h of infection no differences in CFU 
counts (Figure 3B) or cytokine production (Figure 3C) were observed between euglycaemic 
(5 mmol/L) and hyperglycaemic (25 mmol/L) macrophages. We also examined the effect 
of hyperglycaemia on the phagocytic capacity of macrophages and outgrowth of H37Rv 
after prolonged infection. M2 macrophages were able to control MTB growth as was 
demonstrated by a 1 log reduction in CFU over time (Figure 4B). However, differentiation 
and stimulation of M2 macrophages in the presence of 5 or 25 mmol/L of glucose were 
not associated with differences in the phagocytosis of fluorescent P-beads (Figure 4A), 
mycobacterial uptake (D0 Sups) and H37Rv survival throughout the course of infection 
(Figure 4B). We assessed macrophage viability during infection by measuring LDH release 
and staining the cells with Trypan Blue and found no differences in viability between 
glucose conditions (Supplementary Figure 3). Together these data demonstrate that 
hyperglycaemia influences neither in vitro H37Rv infection and survival nor the infection-
induced cytokine response in human M2 macrophages.
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Figure 4 | Effects of high glucose on phagocytic capacity of macrophages and infection 
with H37Rv. M2 macrophages differentiated in the presence of 5 or 25 mmol/L glucose were 
either incubated with P-beads and subjected to flow cytometry measurements to determine the 
percentage of phagocytic cells (A) or were infected for 1 hour with H37Rv at an MOI of 10:1 (B). 
After infection macrophages were washed three times and fresh RPMI containing the different 
glucose media was added. The first wash (Day 0 Sups) of each infection was collected and plated 
in serial dilutions to determine whether different amounts of bacilli were taken up by euglycaemic 
or hyperglycaemic macrophages. Simultaneously macrophages (D0) were lysed and plated for CFU 
counts. Infected macrophages were also lysed on Day 1 (D1), Day 3 (D3), Day 5 (D5) and Day 7 (D7) 
after infection. CFUs were counted at once after 2–3 weeks of growth at 37°C. Data are shown as 
mean ± SEM (n = 4). 
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DISCUSSION
Type 2 diabetes mellitus confers a three-fold increased risk for active tuberculosis, but 
the underlying immunological mechanisms have not been identified [1]. In this study we 
investigated the effects of hyperglycaemia on in vitro cytokine production and mycobacterial 
infection. Hyperglycaemia altered cytokine production by PBMCs and macrophages 
stimulated with H37Rv lysate, although significant effects were mainly observed at the 
higher end of the glucose concentration range. Alternatively, hyperglycaemia did not affect 
the phagocytic capacity of macrophages or their ability to control outgrowth of H37Rv over 
a period of time. 
PBMCs incubated in high glucose concentrations produced higher levels of TNF-α, IL-1β and 
IL-6, whilst IFN-γ, IL-17A and IL-22 levels did not change. This suggests that hyperglycaemia 
mainly affects monocytes but not T cells. As a result, we investigated whether hyperglycaemia 
had a more specific effect on macrophage-derived cytokine production. An increase in IL-6, 
IL-10 and IL1RA levels was found when hyperglycaemic monocyte-derived macrophages 
were stimulated with MTB and LPS. 
To our knowledge, no studies have presented data on the effects of high glucose levels 
on in vitro cytokine production in response to MTB. Previous studies that examined ex vivo 
cytokine production in diabetes patients with or without TB have provided conflicting 
results. Some studies have shown elevated production of pro-inflammatory cytokines 
from whole blood of patients with TB-DM whereas another study using whole blood and 
one using PBMCs reported defects in IFN-γ production in patients with TB-DM [19–21,26]. 
Interestingly, both the increase and decrease of pro-inflammatory cytokines were correlated 
to increased HbA1c levels [19,26]. Differences between studies can be explained by the use 
of different cell types and stimuli. In this study we chose to investigate M0 (serum derived) 
and M2 (M-CSF and serum derived) macrophages, as they most closely represent tissue 
resident macrophages such as alveolar macrophages, in which MTB dominantly resides. 
Furthermore, patient studies are often complicated by variations in age, HBA1c levels, 
metabolic perturbations, medication etc., making it difficult to specifically examine the 
effects of hyperglycaemia. For these reasons we chose to exclusively study the effects of 
hyperglycaemia in vitro. 
In contrast to the effects on cytokine production, the capacity of macrophages to 
phagocytose P-beads remained unaltered under high glucose concentrations. In literature, 
several studies report findings that both support and contrast with our observations on 
the effects of hyperglycaemia or DM on the phagocytic capacity of macrophages. In a TB-
DM animal model in particular no significant differences were found in the phagocytic 
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capacity of alveolar macrophages from diabetic and non-diabetic rats subjected to 
aerosol infection with MTB [27,28]. In patients with DM the phagocytic function of 
macrophages and polymorphonuclear cells (PMN) is even more unclear [14,29–31]. In a 
recent study comparing patients with pulmonary TB, DM or the combination of TB and 
DM, no differences were found in the ability of PMNs to phagocytose, produce hydrogen 
peroxide or reduce nitroblue tetrazolium. In contrast, two studies from the same group 
using monocytes from patients with diabetes [32] showed a reduced association of MTB 
bacilli and reduced phagocytosis via the complement or Fc-γ receptor pathway, although 
this was not demonstrated in the context of MTB itself [33]. 
Similar to phagocytosis, no differences were found in MTB killing or outgrowth between 
hyperglycaemic and euglycaemic macrophages. To our knowledge no other data have 
been published on outgrowth of MTB in hyperglycaemic macrophages or macrophages 
from patients with DM. Of interest however is one study showing increased tuberculosis 
susceptibility in mice with streptozotocin-induced diabetes. In line with our study no 
differences in CFU counts were found in the lungs of acute diabetic mice. These results may 
indicate that hyperglycaemia may have long-term effects on susceptibility that are difficult 
to emulate in vitro. [27,34]. 
Several aspects and limitations of our studies should be considered when discussing 
the relatively mild effects of hyperglycaemia on the immune responses elicited by MTB. 
Firstly, although hyperglycaemia did not directly affect MTB survival in macrophages, it is 
possible that it does after longer periods of time, or contributes to increased susceptibility 
to infection indirectly through effects on other immune cells. Secondly, even though 
hyperglycaemia is regarded as a major hallmark of DM, the pathophysiology of the disease 
is not restricted to high glucose concentrations. Other physiological disturbances in DM 
such as hyperinsulinaemia, diabetic acidosis and metabolic changes have also been found 
to affect immune cell functions,  [35–37] and studies to assess their effects on MTB-induced 
immune responses are needed. Thirdly, DM is often associated with diet-induced conditions 
like dyslipidaemia. As MTB has been found to modulate host lipogenic pathways to survive in 
macrophages [38] it is possible that changes in blood lipid levels or composition contribute 
to the increased risk of active TB disease in DM patients. Furthermore we cannot exclude 
that the unidentified donors used in these experiments suffered from co-morbidities such 
as diabetes, although the chance of that are <1.5% as described above. Finally, it is unclear 
how accurately our in vitro model of hyperglycaemia reflects the in vivo situation during DM. 
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In short, these in vitro studies in PBMC and macrophages suggest that hyperglycaemia 
cannot fully explain the increased susceptibility to MTB in DM patients. Further studies that 
explore a broader range of metabolic parameters and cell types are needed to unravel the 
precise mechanisms underlying the effect of DM on TB.
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 SUPPLEMENTARY MATERIAL
Supplementary Figure 1 | M2 macrophage surface marker expression. M2 macrophage 
differentiation was verified by analysing the cell surface expression of CD14 (FITC, clone HCD14) 
and CD163 (Alexa 647, clone RM3/1) by flow cytometry. The FACS plots display representative 
results for CD14+/CD163+ M2 macrophages (black) versus an unstained sample (grey). 
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Supplementary Figure 2 | Effects of osmolarity on cytokine production from differentiated 
macrophages. Monocytes were differentiated into M0 or M2 macrophages in the presence 
of 5 mmol/L glucose, 5 mmol/L glucose and 20 mmol/L mannitol, or 25 mmol/L glucose, and 
subsequently stimulated with RPMI, H37Rv lysate (1 μg/mL) or LPS (10 ng/mL). Cell culture 
supernatants were collected after 24 h and the pro-inflammatory cytokines TNF-α and IL-6 were 
measured along with the anti-inflammatory cytokines IL-10 and IL-1RA (n=6). Data are shown as 
mean ± SEM, *p<0.05, **p<0.01 and ***p<0.001.
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Supplementary Figure 3 | M2 macrophage viability during prolonged H37Rv infection. M2 
macrophages differentiated for 6 days in the presence of 5 or 25 mmol/L glucose were infected 
for 1 hour with H37Rv at an MOI of 10:1 After infection macrophages were washed three times 
and fresh RPMI containing the different glucose media was added. The percentage of cytotoxicity 
was assessed by measuring LDH release from day 0 to day 7 corrected using spontaneous and 
maximum LDH release controls per time point. Macrophages were additionally stained with Trypan 
Blue as a second measure of cell viability and the resulting percentage of viable cells is indicated 
in the graph with an * at each time point for both conditions. Data are shown as mean ± SD (n=2).
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ABSTRACT
Purpose: Patients with diabetes mellitus have an increased risk of developing tuberculosis. 
Although the underlying mechanism is unclear evidence suggests a role for chronic 
hyperglycemia.  
Methods: We examined the influence of hyperglycaemia on Mycobacterium tuberculosis 
(M. tuberculosis) induced cytokine responses in patients with type 1 diabetes mellitus 
(T1D). PBMCs from 24 male T1D patients with suboptimal glucose control (HbA1c > 7.0% 
(53mmol/l)) and from 24 age-matched male healthy controls were stimulated with M. 
tuberculosis lysate. Cytokine analysis, assessment of aerobic glycolysis, receptor recognition 
and serum cross-over experiments were performed to explore the mechanistic differences. 
Results: PBMCs from T1D patients produced less bioactive IL-1β in response to M. 
tuberculosis. IL-6 and IFN-γ production trended towards a decrease, whilst other cytokines 
such as TNF-α, IL-17 and IL-1ra were normal. The decrease in cytokine production was not 
correlated to HbA1c or plasma glucose levels. Cross-over serum experiments did not alter 
the cytokine profile of T1D or control patients arguing for an intrinsic cellular defect. Cellular 
metabolism and the expression of M. tuberculosis related pattern recognition receptors such 
as TLR2, TLR4 and NOD2 did not differ between T1D patients and healthy controls.
Conclusions: Compared to matched controls T1D patients have a reduced capacity to 
produce pro-inflammatory cytokines in response to M. tuberculosis, which may contribute 
to the increased susceptibility to tuberculosis. This effect appears not to be related to 
prevailing glucose levels but to an intrinsic cellular deficit.
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INTRODUCTION
Diabetes increases the risk of developing active tuberculosis (TB) and is associated with 
worsened outcomes during TB treatment.  It has been estimated that 15% of TB cases 
globally can be attributed to diabetes1. Patients with type 1 diabetes (T1D) may have an 
even higher risk of developing TB compared to those with type 2 diabetes (T2D) 2, 3, 4 . 
Additionally, poor glucose control escalates the risk of TB 5, 6. The epidemiological evidence 
for the relation between diabetes and TB is strong, but the molecular and immunological 
basis for the susceptibility to TB remains largely unclear. 
Recent evidence that points towards a disturbed innate and adaptive immune response 
to TB is mainly derived from studies in T2D patients7. However, T2D is a multifactorial 
disease involving age, obesity, sedentary lifestyle and genetics. It is characterised by 
hyperglycaemia, insulin resistance, hypertension, dyslipidemia and oxidative stress. All 
these factors, including the use of antidiabetic drugs with potential immune modulating 
capacities (i.e. metformin), make it difficult to specifically examine the role of hyperglycemia 
in the increased susceptibility to TB. 
Therefore, we sought to study the response to M. tuberculosis in T1D patients with chronic 
hyperglycaemia. We excluded individuals using drugs other than insulin replacement 
therapy and also those with serious diabetic complications. We examined whether T1D is 
associated with altered production of pro-inflammatory cytokines such as TNF, interleukin 
(IL)-1β and IL-6 from monocytes and interferon-γ (IFN-γ) from CD4+ lymphocytes, all of which 
are pivotal for effective host defenses against tuberculosis8.  Finally, we examined whether 
external factors in serum (i.e. hyperglycaemia) or intrinsic factors (i.e. cellular metabolism and 
expression of pattern recognition receptors) were responsible for differences in cytokine 
responses between healthy controls and T1D patients.
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METHODS
Recruitment and characterization of study subjects
We enrolled 24 male T1D patients with an HbA1c > 7.0% (53 mmol/l) and 24 age- matched 
male healthy controls. Participants were all between 20 and 70 years old. For T1D patients, 
the minimal duration of diabetes was 1 year. Patients using medication other than insulin 
were excluded. HbA1c was measured by standard laboratory methods. Plasma insulin 
was measured by radioimmunoassay9. Plasma cholesterol, TG, glucose (Liquicolor, Human 
GmbH) and free fatty acids (NEFA-C WAKO chemicals, GmbH) were measured enzymatically 
following manufacturer’s protocols. Blood was drawn from a cubital vein and collected into 
sterile EDTA tubes for isolation of PBMCs or from serum tubes (Monoject). The study was 
approved by the Institutional Review board and written informed consent was obtained 
from all subjects. Using similar criteria an additional 6 T1D and 6 controls were recruited for 
a follow-up experiment.
PBMC isolation and stimulation 
PBMC isolation was performed by dilution of blood in pyrogen-free PBS and differential 
density centrifugation over Ficoll-Paque (GE healthcare, UK). Cells were washed twice in 
PBS and re-suspended in RPMI culture medium (Roswell Park Memorial Institute medium; 
Invitrogen, CA, USA) supplemented with 5 mM glucose, 10 μg/ml gentamicin, 10 mM 
L-glutamine, and 10 mM pyruvate. PBMCs were counted with a Coulter counter (Coulter 
Electronics) and adjusted to 5×106 cells/ml. A 100 μl volume was added to round bottom 
96-well plates (Greiner, Frickenhausen, Germany) for PBMC stimulation experiments. Excess 
unstimulated PBMCs were lysed in TRIzol reagent (Invitrogen) and stored at −80°C until RNA 
isolation was performed.
Cells were stimulated with RPMI, 1 μg/ml Mycobacterium tuberculosis lysate for 24 h or 7 d 
(in the presence of 10% human pool serum for lymphocyte derived cytokines). For serum 
cross-over experiments, cells were incubated with 25% serum for 24 h or 7 d. In a follow-up 
experiment, we collected six additional male T1D patients with an HbA1c > 7.0% and six 
age- matched male healthy controls. PBMCs were isolated and stimulated with Escherichia 
coli LPS (serotype 055:B5, Sigma-Aldrich, 1 ng/mL or 10 ng/ml). Supernatants were collected 
and stored at -20°C until cytokine/lactate measurements were performed.
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Cytokine measurements
Cytokine measurements from cell culture supernatants were performed by ELISA; namely 
interleukin (IL)-1β, IL-1 receptor antagonist (IL-1Ra), tumour necrosis factor (TNF)-α (R&D) 
and IL-6 (Sanquin) were measured in the 24 h PBMC stimulation experiments. Supernatants 
of the 7 d stimulations were used to measure IL-22, IL-17 (R&D Systems) or IFN-γ (Sanquin). 
Bioactive IL-1 assay
Active IL-1 was measured indirectly using the mouse thymoma EL4-NOB1 (NOB1) cell line. 
NOB1 cells were cultured in RPMI culture medium supplemented with 1 mM pyruvate, 1 
mM glutamax, 1 mM penicillin/streptomycin and 10% foetal bovine serum (Gibco) until 
confluence was reached. NOB1 cells (105 cells/well) were plated in a flat bottom 96- wells 
plate (Greiner). 70 µL (2x dilution) of supernatant from PBMCs of T1D or healthy controls 
that were stimulated with M. tuberculosis was added to each well. Cytokine measurement 
for murine interleukin (IL)-2 was performed by ELISA (R&D Systems).
Lactate measurements
Lactate was measured from cell culture supernatants using a coupled enzymatic assay 
in which lactate was oxidised and the resulting H
2
O
2
 was coupled to the conversion of 
Amplex® Red reagent to fluorescent resorufin by HRP (horseradish peroxidase). 30 μL of 
lactate standard or 200-fold diluted sample was added to a black 96-well flat-bottom plate 
followed by 30 μL of reaction mix which consisted of 0.6 μL of 10 U/mL HRP (Sigma), 0.6 μL of 
100 U/mL lactate oxidase (Sigma), 0.3 μL of 10 mM Amplex® Red reagent (Life Technologies) 
and 28.5 μL PBS. The assay was incubated for 20 min at room temperature (RT) and the 
fluorescence of resorufin (excitation/emission maxima=570/585 nm) was measured on a 
96-well plate reader (Biotek). 
Transcriptional analysis of isolated PBMCs
RNA was isolated from unstimulated PBMCs using TRIzol reagent (Invitrogen), according 
to the manufacturer’s protocol. RNA was transcribed into complementary DNA by reverse-
transcription using iScript cDNA synthesis kit (BIORAD). Quantitative real-time PCR (qPCR) 
was performed using different primer sets (Biolegio); primer sequences for hexokinase 2 
(HK2), HK3, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3), Pyruvate 
Dehydrogenase Kinase 4 (PDK4), Malate Dehydrogenase 1 (MDH1), MDH2, Toll Like Receptor 
2 (TLR2), TLR4, Nucleotide Binding Oligomerization Domain Containing 2 (NOD2), Caspase 
Recruitment Domain Family Member 9 (CARD9), Receptor Interacting Serine/Threonine 
Kinase 2 (RIPK2), Mitogen-Activated Protein Kinase 9 (MAPK9), TNF Receptor Associated 
Factor 6 (TRAF6), Caspase 1 (CASP-1) are given in Supplementary Table 1. Power SYBR Green 
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PCR Master Mix (Applied Biosystems) was used for qPCR in a AB Step one plus real-time 
PCR system (Applied Biosystems, Life technologies). qPCR data were normalized to the 
housekeeping gene human β2M. 
Statistics
Data are shown as means ± SEM. Differences in cytokine secretion were calculated using 
the Mann-Whitney test for two independent samples. Correlation analysis between glucose 
metabolites and cytokine secretion was performed using Spearman’s rank correlation 
coefficient and the 95% confident interval was calculated accordingly. A p-value of <0.05 
was considered statistical significant. Generation of graphs and statistical analyses were 
performed using Graphpad prism 5.
14997-lachmandas-layout.indd   56 12/10/2017   12:17
57
3
In-vivo hyperglycaemia
RESULTS 
Participant characteristics are shown in Table 1. Age, plasma triglyceride (TG) and free fatty 
acid (FFA) levels were not different between T1D patients and the 24 control subjects (Table 
1). As per definition, HbA1c and plasma glucose levels were significantly increased in T1D 
patients compared to healthy controls. Plasma insulin levels were also higher, whilst plasma 
cholesterol levels were lower in T1D patients. 
TABLE 1 | Descriptive characteristics of study type 1 patients (T1D) and controls (CON)
T1D patients Controls P-value
N 24 24
Age (yr) 48.1 ± 2.7 47.5 ± 2.6 0.91
Duration diabetes (yr) 24.2 ± 2.5 - -
Glucose (mmol/l) 9.3 ± 0.8 4.6 ± 0.2 <0.001***
HbA1c (%) 8.9 ± 0.3 5.4 ± 0.1 <0.0001***
Insulin (mE/l) 31.5 ± 3.8 19.9 ± 2.9 <0.05*
Cholesterol (mmol/l) 3.5 ± 0.1 4.0 ± 0.2 0.05
TG (mmol/l) 1.36 ± 0.15 1.25 ± 0.12 0.70
FFA (mmol/l) 0.25 ± 0.04 0.25 ± 0.04 0.39
Data are mean ± SEM. FFA, free fatty acids; HbA1c, glycosylated haemoglobin; TG, triglycerides.
PBMCs of T1DM patients show reduced pro-inflammatory IL-1β cytokine secretion 
in response to M. tuberculosis. No spontaneous cytokine production was detected 
in unstimulated TID patients or control cells (RPMI; Fig1). In contrast, robust induction of 
cytokine production was observed in response to M. tuberculosis in both groups. Production 
of IL-1β was significantly lower in T1D patients as compared to healthy controls (p < 0.01; 
Fig1). IL-6 and IFN-γ followed a similar trend, albeit borderline significance (p = 0.06). TNF-α, 
IL-1ra, IL-17 and IL-22 levels were not different between T1D patients and controls (Fig1).  The 
decrease in IL-1β production was not specific to M. tuberculosis stimulation. Six additionally 
recruited T1D patients also produced lower levels of IL-1β in response to high dose LPS 
stimulation (Supplementary Fig1).
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Figure 1 | PBMCs from T1D subjects secrete less IL-1β upon stimulation with M. tuberculosis. 
Peripheral blood mononuclear cells (PBMCs, 5x105/well) from type 1 diabetes patients and healthy 
control subjects were stimulated with 1 µg/mL M. tuberculosis lysate. Secretion of (A) interleukin 
(IL)-1β, (B) IL-6, (C) IL-1Ra and (D) tumor necrosis factor (TNF)-α were measured in supernatants by 
ELISA after 24h h of stimulation. (E) Interferon (IFN)-γ, (F) IL-17 and (G) IL-22 were measured after 7 
d of stimulation. Data are mean ± SEM from n=24 individuals per group. ** p <0.01 compared with 
matched healthy controls.
Correlation of IL-1β cytokine secretion with glycaemia. To determine whether the lower 
cytokine production in PBMCs from T1D patients in response to M. tuberculosis stimulation 
was related to glucose control cytokine production was correlated with HbA1c and glucose. 
However, there were no correlations between M. tuberculosis-induced IL-1β, IL-6 or IFN-γ 
secretion from PBMCs and HbA1c or plasma glucose levels of T1D patients (Fig2). Also, no 
correlations were found between cytokine secretion and duration of diabetes (data not 
shown). IL-1β secretion strongly correlated with IL-6 secretion in response to M. tuberculosis, 
but there were no other correlations between cytokine responses.
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Figure 2 | Correlation of cytokine secretion with glycaemia. Associations for T1D patients 
between glycated hemoglobin (HbA1c%), plasma glucose levels and secretion of interleukin (IL)-
1β, IL-6 and interferon (IFN)-y from PBMCs after stimulation with 1 µg/mL M. tuberculosis lysate. (A) 
Spearman’s rank correlation coefficients for all associations. (B) Correlations are shown by linear 
fitted curves and 95% confident intervals for T1D subjects (n=24).
Influence of serum and cellular metabolism on cytokine production. The cross-over of 
autologous serum from control to T1D and vice versa did not influence cytokine production 
of either subject group (Fig3). This suggests that the reduced IL-1β secretion is not directly 
related to plasma glucose concentration or other serum factors, instead it is likely to be an 
intrinsic defect within the immune cells of T1D patients.
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Figure 3 | Influence of T1D serum on cytokine production in response to M. tuberculosis.
(A) Peripheral blood mononuclear cells (PBMCs, 5x105 cells/well) of healthy control (CON) subjects 
were incubated in either 25% of autologous serum or 25% of serum from an age-matched type 1 
diabetes (T1D) subject and vice-versa for PBMCs from T1D subjects. Secretion of (A) interleukin (IL)-
1b, (B) IL-6, (C) tumor necrosis factor (TNF)-a were measured in the supernatants using ELISA after 24 
h of exposure to M. tuberculosis. (D) Interferon (IFN)-γ, (E) IL-22 and (F) IL-17 were determined after 7 
d. Data are mean ± SEM from n=24 individuals per group. *P<0.05 compared with healthy controls. 
Activation of aerobic glycolysis is important for cytokine production in response to M. 
tuberculosis 10. However, lactate production, a marker of glycolysis, was not decreased in 
T1D patients. In fact, M. tuberculosis stimulation increased lactate production in T1D patients 
compared to matched healthy controls (Fig4A). Glucose consumption (Fig4B) and the 
expression levels of glycolysis genes HK2, HK3 and PFKFB3 in PBMCs was similar between 
T1D patients and healthy controls (Fig4 E –G). Finally, no difference in the expression of the 
TCA cycle genes: PDK4, MDH1 and MDH2 (Fig4 H-J) was observed.
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Figure 4 | Cellular metabolism in PBMCs from T1D subjects and controls. (A) Lactate secretion 
and (C) glucose consumption were measured in the supernatant of unstimulated (RPMI) peripheral 
blood mononuclear cells (PBMCs) of type 1 diabetes (T1D) and healthy control (CON) subjects as 
well as (B, D) after 24 h of stimulation with M. tuberculosis lysate.   Relative mRNA expression values 
of (E) HK2, (F) HK3, (G) PFKFB3, (H) PDK4, (I) MDH1 and (J) MDH2 in unstimulated PBMCs from T1D 
and CON subjects. Data are mean ± SEM from n=24 individuals per group.
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Figure 5 | M. tuberculosis recognition and downstream signalling. Relative basal mRNA 
expression values of peripheral blood mononuclear cells (PBMCs) from type 1 diabetes (T1D) are 
shown when compared to matched healthy control (CON) for (A) TLR2, (B) TLR4, (C) NOD2, (D) 
CARD9, (E) RIPK2, (F) MAPK9, (G) TRAF6 and (H) CASP1. Data are mean ± SEM from n=24 individuals 
per group. 
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M. tuberculosis recognition and downstream signalling. To determine whether changes 
in receptors involved in M. tuberculosis recognition could explain the impaired cytokine 
response of PBMCs from T1D patients, we investigated gene expression levels of well-
known M. tuberculosis pattern recognition receptors (PRRs) in PBMCs of both groups. Levels 
of TLR2, TLR4 and NOD2 were unchanged (Fig5 A-C). In addition, no differences were found 
in the expression of genes involved in the intracellular signalling response to M. tuberculosis, 
including CARD9, RIPK2, MAPK9, TRAF6 and CASP1 (Fig5D-H).
Bioactive IL-1 secretion from PBMCs of T1D patients. To determine whether differences 
in cellular processing affected the secretion of IL-1β, we determined the amount of bioactive 
IL-1 in the supernatants of PBMCs stimulated with M. tuberculosis from Fig1. We found that 
PBMCs of T1D patients released significantly lower levels of bioactive IL-1 in response to M. 
tuberculosis.
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Figure 6 | Bioactive IL-1 secretion from PBMCs of T1D patients. Peripheral blood mononuclear 
cells (PBMCs, 5x105/well) from type 1 diabetes patients and healthy control subjects were stimulated 
with 1 µg/mL M. tuberculosis lysate for 24 h and supernatants were. were subsequently incubated 
with the murine thymoma EL4-NOB1 cell line (105 cells/well). Mouse interleukin (IL)-2 cytokine 
secretion in response to present bioactive IL-1 in the supernatant of the PBMCs was measured 
using ELISA. Data are mean ± SEM from n=24 individuals per group. *P<0.05 compared with the 
matched healthy controls.
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DISCUSSION
The primary finding of this study is that PBMCs from patients with T1D have a reduced 
ability to produce IL-1β, IL-6 and IFN-γ in response to M. tuberculosis stimulation, while TNF, 
IL-17 and IL-1Ra production is normal. These changes may be partly responsible for the 
well-known susceptibility of patients with diabetes for TB. The current data suggest that the 
decreased cytokine production after stimulation with M. tuberculosis is an intrinsic cellular 
deficit in PBMCs from T1D patients, since differences in cytokine secretion were not due to 
external factors in serum or related to glucose regulation.
Epidemiological studies that investigated the relation between hyperglycaemia and the risk 
for TB have been contradicting. Both a positive effect5, 6 and no effect11, 12, 13 of hyperglycaemia 
on the risk for TB have been described. These studies vary greatly in size, geography and 
definition of controlled vs uncontrolled glycaemia. To our knowledge this is the first study 
specifically examining the cytokine production capacity of T1D patients to M. tuberculosis. 
At the same time, studies on the cytokine response to other pathogenic stimuli such as 
LPS strongly support our findings. Ex vivo stimulations experiments performed in both T1D 
14, 15, 16 and T2D17, 18 patients describe a similar decrease of IL-1β and IL-6 but not TNF-α, IL-
1ra and IFN-γ production, respectively. As shown in the stimulation experiments with LPS, 
this decrease in cytokine signalling is not specific for M. tuberculosis, thus supporting the 
notion that an intrinsic defect in cytokine production rather than an M. tuberculosis specific 
signalling defect is the mechanism underlying the decrease in cytokine production. 
Interestingly, patients with both tuberculosis and diabetes produce more cytokines 
compared to patients with only tuberculosis19, 20. Together, these findings suggest an initial 
sub-optimal response to infection which promotes bacterial growth and subsequent 
pathology. This hypothesis of a delayed immune response is supported by a mouse model 
of concomitant tuberculosis and diabetes disease21.
The exact type of intracellular defects remains to be elucidated. No change in aerobic 
glycolysis was observed nor altered expression of relevant pattern recognition receptors. 
It is possible that a certain level of accelerated immunosenescence occurs in T1D. This 
process, described for ageing, is characterized by impaired cellular immune function 
(leading to increased death due to infectious diseases), simultaneously with increased 
chronic inflammatory activity (leading to increased incidence of cardiovascular disease)22. 
The observations that T1D patients show enhanced low-grade chronic inflammation and 
cardiovascular diseases23 and at the same time an impaired immune response to pathogens 
as observed in the current study support this hypothesis. The decrease in IL-6 may be a 
secondary effect as IL-1β induces IL-6 production in a paracrine signaling loop. Similarly, 
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IL-18, another product of caspase-1 activity, is important for IFN-γ production. This could 
explain why the decrease in these cytokines is more subtle as compared to IL-1β. This 
avenue will form a cornerstone for further research.
The implications of a decrease in IL-1β production for susceptibility to TB are significant. 
IL-1α/β double knockout mice24 or mice deficient in IL-1R125 display increased susceptibility 
to M. tuberculosis infection. In humans, a positive association between IL-1β levels and 
resistance to tuberculosis was inferred from human IL1B gene polymorphisms26. Moreover, 
patients with gain of function mutations in the inflammasome component NLRP3 have an 
increased capacity to kill M. tuberculosis27. Mechanistically, a recent study elucidated that IL-1β 
promoted bacterial containment through the induction of specific eicosanoids that limited 
excessive and type 1 IFN production28. The current study was performed in T1D patients, 
with chronic hyperglycemia as a key characteristic. The observed impaired cellular cytokine 
response could be similar for T2D patients. However, T2D is a much more heterogeneous 
disease characterized by multiple metabolic disturbances (i.e. hyperglycaemia, insulin 
resistance, hypertension, dyslipidemia and oxidative stress) which may further contribute 
to the increased susceptibility to TB and which needs further investigation.
As a limitation of this study, we did not investigate other host defense mechanisms such as 
phagocytosis, ROS or nitric oxide (NO) production from monocytes or macrophages since it 
is unlikely that reduced IL-1β is the sole factor in susceptibility to TB. A confounding factor in 
the current study could be the significantly higher levels of insulin in blood of T1D patients 
as insulin can affect cytokine production however, we did not find any correlation between 
insulin and cytokine production in T1D patients (data not shown). Lastly, a limitation of this 
study is the relatively small size of our cohort as a result of which subtle associations such as 
those between glucose control and cytokine responses may not be detectable. 
In conclusion, this study specifically identifies a decrease in bio-active IL-1β possibly, due 
to a deficit in intracellular processing rather than chronic hyperglycaemia, to be a strong 
candidate in the susceptibility of T1D patients to tuberculosis.
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Supplementary Figure 1 | Reduced IL-1β secretion by PBMCs from T1D subjects is not 
specific to M. tuberculosis stimulation. Blood peripheral mononuclear cells (PBMCs) of six 
additional type 1 diabetes (T1D) subjects and healthy control (CON) subjects have been challenged 
with low and high dose of lipopolysaccharide (LPS, 1ng/mL and 10ng/mL) for 24 h and interleukin 
(IL)-1b secretion was measured using ELISA. Data are mean ± SEM from n=6 individuals per group. 
Supplementary Table 1 | Primer sequences used for qRT-PCR analysis (5’-3’)
Gene Forward primer Reverse primer
HK2 TTGACCAGGAGATTGACATGGG CAACCGCATCAGGACCTCA
HK3 GTGAGGTTGGGCTAGTTGTAGA GTCCAGGGTATGGTCGAAGGT
PFKFB3 ATTGCGGTTTTCGATGCCAC GCCACAACTGTAGGGTCGT
PDK4 GGAGCATTTCTCGCGCTACA ACAGGCAATTCTTGTCGCAAA
MDH1 GGTGCAGCCTTAGATAAAT AGTCAAGCAACTGAAGTTC
MDH2 TCGGCCCAGAACAATGCTAAA GCGGCTTTGGTCTCGATGT
TLR2 GAATCCTCCAATCAGGCTTCTCT GCCCTGAGGGAATGGAGTTTA
TLR4 GGCATGCCTGTGCTGAGTT CTGCTACAACAGATACTACAAGCACACT
NOD2 CCCTGCAGCTGGACTACAACT AGATGCCTCGGTCTGAGATATTG
CARD9 AAGAAGGTCACAGGCAAGGA GTCATCTTTGGAGCTCAGCA
RIPK2 GCCCTTGGTGTAAATTACC GGACATCATGCGCCACTTT
MAPK9 GAAACTAAGCCGTCCTTTT TCCAGCTCCATGTGAATAA
TRAF6 TTTGCTCTTATGGATTGTC CATTGATGCAGCACAGTTG
CASP-1 AGGATATGGAAACAAAAGTCGGC AGATAATGAGAGCAAGACGTGTG
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ABSTRACT
Type 2 diabetes mellitus confers a three-fold increased risk for tuberculosis, but the 
underlying immunological mechanisms are still largely unknown. Possible mediators of 
this increased susceptibility are short-chain fatty acids, levels of which have been shown 
to be altered in individuals with diabetes. We examined the influence of physiological 
concentrations of butyrate on cytokine responses to Mycobacterium tuberculosis (Mtb) in 
human peripheral blood mononuclear cells (PBMCs). Butyrate decreased Mtb-induced 
pro-inflammatory cytokine responses, while it increased production of IL-10. This anti-
inflammatory effect was independent of butyrate’s well-characterised inhibition of HDAC 
activity, and was not accompanied by changes in Toll-like receptor signalling pathways, the 
eicosanoid pathway or cellular metabolism. In contrast blocking IL-10 activity reversed the 
effects of butyrate on Mtb induced inflammation. Alteration of the gut microbiota, thereby 
increasing butyrate concentrations, can reduce insulin resistance and obesity, but further 
studies are needed to determine how this affects susceptibility to tuberculosis.
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INTRODUCTION
Tuberculosis (TB) is the second leading cause of death from an infectious disease worldwide 
[1]. Susceptibility to TB can be increased by several co-morbidities, one of which is type 2 
diabetes mellitus (DM) [2]. DM patients present with an overall three-fold increased risk of 
developing active TB [3]. Globally, 15% of TB cases are estimated to be attributable to DM 
[4], and with a predicted increase of DM by 155% over the next 20 years, DM will become an 
increasingly important factor challenging TB control [5-7]. 
DM patients exhibit alterations in the immune response against Mycobacterium tuberculosis 
(Mtb), making them more susceptible to infection or progression towards active TB disease, 
and less responsive to treatment [8-11]. However, the underlying biological mechanisms 
remain largely unknown [12, 13]. DM patients have been associated with dysregulated 
cytokine responses to Mtb [14-17]. While pro-inflammatory cytokines are necessary for 
protection against Mtb, anti-inflammatory cytokines may counteract these effects. Possible 
factors that may impact the host response in patients with DM are short-chain fatty acids 
(SCFAs), the main metabolic products of fermentation of non-digestible dietary fibres by 
the gut microbiota. Numerous reports have demonstrated that DM patients present with 
an altered composition of their gut microbiota, which subsequently alters their SCFA levels 
[18-24]. SCFAs strongly modulate immune and inflammatory responses [22, 25-31], thereby 
influencing the host response to Mtb. SCFAs, of which butyrate (C4) is the most thoroughly 
studied, act on immune and endothelial cells via at least two mechanisms: activation of 
G-protein coupled receptors (GPCRs) and inhibition of histone deacetylase (HDAC) [32]. 
They affect the function of various cell types such as lymphocytes [33, 34], neutrophils [25, 
31, 35], and macrophages [28, 36-38]. In light of the emerging role of the microbiota in 
inflammation and immunity we hypothesized that SCFAs, and in particular butyrate, may 
affect the immune response and susceptibility to Mtb in type 2 DM patients. 
In this study we investigated the role of physiological concentrations of SCFAs on the 
cytokine response against Mtb in human peripheral blood mononuclear cells (PBMCs). 
We subsequently examined a number of possible mechanisms via which altered 
concentrations of one particular SCFA, C4, might affect the host immune response to Mtb 
in DM patients. To this purpose, we studied the influence of physiological concentrations 
of C4 on HDAC activity, immune signalling pathways, the eicosanoid pathway and cellular 
metabolism. To our knowledge, this is the first study reporting on the effects of physiological 
plasma concentrations of C4 on Mtb-induced cellular responses. Physiological plasma 
concentrations of C4 are in the micromolar range [39], while in previous studies C4 was 
used in the millimolar range. Therefore, this study substantially adds to our knowledge 
of SCFAs as possible mediators of altered immune responses to Mtb in DM patients. The 
authors declare that there is no conflict of interest regarding the publication of this paper.
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METHODS
Human samples
PBMCs were isolated from buffy coats donated after written informed consent by 
healthy volunteers to the Sanquin Bloodbank (http://www.sanquin.nl/en/) in Nijmegen. 
Experiments were conducted according to the principles expressed in the Declaration of 
Helsinki. Since blood donations were anonymous no tuberculosis skin test or IFN-γ release 
assay was performed. However the incidence of TB in the Dutch population is extremely 
low (4/100,000), and Bacillus Calmette-Guérin (BCG) vaccination is not part of the routine 
vaccination program. Blood donors were not screened for DM as prevalence of DM among 
people under 45 years of age (median age of blood donors) is about 1.5% and therefore DM 
is unlikely to be a confounding factor [34]. 
H37Rv lysates and culture
H37Rv Mtb was grown to mid-log phase in Middlebrook 7H9 liquid medium (Difco, Becton-
Dickinson) supplemented with oleic acid/albumin/dextrose/catalase (OADC) (BBL, Becton-
Dickinson), washed three times in sterile saline, heat killed and then disrupted using a bead 
beater, after which the concentration was measured using a bicinchoninic acid (BCA) assay 
(Pierce, Thermo Scientific). 
Cell stimulation experiments
Isolation of PBMCs was performed by differential centrifugation over Ficoll-Paque (GE 
Healthcare). Cells were adjusted to 5 x 106 cells/ml (Beckman Coulter) and suspended in 
RPMI 1640 (Gibco) supplemented with 10 µg/ml gentamicin (Lonza), 10 mM L-glutamine 
(Life Technologies), and 10 mM pyruvate (Life Technologies). 100 μl of PBMCs were incubated 
in round-bottom 96-well plates (Greiner), pre-treated with SCFAs for 1 h and stimulated with 
1 μg/ml of H37Rv lysate or 10 ng/ml LPS (Sigma-Aldrich, E. coli serotype 055:B5. Cells were 
incubated for 24h or 7 days at 37°C in a 5% CO
2
 environment (n = 6 to 11). Alternatively, 
PBMCs were pre-treated for 1 hour (37°C, 5% CO
2
) with ranolazine (ITK-Diagnostics), 
trimetazidine (Sigma), pertussis toxin (Enzo Life Sciences), etomoxir (Sigma) (inhibitors of 
β-oxidation, n = 3), aspirin (Aspégic injection powder, n = 3), cycloheximide (Sigma, n = 6 to 
7), anti-IL-10 antibody IgG2a (BioLegend, n = 10 to 12), or IgG2a isotype control (Biolegend, 
n = 10 to 12) prior to stimulation. Cell culture supernatants were collected and stored at 
-20°C for cytokine measurements, performed by ELISA: TNF-α, IL-1β, IL-17A, IL-22, IL-1Ra 
(R&D Systems); IL-6, IFN-γ and IL-10 (Sanquin). 
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Quantification of gene expression
For quantitative real-time PCR (qPCR) analysis RNA was isolated from PBMCs using TRIzol 
reagent (Invitrogen Life Technologies) according to the manufacturer’s protocol. RNA was 
transcribed into complementary DNA (cDNA) by reverse-transcription using iScript cDNA 
synthesis kit (BIORAD, Hercules, CA). Primer sequences (Biolegio) are given in Table 1. Power 
SYBR Green PCR Master Mix (Applied Biosystems) was used for qPCR on an AB Step one plus 
real-time PCR system (Applied Biosystems). qPCR data was normalized to the housekeeping 
gene human β2M (n = 3 to 10). 
Table 1 | Primer sequences used for gene expression measurements by qPCR.
Target Forward 5’ > 3’ Reverse 5’ > 3’
h-β2M ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
h-COX2 CTGGCGCTCAGCCATACAG CGCACTTATACTGGTCAAATCCC
h-CS GGTGGCATGAGAGGCATGAA TAGCCTTGGGTAGCAGTTTCT
h-HDAC1 CCGCATGACTCATAATTTGCTG ATTGGCTTTGTGAGGGCGATA
h-HDAC8 TCGCTGGTCCCGGTTTATATC TACTGGCCCGTTTGGGGAT
h-HIF1-α GAACGTCGAAAAGAAAAGTCTCG CCTTATCAAGATGCGAACTCACA
h-IDH2 CGCCACTATGCCGACAAAAG ACTGCCAGATAATACGGGTCA
h-IL-10 CAACCTGCCTAACATGCTTCG TCATCTCAGACAAGGCTTGGC
h-IL-1β GCCCTAAACAGATGAAGTGCTC GAACCAGCATCTTCCTCAG
h-IL12-p35 CCTTGCACTTCTGAAGAGATTGA ACAGGGCCATCATAAAAGAGGT
h-IL23-p19 CTCAGGGACAACAGTCAGTTC ACAGGGCTATCAGGGAGC
h-MDH2 TCGGCCCAGAACAATGCTAAA GCGGCTTTGGTCTCGATGT
h-SOCS1 TTTTCGCCCTTAGCGTGAAGA GAGGCAGTCGAAGCTCTCG
h-SOCS3 TGCGCCTCAAGACCTTCAG GAGCTGTCGCGGATCAGAAA
h-ST2 TTGTCTACCCACGGAACTACA GCTCTTTCGTATGTTGGTTTCCA
h-TNF-α CCTCTCTCTAATCAGCCCTCTG GAGGACCTGGGAGTAGATGAG
h-Tollip TGGGCCGACTGAACATCAC GTGGATGACCTTATTCCAGCG
Protein phosphorylation measurements
Western blotting was carried out using a Trans Turbo Blot system (Bio-Rad) according to 
manufacturer’s instructions. 5x106 PBMCs were lysed in 100 μl lysis buffer. The resulting lysate 
was used for Western blot analysis. Equal amounts of protein were separated by SDS-PAGE 
on 4-15% polyacrylamide gels (Bio-Rad) and transferred to PVDF (Bio-Rad) membranes. 
Membranes were blocked for 1 hr and then incubated overnight with primary antibody 
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(dilution 1:1000) in 5 % (w/v) BSA or milk in TBS-Tween buffer (TBS-T). Blots were washed in 
TBS-T 3 times and incubated with HRP-conjugated anti-rabbit antibody (1:5000; Sigma) in 
5% (w/v) milk in TBS-T for 1 h at room temperature (RT). After washing, blots were developed 
with ECL (Bio-Rad) following manufacturer’s instructions. Primary antibodies used were 
rabbit anti-p38 MAPK, rabbit anti-phospho p38 MAPK, rabbit anti-ERK1/2 (p44/p42 MAPK), 
rabbit anti-phospho ERK1/2 (P44/42 MAPK, T202/Y204) and rabbit anti-phospho-JNK (T183/
Y185) (all Cell Signalling) (n = 2).
Metabolite measurements
Lactate was measured from cell culture supernatants using a coupled enzymatic assay 
in which lactate was oxidised and the resulting H
2
O
2
 was coupled to the conversion of 
Amplex® Red reagent to fluorescent resorufin by HRP (horseradish peroxidise). 30 μl of 
lactate standard or 200x diluted sample was added to 30 μl of reaction mix. The 30 μl of 
reaction mix consisted of 0.6 μl of 10 U/ml HRP (Sigma), 0.6 μl of 100 U/ml lactate oxidase 
(Sigma), 0.3 μl of 10 mM Amplex® Red reagent (Life Technologies) and 28.5 μl PBS. Samples 
were incubated for 20 min at RT and fluorescence (excitation/emission maxima=570/585 
nm) was measured on an ELISA reader (Biotek) (n = 3 to 5). 
Measurements of the NAD+/NADH redox ratio were adapted from Zhu et al [40]. Briefly, 1.5 
million stimulated PBMCs were lysed in 75 μl of homogenization buffer (10 mM nicotinamide 
(Sigma), 10 mM Tris-Cl (Sigma), 0.05% (w/v) Triton X-100 (Sigma), pH 7.4). The lysate was 
centrifuged at 12000 g for 1 min. From the resulting supernatants two 18 μl aliquots were 
removed and either 2 μl of 0.2M HCl or 0.2 M NaOH was added to each aliquot. The samples 
were heated for 30 min at 65°C and after incubation 2 μl of opposite reagent (NaOH or HCl) 
was added to each aliquot. 5 μl of sample or NAD+ (β-nicotinamide adenine dinucleotide 
hydrate; Sigma) standard was then mixed with 85 μl of reaction mix and 60 μl of fluorescence 
mix in a black 96-well plate. The reaction mix consisted of 100 mM bicine (N,N-Bis(2-
hydroxyethyl)glycine; Sigma), 0.6 mM ethanol (Sigma) and 5 mM EDTA (Life Technologies). 
The fluorescence mix consisted of 0.5 mM PMS (phenazine methosulfate; Sigma), 0.05 mM 
resazurin (Sigma) and 0.2 mg of ADH (alcohol dehydrogenase; Sigma). The reaction was 
incubated for 15 min at RT and fluorescence (excitation/emission maxima=540/586 nm) 
was measured on an ELISA reader (Biotek) (n = 3 to 5). 
HDAC activity assay
HDAC Fluorimetric Cellular Activity Assay BML-AK503 (Fluor de Lys, Enzo Life Sciences, Inc., 
Farmingdale, VS) was used to determine HDAC activity in PBMCs pre-treated with C4 (30 
min) and then stimulated with H37Rv (30 min). Subsequently PBMCs were incubated with 
14997-lachmandas-layout.indd   76 12/10/2017   12:17
77
4
SCFAs in TB-DM
acetylated substrate for 2 hours, after which a developer was added to generate a fluorescent 
signal from the deacetylated substrate. Fluorescence was measured on a microplate reader 
(Biotek). Trichostatin A (TSA) was used as a positive control for HDAC inhibition (n = 5 to 6).
Flow cytometry
PBMCs were treated with 50 µmol C4 for 1 h and stimulated with 1 µg/ml H37Rv or 10 ng/ml 
LPS for 7 days. Subsequently cells were re-stimulated with 200 µL RPMI supplemented with 
10% serum, Golgi-plug inhibitor (GPI Brefeldin A; 1 µg/ml, BD Pharmingen), PMA (phorbol 
12-myristate 13-acetate; 50 µg/ml, SIGMA Aldrich) and ionomycin (1 µg/ml, SIGMA Aldrich) 
for 4-6 h at 37°C and 5% CO
2
. Cells were then washed with PBA (PBS 1% BSA (albumin from 
bovine serum) and stained extra-cellularly for 30 min with CD4-PeCys7 (ITK) for T-helper 
17 (Th17) cells at 4°C. Next, cells were washed and permeabilized by fix and perm buffer 
(e-bioscience) according to the manufacturer’s protocol for 45-60 min at 4°C. Finally cells 
were washed and re-suspended in 300 µL PBA to be measured using the Cytomics FC500 
(Beckman Coulter) (n = 8).
Cell death was measured by staining PBMCs with Annexin V-FITC (BioVision) and Propidium 
Iodide (PI) (Invitrogen Molecular Probes). Cells were incubated in the dark on ice with 
Annexin-V staining solution (RPMI supplemented with 5 mM CaCl
2
 and 0.1 µl/ml Annexin-V) 
for 15 minutes. Subsequently PBMCs were stained with PI for 5 minutes. Cells were measured 
with the Cytomics FC500 (Beckman Coulter, Woerden, The Netherlands), and data were 
analysed using CXP analysis software v2.2 (Beckman Coulter) (n = 3 to 5).
Statistical analysis
All data were analysed using a paired non-parametric Wilcoxon signed rank test, as the 
data were not-normally distributed. Differences were considered statistically significant at 
a p-value <0.05. Data are shown as cumulative results of levels obtained in all volunteers 
(means ± SEM).
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RESULTS
Short-chain fatty acids inhibit Mtb-induced cytokine responses. DM is associated with 
altered gut microbiota and consequently altered SCFA levels [18-22]. In line with current 
literature [22, 25-31], we hypothesized that SCFAs have the potential to influence the host 
inflammatory response against Mtb. In particular we investigated the effects of varying doses 
of acetate (C2), propionate (C3), and butyrate (C4) on H37Rv-induced cytokine responses, 
with RPMI as negative control and LPS as positive control (Figure 1). SCFAs themselves did not 
induce cytokine production (results not shown), but significantly affected H37Rv-induced 
cytokine release. C2, C3 and C4 significantly, dose-dependently decreased H37Rv-induced 
production of pro-inflammatory cytokines TNF-α, IL-1β, and IL-17, while non-significant 
effects were found for IL-6, IFN-γ, and IL-22 production. In contrast, C3 and C4 induced a 
significant increase in H37Rv-induced production of the anti-inflammatory cytokine IL-10. 
Similarly, C3 and C4, but not C2 decreased LPS-induced production of TNF-α and IL-6, while 
the release of IL-1β was significantly decreased in response to all three SCFAs (results not 
shown). LPS did not induce production of IFN-γ, IL-17, or IL-22. Moreover, all three SCFAs 
incurred a dose dependent, non-significant decrease in LPS-induced IL-10 production 
(results not shown). 
Overall, C4 resulted in some of the most significant changes in cytokine responses (Figure 
1 B). Moreover, the potency of butyrate in reducing cytokine responses to H37Rv and LPS 
was greater than for the other SCFAs. Importantly, changes in cytokine levels could not be 
explained by altered pH levels or cell death (Supplementary Figure 1 A and B). Therefore, 
following this screen we continued our study with C4 at a concentration of 50 µM, which 
is physiologically relevant because it is comparable to human plasma concentrations [39].
Influence of butyrate on HDAC expression and activity. Butyrate is reported to be a 
strong HDAC inhibitor. Because this might account for its anti-inflammatory effects [41-44], 
we examined the effect of C4 on HDAC expression and activity. C4 significantly decreased 
HDAC8 but not HDAC1 gene expression upon H37Rv stimulation of PBMCs (Figure 2 A). 
Consistent with previous reports [36, 42-44], C4 at a high dose of 1 mM decreased HDAC 
activity upon both RPMI and H37Rv stimulation. However, different from its effect on gene 
expression, C4 at a physiological dose of 50 µM had no effect on actual HDAC activity 
(Figure 2 B), while trichostatin A (TSA, positive control) strongly decreased HDAC activity. 
These data suggest that butyrate’s inhibition of HDAC activity is unlikely to play a role in 
the effects of low doses of C4 on Mtb-induced inflammatory responses and stresses the 
importance of studying the effects of butyrate at physiologically relevant concentrations.
14997-lachmandas-layout.indd   78 12/10/2017   12:17
79
4
SCFAs in TB-DM
      TNF-α
0
100
200
300
400
500
*
C2          C3            C4
H37Rv 
pg
/m
L
        IL-1β
0
1000
2000
3000
4000
*
C2          C3            C4
H37Rv 
pg
/m
L
         IL-6
0
5000
10000
15000
20000
C2          C3            C4
H37Rv 
No SCFA
2 µM
10 µM
50 µM
250 µM
pg
/m
L
       IFN-γ
0
200
400
600
800
C2          C3            C4
H37Rv 
pg
/m
L
        IL-17
0
500
1000
1500
2000 *
C2          C3            C4
H37Rv 
pg
/m
L
       IL-22 
0
200
400
600
800
C2          C3            C4
H37Rv 
pg
/m
L
       IL-10
0
200
400
600
800
*
C2          C3            C4
H37Rv 
pg
/m
L
A
B TNF-α IL-1β IL-6 IFN-γ IL-17 IL-22 IL-10
H37Rv Low
2
10
50
250
2
10
50
250
2
10
50
250 High
C2
	(μ
M
)
C3
	(μ
M
)
C4
	(μ
M
)
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Figure 1 | Short-chain fatty acids inhibit Mtb-induced cytokine responses. (A) PBMCs were 
pre-incubated with 2-250 µM SCFAs for 1 h prior to stimulation with Mtb lysate for 24 h and 7 d. 
Hereafter TNF-α, IL-6, IL-10, IFN-γ, IL-17 and IL-22 were measured in supernatants by ELISA. Data are 
means ± SEM (n = 6), Wilcoxon signed rank test, representative of 2 independent experiments. * p 
< 0.05 (B) Heatmap of log-transformed mean cytokine responses as measured by ELISA, showing 
cytokines up-regulated (red) and down-regulated (blue) upon H37Rv stimulation in the presence 
of different doses of SCFAs. Cytokine responses are shown as compared to H37Rv stimulation alone. 
* p < 0.05
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Figure 2 | Influence of butyrate on HDAC expression and activity. (A) PBMCs were pre-incubated 
with 50 µM C4 for 1 h prior to stimulation with Mtb lysate or LPS for 4 h. Gene expression levels of 
HDAC1 and HDAC8 were measured by qPCR. Data are means ± SEM (n = 10), Wilcoxon signed rank 
test, representative of 3 independent experiments. * p < 0.05 (B) Percentage general HDAC activity 
relative to RPMI stimulated PBMCs, as measured by levels of substrate deacetylation after 30 min of 
pre-incubation with C4 (50 µM) and 30 min of stimulation with Mtb lysate. Data are means ± SEM 
(n = 5 to 6), Wilcoxon signed rank test, representative of 3 independent experiments. * p < 0.05
The effects of butyrate on TLR-signalling mediators and the eicosanoid pathway. 
Signalling of Toll-like receptors (TLRs), important receptors for Mtb recognition [45-47], 
is controlled by feedback mechanisms regulated by several intracellular kinases [48, 49]. 
Because impaired Mtb recognition and insufficient TLR signalling may account for the 
anti-inflammatory effects of C4, we examined whether C4 affects these feedback loops. 
However, C4 had no effect on phosphorylation of the MAP kinases p38, ERK (Figure 3 A), or 
JNK (Supplementary Figure 2). C4 has also been reported to induce expression of inhibitors 
of 
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TLR-signalling pathways [50], but we found that C4 significantly decreased mRNA expression 
of TLR-signalling inhibitors SOCS1 and Tollip, and did not affect expression of SOCS3 or ST2 
(Figure 3 B). Of note, these results were not explained by cell death (Supplementary Figure 
1 B).
Aside from TLR-signalling, C4 possibly exerts its anti-inflammatory effects through 
modulation of the eicosanoid pathway. Eicosanoids, oxygenated metabolites of arachidonic 
acid, modulate the host immune response to Mtb [51-55]. C4 has been reported to up-
regulate key enzymes of the eicosanoid pathway upon LPS stimulation [30], but a reversed 
effect has also been described [56]. We did not observe a significant impact of C4 on 
transcript levels of cyclo-oxygenase 2 (COX-2), one of the main eicosanoid enzymes, upon 
H37Rv or LPS stimulation (Supplementary Figure 3 A). Alternatively, C4 has been described 
to induce release of the anti-inflammatory prostaglandin PGE
2
 [26, 30, 57]. Inhibition of PGE
2
 
with aspirin could not counteract the inhibitory effects of C4 on TNF-α and IL-1β cytokine 
responses upon either H37Rv or LPS stimulation (Supplementary Figure 3 B). The eicosanoid 
pathway is therefore unlikely to be the mediator pathway through which C4 exerts its anti-
inflammatory effects. 
Influence of butyrate on cellular metabolism. Another possible explanation for butyrate’s 
anti-inflammatory effects is its influence on cellular metabolism. A recent paper described 
that microbiota have a strong effect on energy homeostasis in the mammalian colon, and 
showed that C4 regulates different aspects of energy metabolism acting as an important 
energy source for colonocytes [58]. Contrary to this previous study, we observed no effects 
of C4 on cellular lactate production, the NAD+/NADH redox ratio, TCA cycle gene expression 
(Figure 4); nor on β-oxidation (Supplementary Figure 4). These data strongly suggest that C4 
modulates the immune response to Mtb independently of cellular metabolism.
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Figure 3 | The effects of butyrate on TLR-signalling mediators. (A) PBMCs were pre-incubated 
with 50 µM C4 (1 h) and stimulated with Mtb lysate or LPS. Cell lysates were harvested at 30 min 
post stimulation. Phospho-p38, p38, phospho-ERK, and ERK protein levels were determined by 
western blot using specific antibodies (n = 2). (B) Gene expression levels of SOCS1, SOCS3, ST2, 
and Tollip in PBMCs pre-incubated with 50 µM C4 (1 h) and stimulated with Mtb lysate or LPS (4 
h) as measured by qPCR. The boxplot represents median with first and third quartiles; the whiskers 
represent minimum and maximum values. n = 10, Wilcoxon signed rank test, representative of 3 
independent experiments. * p < 0.05
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Figure 4 | Influence of butyrate on cellular metabolism. (A and B) Kinetics of lactate production 
(A) and intracellular NAD+/NADH ratios (B) from days 1, 3 and 7 of PBMCs pre-incubated with 50 
µM C4 (1 h), with and without stimulation with Mtb lysate. Data are means ± SEM (n = 3 to 5), 
Wilcoxon signed rank test, representative of 1-2 independent experiments. (C) Expression levels of 
glycolysis and TCA cycle genes in PBMCs pre-incubated with 50 µM C4 (1 h) and stimulated with 
Mtb lysate or LPS (4 h) as measured by qPCR. Data are means ± SEM (n = 6), Wilcoxon signed rank 
test, representative of 2 independent experiments. 
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Butyrate transcriptionally influences cytokine responses to Mtb, possibly mediated 
through IL-10 induction. We next examined whether the inhibitory effect of C4 on 
Mtb-induced pro-inflammatory cytokine responses, with a concomitant increase in anti-
inflammatory IL-10 production (Figure 1) and decrease in Th17 proliferation (Supplementary 
Figure 5 A), was also present at the level of gene transcription. C4 led to a decrease in TNF-α, 
IL-12 and IL-23 mRNA levels upon H37Rv stimulation, and a parallel increase in IL-10 mRNA 
(Figure 5 A), while no effect on production of the anti-inflammatory cytokine IL-1Ra was 
observed (Supplementary Figure 5 B). These data point to IL-10 as a possible intermediary 
mediator of the anti-inflammatory effects of C4. We therefore assessed whether removing 
IL-10 protein from the cellular environment could counteract the inhibitory effects of C4. 
To this end, we pre-treated PBMCs with cycloheximide (CHX), an inhibitor of translation. 
Stimulation of PBMCs with H37Rv in the presence of C4 in combination with CHX resulted 
in higher TNF-α responses, as compared to incubation with H37Rv and C4 alone. Upon LPS 
stimulation, this effect was not present (Figure 5 B). We subsequently examined whether 
blocking IL-10 specifically using an anti-IL-10 antibody could counteract the inhibitory 
effects of C4 on pro-inflammatory cytokine response. Blocking IL-10 completely restored 
IL-6 cytokine responses in response to H37Rv and C4, while TNF-α and IL-1β production 
was partly restored (Figure 5 C). This suggests an important role for intermediary protein 
synthesis, specifically IL-10, in mediating the anti-inflammatory effects of C4.
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Figure 5 | Butyrate transcriptionally influences cytokine responses to Mtb, possibly mediated 
through IL-10. (A) Cytokine gene expression levels in PBMCs pre-incubated with 50 µM C4 for 1 
h prior to stimulation with Mtb lysate or LPS for 4 h, as measured by qPCR. The boxplot represents 
median with first and third quartiles; the whiskers represent minimum and maximum values. n 
= 6 to 10, Wilcoxon signed rank test, representative of 2+ independent experiments. * p < 0.05. 
(B) To block translation PBMCs were pre-incubated with cycloheximide (CHX) for 1 h, prior to 1 h 
incubation with C4 (50 µM). TNF-α transcript levels were measured by qPCR 4 h after stimulation 
with Mtb lysate or LPS. Data are single values (n = 6 to 7), Wilcoxon signed rank test, representative 
of 3 independent experiments. * p < 0.05. (C) To block IL-10 activity, PBMCs were pre-incubated 
with IL-10 and C4 (50 µM) for 1 h. IL-6, TNF-α, and IL-1β production was measured by ELISA after 24 
h of stimulation with Mtb lysate. Data are means ± SEM (n = 10 to 12), Wilcoxon signed rank test, 
representative of 4 independent experiments.
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DISCUSSION
Diabetes is associated with a three-fold increased risk of active TB, but the underlying 
immunological mechanisms remain largely unknown [3, 12, 13]. Alterations in the gut 
microbiota of DM patients are associated with changes in plasma SCFA concentrations. 
Multiple papers have reported a decrease in C4-producing bacteria in type 2 DM patients 
[18, 19, 21, 23, 24]. We here show that SCFAs, especially C4, exhibit anti-inflammatory 
properties; low doses of C4 decreased Mtb-induced pro-inflammatory cytokine responses 
both on the transcriptional and translational level, while production of IL-10 was increased. 
This anti-inflammatory effect was independent of HDAC activity, Toll-like receptor signalling, 
the eicosanoid pathway, or cellular metabolism.
We observed a general anti-inflammatory effect of C2, C3, and C4 on Mtb-induced 
cytokine production. C4 induced some of the most significant and most potent changes 
in cytokine responses, which is in line with published results [29], although our study is 
the first to examine the effects of physiological concentrations of SCFAs on Mtb-induced 
cytokine responses in vitro. Several observations were made regarding the effect of SCFA 
on cytokines. Firstly, the inhibitory effect of all three SCFAs on production of TNF-α and 
IL-1β was comparable for Mtb and LPS stimulation. However, while C3 and C4 had a clear 
effect on LPS-induced IL-6 release, this was not found for Mtb. This suggests that SCFAs do 
not affect Mtb-induced IL-6, although IL-6 has been assigned an important role in Mtb host 
responses [59-62]. Secondly, C2, C3, and C4 had a much stronger inhibitory effect on T-cell 
derived cytokine IL-17, than on T-cell derived cytokines IFN-γ and IL-22. Because C4 also 
strongly decreased Th17 proliferation (Supplementary Figure 5 A), SCFAs may affect Th17 
subsets more than other T-cell subsets. This may be of great relevance since Th17 cells, 
and IL-17 in particular, have been reported to be essential in protective immunity against 
Mtb [63, 64], but inversely associated with DM complications [65-67]. Lastly, the stimulatory 
effect of C3 and C4 on anti-inflammatory IL-10 release was Mtb-specific and not seen with 
LPS-stimulation. IL-10 has been delineated as an important mediator in Mtb infection: 
it has been reported to block bacterial killing in Mtb-infected macrophages, suppress 
multinucleated giant cell formation and cytokine production, and inhibit the development 
of protective immunity [68-74]. In contrast to TB, IL-10 may have a protective role in type 
2 DM, by reducing insulin resistance and obesity [75-77]. Therefore, the increase in IL-10 
production we see as induced by C4 is very relevant for the course of both DM and TB 
disease.
We examined several possible mechanisms underlying the effect of C4 on cytokine 
production, starting with HDAC activity, which is known to be inhibited by SCFAs. C4 at 
a physiological low dose of 50 µM had little effect, while millimolar concentrations of C4 
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(as used in other studies [36, 41-44]) decreased HDAC activity upon H37Rv stimulation. 
This is expected as the IC50 values of HDAC inhibition by C4 are > 100 µM, depending on 
the class of HDAC [43]. The strongest effect was noted for HDAC8, which is reported to 
be most sensitive to C4 [43]. This argues that physiological C4 concentrations in human 
plasma do not exert HDAC inhibition, and underlines the importance of using physiological 
concentrations within in vitro experimental models.
In contrast to a previous study [50], we observed a decreased gene expression of the TLR-
modulatory factors SOCS1 and Tollip when PBMCs were stimulated in the presence of C4, 
which thus cannot explain the inhibitory effects on cytokine production. This, together with 
our data showing that C4 does not affect MAP kinase activity, suggests that C4 does not act 
at the level of TLR signalling, as shown previously [36].
As a third possible mechanism, we assessed whether C4 exerts its effects through eicosanoid 
metabolism. The eicosanoid pathway is under influence of SCFAs [30, 56] and may modulate 
the host response to Mtb [51-55]. C4 did not affect expression of COX-2, a key enzyme in 
the eicosanoid pathway, in contrast to previous reports that used supraphysiological C4 
concentrations [30, 56]. In addition, inhibition of the eicosanoid pathway using aspirin 
did not counteract the effects of C4. Therefore, the eicosanoid pathway is unlikely to be 
involved in mediating the effects of C4. 
The effect of diabetes on the host immune response to Mtb might also be explained by 
altered cellular metabolism, with a possible role for SCFA. Cellular metabolism is increasingly 
linked to immunology [78-80]. One previous study noted that C4 influences metabolic 
processes in colonocytes [58], which use butyrate as their primary energy source [58]. 
However, we did not observe any effect of C4 on lactate production, the redox status, 
TCA cycle gene expression, or β-oxidation in PBMCs. We therefore conclude that cellular 
metabolism does not mediate the effect of C4 on Mtb-induced cytokine production.
Finally, we further examined the effect of C4 on the anti-inflammatory cytokine IL-10. IL-
10 is detrimental to TB outcome, while it may improve DM symptoms [68-77]. In line with 
previous studies [33, 81, 82], we report an up-regulation in IL-10 production induced by C4. 
Removal of all intermediary protein, including IL-10, from PBMCs stimulated with H37Rv 
and C4 led to a significant increase in TNF-α transcript, thereby counteracting the decrease 
in TNF-α production induced by C4. Moreover, blocking IL-10 specifically fully restored IL-6 
responses in PBMCs stimulated with H37Rv and C4, and partly restored TNF-α and IL-1β 
responses. These data suggest that the anti-inflammatory cytokine IL-10 may play a role in 
the inhibitory effects of C4 on Mtb-induced inflammatory responses.
14997-lachmandas-layout.indd   87 12/10/2017   12:17
88
Chapter 4
Currently, much research is focuses on modulation of the gut microbiota in order to treat 
obesity and type 2 DM [83-86]. Administration of sodium butyrate or butyrate-inducing 
probiotics in mice significantly increased plasma insulin levels and insulin sensitivity and 
suppressed body weight gain [87-89]. The anti-inflammatory effects of C4 may attenuate the 
chronic inflammatory state associated with type 2 DM, thereby improving DM symptoms. If 
chronic inflammation is a causal factor of the impaired host response to Mtb in type 2 DM 
patients, attenuation of this hyper-inflammatory state may not only improve DM but also TB 
outcome in patients with coincident DM and TB disease. 
Some limitations of our study need to be addressed. Firstly, we studied the effects of 
C4 on Mtb-induced inflammation in PBMCs in vitro. SCFA levels have been shown to be 
altered in DM patients [18-22], but this in vitro model does not include other aspects of 
the pathophysiology of DM such as hyperglycemia, hyperinsulinemia, or dyslipidemia, 
phenomena which have also been reported to affect immunity [90-94]. Furthermore, DM 
medications possibly interfere with the intestinal microbiota and immune responses in 
patients [95-97]. It is therefore unclear how accurately our in vitro model reflects the in vivo 
situation in DM patients. 
In conclusion, we show an anti-inflammatory effect of low, physiological doses of C4 on 
Mtb-induced inflammatory responses. The anti-inflammatory cytokine IL-10 may play a role 
in mediating the inhibitory effects of C4 on the host immune response to Mtb. Further 
studies are needed to precisely explore the pathways by which physiological concentrations 
of C4 exert their anti-inflammatory effects, and to define the mechanism of increased TB 
sensitivity in type 2 DM patients. Moreover, current research on modulating gut microbiota 
in DM should include its possible effects on TB.
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Supplementary Figure 1
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B
Supplementary Figure 1 | Effect of SCFAs, CHX, and aspirin on pH and cell death. (A) PBMCs 
were incubated with 2-250 µM SCFAs, immediately after which pH levels of culture medium were 
measured (n = 1).  (B) PBMCs were pre-incubated with cycloheximide (CHX) or aspirin for 1 h, prior 
to 1 h incubation with C4 (50 µM). After 24 h stimulation with Mtb lysate or LPS cells were harvested 
and stained with Annexin-V / PI-stain to determine levels of cell death. Data are % means ± SEM (n 
= 3 to 5), representative of 1-2 independent experiments.
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Supplementary Figure 2
P-JNK
Supplementary Figure 2 | PBMCs were pre-incubated with 50 µM C4 (1 h) and stimulated with 
Mtb lysate or LPS. Cell lysates were harvested at 30 min post stimulation. Phospho-JNK protein 
levels were determined by western blot using specific antibody (n = 2).
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Supplementary Figure 3 | Influence of butyrate on the eicosanoid pathway. (A) COX-2 
expression levels in PBMCs pre-incubated with 50 µM C4 for 1 h prior to stimulation with Mtb 
lysate or LPS for 4 h, as measured by qPCR. Data are single values (n = 10), Wilcoxon signed rank 
test, representative of 3 independent experiments. (B) To inhibit PGE2, PBMCs were pre-incubated 
with aspirin for 1 h, prior to 1 h incubation with C4 (50 µM). TNF-α and IL-1β transcript levels were 
measured by qPCR 4 h after stimulation with Mtb lysate or LPS. Data are means ± SEM (n = 3), 
Wilcoxon signed rank test, representative of 1 experiment. 
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Supplementary Figure 4
Supplementary Figure 4 | Butyrate modulates the immune response to Mtb independently 
of β-oxidation. PBMCs were pre-incubated with Etomoxir, Ranolazine, Trimetazidine, or Pertussis 
toxin for 1 h prior to incubation with 50 µM C4 (1 h). After 24 h stimulation with Mtb lysate TNF-α 
and IL-1β cytokine levels were measured in supernatants by ELISA. Data are means ± SEM (n = 3), 
Wilcoxon signed rank test, representative of 1 experiment.
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Supplementary Figure 5 | Butyrate modulates Mtb-induced cytokine responses. (A) PBMCs 
were pre-incubated with 50 µM C4 for 1 h prior to stimulation with Mtb lysate or LPS. After 7 days 
cells were re-stimulated and stained extracellularly for CD4 (CD4-PeCys7) and intracellularly for IL-17 
and IL-22 (IL-17-AlexaFluor, IL-22-PE). Data are % means ± SEM (n = 8), Wilcoxon signed rank test, 
representative of 3 independent experiments. ** p < 0.01 (B) Cytokine levels of IL-1Ra in PBMCs pre-
incubated with 50 µM C4 (1 h) and stimulated with Mtb lysate or LPS (24 h) as measured by ELISA. 
The boxplot represents median with first and third quartiles; the whiskers represent minimum and 
maximum values. n = 11, Wilcoxon signed rank test, representative of 4 independent experiments. 
* p < 0.05
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ABSTRACT
Cells in homeostasis metabolise glucose mainly through the tri-carboxylic acid (TCA) cycle 
and oxidative phosphorylation (OXPHOS), whilst activated cells switch their basal metabolism 
to aerobic glycolysis. In thus study, we examined whether metabolic reprogramming 
towards aerobic glycolysis is important for the host response to Mycobacterium tuberculosis 
(Mtb). Through transcriptional and metabolite analysis we show that Mtb induces a 
switch in host cellular metabolism towards aerobic glycolysis in human peripheral 
blood mononuclear cells (PBMCs). The metabolic switch is TLR2-dependent but NOD2-
independent, and is mediated in part through activation of the AKT-mTOR pathway. We 
show that pharmacological inhibition of the AKT/mTOR pathway inhibits cellular responses 
to Mtb both in vitro in human peripheral blood mononuclear cells, and in vivo in a model of 
murine tuberculosis. Our findings reveal a novel regulatory layer of host responses to Mtb 
which will aid understanding of host susceptibility to Mtb, and which may be exploited for 
host-directed therapy. 
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M. tuberculosis induces glycolysis
INTRODUCTION
In the absence of HIV co-infection, it is mostly unknown what determines susceptibility to 
Mycobacterium tuberculosis (Mtb), which accounts for almost two million deaths annually. 
Recent studies suggest that immune activation and cellular energy metabolism may be 
relevant since changes in metabolism profoundly influence cell fate and effector functions. 
For example, it has been shown that changes in glucose metabolism influence T-cell 
lineage polarisation, innate and adaptive cellular memory and even protein transport and 
secretion in response to cellular activation [1-4]. Naïve and tolerant cells appear to primarily 
rely on the tri-carboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) for 
metabolising glucose and generating stores of ATP necessary for cell survival and function. 
Upon activation however, a switch towards aerobic glycolysis rewires intracellular glucose 
metabolism [5]. This permits a significant increase in ATP production and, through the 
pentose phosphate pathway, provides the nucleotides necessary for cell proliferation [6]. 
Recent studies by Shi et al. and Gleeson et al. have shown that a shift towards glycolysis is 
an important component of host defence in murine models of tuberculosis [7, 8]. Taking 
these studies further, we have investigated which cells, receptors and regulators promote 
the Mtb-induced switch to glycolysis in humans. We have tested our hypotheses both in in 
vitro and in vivo experimental models and verified if such metabolic reprogramming also 
occurs in patients with active pulmonary TB. 
14997-lachmandas-layout.indd   103 12/10/2017   12:17
104
Chapter 5
MATERIALS AND METHODS
Healthy Volunteers
Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA tubes or buffy coats 
obtained after informed consent of healthy volunteers (Sanquin Bloodbank, Nijmegen, 
Netherlands). As donations were anonymous, no tuberculosis skin tests or IFN-γ release 
assay was performed. The incidence of tuberculosis in the Dutch population is extremely 
low (1.5/100,000), and Bacillus Calmette-Guérin (BCG) vaccination is not part of the routine 
vaccination program. Experiments were conducted according to the principles expressed 
in the Declaration of Helsinki.
Isolation of PBMCs, CD14+ Monocytes and CD3+ T cells
Isolation of PBMCs was performed as described previously [32]. CD14+ monocytes or CD3+ T 
cells were purified from freshly isolated PBMCs using MACS microbeads by positive selection 
according to the manufacturer’s instructions (Miltenyi Biotec, Germany).
Stimulation Experiments
For stimulation experiments, 5x106 PBMCs/mL or 1×106 monocytes/mL were stimulated 
with RPMI, 1 μg/mL Mycobacterium tuberculosis strain H37Rv (Mtb) lysate, 10 μg/mL Pam3Cys 
(EMC Microcollections, Germany) and/or 10 μg/mL muramyl dipeptide (MDP; Sigma) in the 
presence or absence of 1 nM or 10 nM rapamycin (LC-laboratories), 100 nM Torin (Tocris), 50 
μM or 500 μM sodium L-ascorbate (Sigma), 50 μM or 500 μM AICAR (Brunschwig chemie), 
100 nM wortmannin (Cayla Invivogen), or 20 ng/mL or 100 ng/mL of TLR4 inhibitory ligand 
double-extracted Bartonella quintana LPS for 24 h or with 10% pooled human serum for 7 
d. PBMCs from patients with the homozygous carriage of a frameshift in Nod2 due to an 
insertion of cysteine at position 1007 (1007finsC) (rs2066847) were stimulated with RPMI, 
MDP or Mtb for 1 or 7 d. Culture supernatants were collected and stored at −20°C. For 
Western blots, 5x106 PBMCs were stimulated with RPMI, 1 μg/mL Mtb lysate or 50 ng/mL GM-
CSF in the presence or absence of the aforementioned inhibitors. Cytokine measurements 
from cell culture supernatants were performed by ELISA namely interleukin (IL)-1β, tumour 
necrosis factor (TNF)-α, IL-17A, IL-22 (R&D Systems, Minneapolis, MN); and IL-6, interferon 
gamma (IFN-γ) and IL-10 (Sanquin, Amsterdam, Netherlands) were measured.
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Animal Experiments
TLR2 knockout mice were kindly provided by Prof S. Akira (Department of Host Defense, 
Research Institute for Microbial Diseases, Osaka University, Osaka, Japan) and were fully 
backcrossed to the C57BL/6 background. Age- and sex-matched control C57BL/6 mice 
were obtained from Charles River Wiga (Sulzfeld, Germany). 
Wild-type, NOD1, NOD2 and NOD1/NOD2 double knockout mice were bred and maintained 
in the St. Jude Children’s Research Hospital (Memphis, Tennessee). After dissection of mouse 
legs, the bone marrow was flushed out using sterile PBS and cells obtained were differentiated 
over a period of 7 d at 37°C, 5% CO
2
 in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, 
Invitrogen, Carlsbad, CA, USA) supplemented with 30% L929 medium, 10% heat-inactivated 
filtered foetal bovine serum (Invitrogen, Carlsbad, CA, USA), 1% nonessential amino acids 
(Life Technologies), 100 U/mL penicillin and 100 mg/mL streptomycin. On day 6 BMDMs 
were washed, counted and seeded in 96-well plates at a concentration of 1×105 cells/well 
or in 6-well plates at 1×106 cells/well for Western blotting. Cells were left to rest overnight 
at 37°C, after which they were stimulated with medium, namely 10 µg/mL Pam3Cys, 1 µg/
mL Mtb or 100 nM insulin. Experiments were approved by the Ethics Committee on Animal 
Experimentation of the Radboud University Medical Center and protocols were approved 
by the St. Jude Children’s Research Hospital Committee on the Use and Care of Animals.
Female 8- to 10-week-old C57BL/6 mice were kept under pathogen-free conditions at the 
Max Planck Institute for Infection Biology in Berlin, Germany (ethical approval of the Berlin 
Office for Health and Social Affairs reference number G 0179/12). Mtb strain H37Rv was 
grown in Middlebrook 7H9 broth (BD Biosciences) supplemented with 0.2% glycerol, 0.05% 
Tween 80 and 10% ADC enrichment (BD Biosciences) until it reached a mid-logarithmic 
growth phase and then stored at –80°C. Animals were aerosol-infected with 200 CFUs using 
a Glas-Col inhalation exposure system. Rapamycin (Sigma) or vehicle (PBS/100% EtOH) was 
injected the day before aerosol infection and thereafter daily for 28 days. Splenocytes were 
isolated from single-cell suspensions prepared by mechanical dissociation through a 70-µm 
nylon mesh in RPMI 1640 medium with 10% foetal calf serum (Gibco). Splenocytes were 
seeded in a 24-well-plate at a concentration of 2.5×106 cells /mL and stimulated with 1 mg/
mL of Mtb lysate, 1 mg/mL of PPD (Staten Serum Institut, Copenhagen), 10 mg/mL PHA 
(Sigma) or 10 ng/mL of LPS (from E. coli 055:B5,Sigma). After 6 d supernatants were collected 
and stored at –20°C. Cytokines were analysed using a bead-based assay (Bio-Rad).
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Metabolite Measurements
Lactate was measured from cell culture supernatants using a coupled enzymatic assay in 
which lactate was oxidised and the resulting H
2
O
2
 was coupled to the conversion of Amplex® 
Red reagent to fluorescent resorufin by HRP (horseradish peroxidase) [33]. Measurement of 
the NAD+/NADH redox ratio was adapted from Zhu et al [34]. Glucose consumption was 
measured according to the manufacturer’s instructions using the Amplex® Red Glucose/
Glucose Oxidase Assay Kit (Life Technologies). 
Real-time analysis of the extracellular acidification rate (ECAR) and the oxygen consumption 
rate (OCR) on CD14+ monocytes was performed using an XF-96 Extracellular Flux Analyzer 
(Seahorse Bioscience). Briefly, monocytes were plated in XF-96 cell culture plates (2 × 105 
monocytes/well) in the presence of RPMI or Mtb lysate for 24 h in 10% human pooled 
serum. The monocytes were washed and analysed in XF Base Medium (unbuffered DMEM 
with 25mM glucose and 2 mM L-glutamine, pH was adjusted to 7.4). Basal OCR and ECAR of 
the monocytes was measured every 5 min for 20 min in total.
Cell Viability Assessment
The percentage of cells that underwent early or late apoptosis was determined by labelling 
with annexin V–fluorescein isothiocyanate (FITC, Biovision) and staining with propidium 
iodide (PI, Sigma Aldrich), according to the manufacturer’s instructions. Briefly, stimulated 
PBMCs were re-suspended in 200 μL of RPMI and incubated on ice in the dark with 1 μL of 
Annexin V-FITC for 15 min followed by a 5 min incubation with 1.5 μL of PI. The relative level of 
apoptotic cells was detected by flow cytometry within 1 h, using a FC500 flow cytometer 
(Beckman Coulter) and data were analysed using Kaluza 1.3 software (Beckman Coulter). 
Western Blotting 
Western blotting was carried out using a Trans Turbo Blot system (Bio-Rad) according 
to the manufacturer’s instructions. 5x106 PBMCs or 1 x 106 CD14+ monocytes or 1 x 106 
CD3+ T cells were lysed in 100 μL lysis buffer. The cell homogenate was frozen, thawed 
and processed for Western blot analysis. Equal amounts of protein were resolved by SDS-
PAGE on 4-15% polyacrylamide gels (Bio-Rad). Separated proteins were transferred to PVDF 
(Bio-Rad) membranes. According to the manufacturer’s instructions, the membrane was 
blocked for 1 h and then incubated overnight with a primary antibody at a dilution of 
1:1000 in 5% (w/v) bovine serum albumin (BSA, Sigma) or milk in TBS-Tween buffer (TBS-T). 
After overnight incubation, blots were washed in TBS-T 3 times and incubated with HRP-
conjugated anti-rabbit antibody (1:5000; Sigma) in 5% (w/v) milk in TBS-T for 1 h at RT. After 
washing the blots were developed with ECL (Bio-Rad) according to the manufacturer’s 
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instructions.  The primary antibodies used were rabbit anti-actin (Sigma), mAB phospho-p70 
S6 Kinase (Thr389) (Cell Signalling), phospho-AKT (Cell Signalling), and phospho-4EBP1 (Cell 
Signalling). 
Transcriptome Analyses 
We obtained previously published transcriptome data for our analysis (GSE42606)  [35] Briefly, 
PBMCs were stimulated with RPMI or Mtb (1μg/mL) for 24 h at 37°C and 5% CO
2
. Total RNA 
was extracted in 800 μL of TRIzol reagent (Invitrogen). Global gene expression was profiled 
using an Illumina Human HT-12 Expression BeadChip according to the manufacturer’s 
instructions. Image analysis, bead-level processing and quantile normalisation of array data 
were performed using the Illumina LIMS platform, BeadStudio. The quantile normalised 
expression data for glycolysis and TCA cycle genes (derived from KEGG pathway) were 
extracted to perform differential expression analysis between RPMI and Mtb stimulations. 
Human Gene Expression Analysis 
Publicly available micro-array data (Illumina Human HT-12 V3 BeadChip) from cohorts of 
patients with active and latent tuberculosis and uninfected controls in the UK and South-
Africa [9]) were obtained from the Gene Expression Omnibus (GEO) under accession 
number GSE19491. We restricted our analysis to the expression data form whole blood 
(collected in Tempus tubes, Applied Biosystems) from the UK test cohort and the South-
African validation cohort. Genes implicated in glycolysis (path:hsa00010) and TCA cycle 
(path:hsa00020) pathways were extracted from KEGG, putative genes were removed and 
the remaining genes were converted into Illumina probe numbers using DAVID [36, 37]. 
Probes that had a negative expression for one of the samples were excluded.
Statistical Analysis
Principal component analysis (PCA) was performed on log-transformed data using singular 
value decomposition separately for the glycolysis and TCA cycle pathways in Python. Scores 
of the samples projected on principal component (PC) 1 for glycolysis were plotted against 
the scores on PC1 for the TCA cycle, to show the maximum combined variance of both 
pathways in one graph. Additionally, binary regression analysis was performed on the 
scores projected on PC1 for both pathways with LTBI (0) versus PTB (1) for the South-African 
cohort in SPSS 21.
The heat-maps show differences in expression based on log
2
 transformed data from the 
different groups. Statistical testing of the in vitro data set was performed on the mean 
expression between the unstimulated (RPMI) and stimulated (Mtb) samples using a Wilcoxon 
signed-rank test for parametric data; adjusted p-values less than 0.05 were considered 
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significant. LTBI versus PTB patients were compared using Mann-Whitney U tests. Colour 
coding was based on the minimum and maximum for each of the comparisons. In the 
legend, changes were transformed back for interpretability. Genes that showed a differential 
expression in any of the datasets are presented in the figure.
Differences in cytokine production were analysed using the Wilcoxon signed-rank test for 
non-parametric distributions. Data were considered statistically significant at a p-value < 
0.05. Data are shown as cumulative results of levels obtained in all volunteers (means ± 
SEM). 
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RESULTS
Transcriptome analysis of whole blood from patients with pulmonary TB and human 
PBMCs stimulated with Mtb reveals a shift towards glycolysis.  Based on expression of 
genes coding for glycolysis or TCA cycle pathways, pulmonary TB patients (PTB) could be 
clearly separated from individuals with latent tuberculosis infection (LTBI) or healthy controls 
(CON) using principal component analysis (PCA) of publically sourced human expression 
data [9] (Figure 1A and 1B). Regression analysis on the first component of both groups 
showed that both pathways were significantly different between LTBI and PTB (p < 0.001 for 
both) groups. Individuals on anti-tuberculosis treatment were spread throughout the plot 
with untreated cases closer to PTB and those on 12 months of treatment interspersed with 
the LTBI and CON groups. Analysis of individual genes in the PTB versus CON groups clearly 
showed an up-regulation of glycolysis genes glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and hexokinase-3 (HK3) (Figure 1C and 1D), which returned towards normal 
following treatment. The opposite was observed for the TCA cycle gene isocitrate 
dehydrogenase 3 (NAD+) beta (IDHB3B) (Figure 1E).   
We next examined expression of similar metabolic genes in an in vitro model. Similar to 
the in vivo dataset described above, Mtb-stimulated PBMCs also displayed a strong up-
regulation of some genes involved in glycolysis and down-regulation of some involved in 
the TCA cycle (Figure 1F).
Based on the in vitro and in vivo data analyses, an intracellular map was generated to reflect 
the switch to aerobic glycolysis induced upon Mtb stimulation (Figure 1J). The general 
metabolic shift is further supported by altered expression of individual genes. SLC16A3 
(solute carrier family 16 monocarboxylate transport MCT, member 3), which encodes a 
lactate transporter, was significantly upregulated in PTB patients and returned to normal 
levels upon treatment (Supporting Information Figure 1A). Conversely, sirtuin 5 (SIRT5), 
a protein whose activity is directly linked to the energy status of the cell via the cellular 
NAD+/NADH ratio, was down-regulated in PTB patients and normalised upon treatment 
(Supporting Information Figure 1B).
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Figure 1 | Transcriptional regulation of glucose metabolism during active TB disease and in PBMCs 
stimulated with Mtb. (A, B) Principal component analysis (PCA) of the glycolysis and TCA cycle whole 
blood gene signatures of microarray data from publically available cohorts from (A) the United Kingdom 
(UK) and (B) South Africa (SA), previously published by Berry et al (Series GSE19444) [9]. Data for each 
sample, including active pulmonary TB (PTB), LTBI (TST-positive) and CON (TST-negative) individuals were 
plotted along PC1 for glycolysis versus PC1 for the TCA cycle. For the UK cohort, PC1 accounted for 37% of 
the total variation for both glycolysis and the TCA cycle. For the South African cohort PC1 accounted for 
44% and 34% of the variance for glycolysis and the TCA cycle respectively. (C-E) Individual and mean whole 
blood gene expression for (C) GAPDH, (D) HK3 and (E) IDH3B in controls and PTB patients on 0 m, 2 m or 
12 m of TB treatment (Series GSE19435). Microarray data derived from Berry et al [9]. Symbols represent 
individual samples and data are shown as means ± SEM; means were compared using the Mann-Whitney 
U test. *p<0.05, **p<0.01, ***p<0.001. (F) Heatmap of gene expression pattern of glycolysis or TCA cycle 
genes in in vitro-stimulated PBMCs and in vivo whole blood (UK and SA publically available cohorts). All 
data was log-2 transformed. The in vitro Mtb stimulations were normalised to RPMI by subtracting means 
whereas the in vivo PTB cohort was normalised to the corresponding LTBI cohort. P-values were considered 
significant when less than 0.05 as determined by the Wilcoxon signed-rank test for the in vitro data set 
and by the Mann-Whitney U test for the in vivo data sets. Red represents a significant up regulation, blue a 
significant down regulation and grey no difference. (G) Schematic representation of up-regulated (in red) 
and down-regulated (blue) genes in the glycolysis and TCA cycle pathways as determined by microarray 
analysis of Mtb-stimulated PBMCs. 
Mtb drives cellular commitment to aerobic glycolysis in human monocytes and 
macrophages. Monocytes, macrophages, dendritic cells, T helper (T
H
)1 and T
H
17 cells 
use glucose as a substrate for energy production [10]. To determine the commitment to 
glycolytic metabolism in stimulated monocytes, we analysed the extracellular acidification 
rate (ECAR) as an indicator of the glycolytic rate 24 h post-stimulation. There was a 
significant increase in all three baseline measurements and ECAR levels were approximately 
3.3 fold higher in Mtb stimulated cells (Figure 2A). This increase in ECAR was responsible 
for a decrease in the OCR/ECAR ratio, as previously described for LPS [11] (Supporting 
Information Figure 2A), despite a slightly higher oxygen consumption rate (OCR) (Figure 
2B). Similarly, macrophages infected with live Mtb or stimulated with Mtb lysate produced 
increased levels of lactate, one of the hallmarks of glycolysis (Figure 2C). Additionally, PBMCs 
challenged with Mtb showed increased glucose consumption (Figure 2D) and lactate 
production (Figure 2E). Generation of lactate requires the oxidation of NADH to co-factor 
NAD+ by lactate dehydrogenase. Accordingly, we observed a significant increase in the ratio 
of NAD+/NADH in Mtb stimulated PBMCs (Figure 2F). Conversely, resting PBMCs displayed a 
lower NAD+/NADH ratio reflecting cellular metabolism mostly via the TCA cycle rather than 
glycolysis (Figure 2F).
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Figure 2 | Physiology of the PBMC metabolic response to Mtb stimulation. (A, B) CD14+ 
monocytes were stimulated for 24 h with Mtb and (A) ECAR and (B) OCR rates were determined 
using the Seahorse metabolic analyser. Three baseline measurements were determined. Data are 
shown as means ± SEM (n = 7). (C) Lactate production from macrophages stimulated with live 
H37Rv (10:1 MOI) was measured by a fluorescent coupled enzymatic assay. Data are shown as 
means ± SEM of n = 4, pooled from two independent experiments. (D-F) PBMCs were stimulated 
with Mtb lysate and the kinetics of (D) glucose consumption, (E) lactate production and (F) the 
intracellular NAD+/NADH ratios from days 1, 3 and 7 was measured by metabolite specific coupled 
enzymatic assays. Data are shown as means ± SEM of n = 6 to 8, pooled from three independent 
experiments. Means were compared using the Wilcoxon signed-rank test, *p<0.05). 
Mtb activates AKT and mTOR in human PBMCs. As mammalian target of rapamycin 
(mTOR) is the master regulator of cell growth, proliferation and metabolism, [12] and AKT-
mediated mTOR activation induces glucose metabolism, [13, 14] we assessed whether Mtb 
activated the AKT-mTOR pathway (Figure 3A). Indeed, sensing of the microorganism induced 
AKT activation, which was inhibited by the phosphatidylinositol-3 kinase (PI-3K) inhibitor 
wortmannin (Figure 3B). In addition, p70-S6K and 4E-BP1, two canonical downstream 
targets of mTOR, were activated upon Mtb stimulation. Purification of CD14+ monocytes 
and CD3+ T cells from stimulated PBMCs revealed that Mtb induced mTOR activation in 
monocytes but not T-cells (Figure 3C). 
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Figure 3 | Induction of glycolysis in human PBMCs is mediated by the AKT-mTOR Pathway. 
(A-D) PBMCs were stimulated with RPMI or Mtb in a time-dependent manner in the presence 
or absence of DMSO (vehicle control), wortmannin (PI3K/AKT inhibitor) or rapamycin (mTOR 
inhibitor). (C) CD14+ and CD3+ T cells were separated from PBMCs stimulated for 2 h with Mtb. 
Where indicated, GM-CSF stimulation was included as a positive control. (A, B) AKT, (C, D) p70-
S6K and 4E-BP1 phosphorylation and actin levels were determined by western blot using specific 
antibodies. (A, B) Cell lysates were harvested at 15, 30, 60 and 120 min post-stimulation. (C, D) Cell 
lysates were harvested at 30, 60, 120 and 240 min post-stimulation.  Representative blots from two 
of four donors are shown. (E-G) PBMCs were pre-incubated with 10 nM rapamycin, 100 nM torin or 
100 nM wortmannin for 1 h prior to stimulation with Mtb lysate. Data are shown as means ± SEM 
of n = 9, pooled from three independent experiments. Means were compared using the Wilcoxon 
signed-rank test (*p<0.05, **p<0.01). 
Activation of these mTOR targets was inhibited by rapamycin, an mTOR inhibitor, in both 
PBMCs (Figure 3D) and CD14+ monocytes (Supporting Information Figure 3A). 
Additionally, rapamycin, torin and wortmannin significantly decreased lactate release 
induced by Mtb, further demonstrating the involvement of the mTOR/AKT pathway in 
induction of glycolysis by Mtb (Figures 3E, 3F and 3G).
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Figure 4 | mTOR regulation of Mtb-induced T-cell cytokine responses. (A-D) PBMCs were pre-
incubated with DMSO (vehicle control) or (A) 1 mM or 5 mM 2DG, (B) 1 nM or 10 nM rapamycin, 100 
nM torin, (C) 500 μM AICAR or (D) 50 μM or 500 μM ascorbate or for 1 h prior to stimulation with 
Mtb lysate. IL-17, IFN-γ and IL-22 levels were measured from culture supernatants by ELISA.  Data 
are shown as means ± SEM of n = 6 to 9 pooled from three independent experiments. Means were 
compared using the Wilcoxon signed-rank test (*p<0.05, **p<0.01).
mTOR regulates TH cell-derived cytokines from PBMCs in response to Mtb. 
T-lymphocytes form a crucial component of the host defence against Mtb. Direct inhibition 
of glycolysis by 2-deoxy-glucose (2DG) led to a dose-dependent decrease in the production 
of the T
H
 cytokines IFN-γ, IL-17 and IL-22 from PBMCs in response to Mtb (Figure 4A). Direct 
inhibition of mTOR by rapamycin or torin or indirectly by AICAR (an AMPK activator; Figures 
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4B and 4C), and inhibition of mTOR-dependent HIF-1α activation by ascorbate also resulted 
in reduced T
H
-derived cytokine production (Figure 4D). IL-10 production in response to Mtb 
was also significantly inhibited upon mTOR inhibition (Supporting Information Figures 4A, 
4B and 4D). Production of monocyte-derived TNF-α, IL-6 and IL-1β was mostly reduced 
upon inhibition of glycolysis with 2DG (Supporting Information Figure 4A). Interestingly, 
production of monocyte-derived cytokines remained mostly unchanged in the presence 
of rapamycin, torin and ascorbate (Supporting Information Figures 4B, 4C and 4D). These 
inhibitors did not affect cell survival at the time points used for the stimulation experiments 
(Supporting Information Figures 5A, 5B, 5C, 5D and 5E).
Induction of glycolysis by Mtb is TLR2-dependent but NOD2-independent 
We next examined which of the main pattern recognition receptors (PRRs) that mediate 
recognition of Mtb, [15] are necessary for a metabolic switch towards aerobic glycolysis. 
PBMCs isolated from patients with a complete deficiency in NOD2 showed decreased 
cytokine production in response to Mtb (Figure 5A), but no decrease in lactate production 
(Figure 5B). In addition, bone marrow-derived macrophages (BMDMs) from NOD2 knockout 
(NOD2-/-) and NOD1/NOD2 double knockout (NOD1-/-/NOD2-/-) mice stimulated with Mtb 
showed decreased KC and IL-6 production. However, as with the NOD2 deficient patients, 
no change in lactate production was observed and no major differences were apparent 
after stimulation of BMDMs from NOD1 knockout (NOD1-/-) mice either (Figure 5C and 5D). 
We then examined possible synergy with regard to lactate production between NOD2 
and the TLRs involved in recognition of Mtb. As expected, cytokine production of PBMCs 
stimulated with LPS (TLR4 ligand), Pam3Cys (P3C, TLR2 ligand) or Mtb increased in the 
presence of muramyl dipeptide (MDP, an NOD2 ligand), whilst MDP by itself did not induce 
cytokine production (Figures 6A and 6B). On the other hand, MDP showed no synergistic 
effect for lactate production upon stimulation with the various other TLR ligands (Figure 
6C). 
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Figure 5 | Role of NOD2 in the induction of glycolysis. (A, B) PBMCs from NOD2-deficient patients 
(n=2) and healthy volunteers (n=4) were stimulated with RPMI, MDP and Mtb for 24 h and 7 d. The 
levels of (A) indicated cytokines or (B) lactate production were measured from culture supernatants 
by ELISA and an enzymatic couple assay respectively.  Data are shown as means ± SEM of the 
indicated number of donor samples and are from a single experiment. (C, D) Bone marrow-derived 
macrophages (BMDMs) from wild type (WT), NOD1 knockout (-/-), NOD2 knockout (-/-) and NOD 
1/2 double knockout (-/-) mice were stimulated with RPMI or 1 μg/mL Mtb lysate for 24 h (n=2). The 
levels of (C) IL-6 and KC and (D) lactate production were measured as described above.  Data are 
shown as means ± SEM of n = 2 from a single experiment. 
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To investigate the role of TLR4 in the induction of aerobic glycolysis by Mtb, we blocked 
TLR4 by pre-incubation of PBMCs with Bartonella quintana LPS, a potent natural antagonist 
of TLR4 (Popa et al., 2007), before stimulating with Mtb or E. coli LPS. Although a potent 
decrease in IL-6 and lactate levels was observed for LPS, indicating effective blocking of 
TLR4, no effect of the TLR4 blockade on Mtb-induced lactate was seen (Figures 6D and 6E). 
To investigate the role of TLR2, we stimulated BMDMs and peritoneal macrophages from 
TLR2 knockout (TLR2-/-) mice with Mtb and Pam3Cys. Production of KC (IL-8) and lactate 
was potently decreased in TLR2-/- BMDMs compared to wild-type controls (Figures 6F, 
6G and 6H). In addition, stimulation of cells isolated from TLR2-/- mice with Mtb led to a 
decrease in AKT activation compared to controls, whilst the induction of AKT with insulin, 
in a TLR independent manner, was unaffected (Figure 6I). Collectively, these data implicate 
TLR2, and not TLR4 or NOD2, as the major pattern recognition receptor that induces AKT/
mTOR pathway activation and thus mediates the switch to aerobic glycolysis upon Mtb 
stimulation.
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Figure 6 | Stimulation via TLR2 initiates rewiring of cellular metabolism in mouse 
macrophages.  (A-C) PBMCs from healthy volunteers (n=6) were stimulated with RPMI, MDP +/- 
LPS, Pam3Cys (P3C) or Mtb lysate for 24 h. The levels of (A) IL-1β, (B) IL-6 and (C) lactate in cell 
culture supernatants were measured as described above.  Data are shown as means ± SEM of n = 
6 pooled from 2 experiments. Means were compared using the Wilcoxon signed-rank (*p<0.05). (D, 
E) PBMCs were pre-incubated with TLR4 antagonist Bartonella quintana LPS (20 and 100 ng/mL) 
prior to stimulation with RPMI, Mtb lysate or LPS. The levels of (D) IL-6 production and (E) lactate in 
culture supernatants were determined by ELISA and a coupled enzymatic assay respectively. Data 
are shown as means ± SEM of n = 6 to 8 pooled from three experiments. Means were compared 
using the Wilcoxon signed-rank test (*p<0.05). (F-H) BMDMs and peritoneal macrophages (Mfs) 
from TLR2 knockout (TLR2-/-) mice were stimulated with RPMI, P3C (positive control) and Mtb lysate. 
The levels of (F) KC (IL-8) and (G, H) lactate in culture supernatants were measured by ELISA and a 
coupled enzymatic assay. Data are shown as means ± SEM of n =3-6 pooled from two experiments. 
Means were compared using the Wilcoxon signed-rank test. (I) Levels of AKT activation from TLR2-
/- BMDMs stimulated with RPMI, insulin (control; INS) and Mtb lysate (Mtb) was determined by 
western blot. Actin was used as loading control. One of two representative blots is shown.
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mTOR inhibition in an in vivo murine experimental model of TB
We then examined the in vivo effects of mTOR inhibition on Mtb-induced cytokine 
responses. C57BL/6 mice were injected with rapamycin or control vehicle one day before 
aerosol infection with Mtb and thereafter daily for 28 d (Figure 7A). At 28 d post infection, 
ex vivo stimulations of splenocytes with Mtb lysate, PPD, PHA and LPS revealed a potent 
reduction in the capacity of the rapamycin-treated mice to respond to both Mtb lysate 
(Figure 7B) and non-specific stimuli like PPD, PHA and LPS (Supporting Information Figures 
6A - 6V). Notably, the production of the T
H
-derived cytokines IFN-γ and IL-17 was inhibited by 
rapamycin (Figure 7B), as previously observed in vitro. Systemic inhibition of mTOR also led 
to the inhibition of pro-inflammatory cytokines IL-12 p70 and TNF-α (Figure 7B). It is highly 
likely that due to the anti-mycobacterial effects of rapamycin [16], rapamycin injections did 
not affect Mtb outgrowth (Supporting Information Figure 6W).
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Figure 7 | In vivo effects of mTOR inhibition. (A, B) C57/BL6 mice were treated with rapamycin 
or vehicle (mixed PBS/100% EtOH) from 1 d prior to aerosol infection with Mtb until 28 d post-
infection. Mice were euthanised and splenocytes were harvested and re-stimulated with Mtb lysate 
(1 mg/mL) for 6 d, after which (B) a bead-based immunoassay for mTNF-α, mIL-12p70, mIIL-17 and 
mIFN-γ was performed. Data are shown as means ± SEM of n =6 samples from a single experiment. 
Means were compared using the Mann–Whitney U test (*p<0.05). 
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DISCUSSION
A metabolic switch to aerobic glycolysis, also known as the Warburg effect, was first described 
by Otto Warburg in cancer cells [17]. In recent years an increasing body of literature has 
shown that a similar pattern of metabolic rewiring is important for differentiation of effector 
T
H
 lymphocytes [5], activation of macrophages and dendritic cells [1] and more recently 
for Mtb infection [7, 8]. Expanding on this, we used transcriptome data to demonstrate 
that this switch takes place in patients with active TB disease and we thereafter performed 
functional experiments to identify the molecular mechanisms governing this switch to 
glycolysis. Specifically, we show that the switch to glycolysis in cells that encounter Mtb 
relies on TLR2 recognition and is in part dependent on the intracellular AKT-mTOR axis.
Aerobic glycolysis is an ancient process for generating ATP seen even in early single-cell 
eukaryotes such as yeast. Although primitive in comparison to the TCA cycle and OXPHOS, 
aerobic glycolysis rapidly facilitates the high bio-energetic needs of cells responding to 
intruding pathogens. We show that this metabolic switch is also necessary for cells to 
mount an efficient response to Mtb. 
The mTOR regulatory complex has been highly conserved throughout evolution. It 
integrates extracellular and intracellular signals to regulate cell growth, metabolism, 
proliferation and survival. The mTOR protein can form two distinct multi-protein complexes: 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Mtb stimulation increased 
mTORC1 activity as measured by an increase in phosphorylation of its targets 4E-BP1 and 
p70-S6K1. Additionally, rapamycin inhibits mTORC1 but cannot physically interact or acutely 
inhibit mTORC2. This suggests that the Mtb-induced switch to aerobic glycolysis is in part 
due to mTORC1 activation. The involvement of mTORC1 is further supported by studies 
showing that naive T helper cells preserve their ability to differentiate into T
H
1 and T
H
17 cells 
in the absence of mTORC2 signalling, but not in the absence of mTORC1 signalling [18]. 
Mechanistically it would be highly interesting to determine whether mTORC2-deficient 
cells could commit to glycolysis. Of note, blockade by rapamycin, torin and wortmannin 
individually does not completely ablate lactate production suggesting redundancy of 
these regulators, regulation by other pathways or incomplete pharmacological inhibition. 
Dissecting if the mTOR/AKT pathway is the sole regulator of glycolysis would therefore be 
of future interest. 
NOD2 and TLR receptors are major pattern recognition receptors for Mtb, with  synergistic 
effects on Mtb-medicated cytokine production [19, 20]. It is thus interesting that rewiring 
of cellular glucose metabolism is strictly TLR2-dependent (but NOD2-independent), 
and that the NOD2 agonist MDP does not potentiate TLR2-induced lactate production. 
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The discrepancy between the effects of NOD2 on cytokine responses and induction of 
glycolysis suggests the presence of distinct intracellular pathways responsible for these 
two processes. Whilst NOD2 stimulation is known to induce MAPK activation and NF-kB 
translocation leading to cytokine induction [21], activation of the AKT/mTOR pathway is 
not demonstrated. In contrast, TLRs induce both MAPK, NF-kB and the AKT/mTOR pathway 
[22, 23]. Moreover, activation of AKT inhibits the NOD2-mediated NF-kB pathway [24], while 
NOD1 stimulation (that activates similar intracellular pathways) inhibits AKT phosphorylation 
induced by insulin [25]. These data strongly suggest a fundamental difference between TLRs 
and NOD2 for activation of AKT/mTOR pathway, with NOD2 unable to induce AKT activation 
and thus metabolic reprogramming. Future studies that compare this requirement for TLR2 
in other infectious stimuli, such as Gram positive or negative bacteria, would be of interest. 
T
H
 cells exert different effector functions and thus it is not surprising that they exhibit 
distinct metabolic programs. T effector cells primarily rely on mTOR-driven aerobic glycolysis 
for energy, whilst regulatory T cells rely on lipid oxidation and mitochondrial respiration 
mediated by AMPK [1]. Mtb induced T
H
17 cells appear to be more dependent on aerobic 
glycolysis than T
H
1 cells, possibly due to the upregulation of HIF-1α [26]. HIF-1α is a hypoxia-
induced transcription factor that directly controls gene expression of enzymes in the 
glycolysis pathway [27]. The role of HIF-1α in the generation of IFN-γ-producing T
H
1 cells 
is unclear, as either enhanced or no differences in IFN-γ production have been observed 
in experimental models lacking HIF-1α [28, 29]. The use of ascorbate, an HIF-1α inhibitor, 
emulates these observations, as a significant decrease in IL-17 but not IFN-γ production was 
found in PMBCs. 
In vitro inhibition of mTOR with rapamycin or torin led to either no differences or an increase 
in TNF-α, IL-6 and IL-1β production, in line with literature showing that mTOR inhibits pro-
inflammatory cytokine production via negative regulation of NF-κB, whilst inhibiting T cell 
proliferation [30]. Nonetheless, in our in vivo Mtb infection model, prolonged exposure to 
rapamycin inhibited overall cytokine responses to Mtb including pro-inflammatory cytokines 
such as IL-12 and TNF-α. Likewise, 2-DG, a direct competitive inhibitor of glycolysis, inhibited 
both monocyte and T cell-derived cytokines. As mentioned above, the HIF-1α inhibitor 
ascorbate did not influence monocyte-derived cytokines, in contrast to a previous study 
showing HIF-1α dependent LPS-mediated IL-1β production in murine macrophages [31]. 
This may be explained by the differences in required doses of ascorbate, or discrepancies 
between human and mouse glucose metabolic processes.
In this study we take a step further in dissecting the role of leukocyte energy metabolism 
in the immune responses to Mtb in vitro and in vivo. Recognition of the fact that metabolic 
rewiring towards glycolysis is crucial for host immunity leads to the hypothesis that 
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perturbations in leukocyte metabolism could be detrimental for the host. For instance, 
impaired glucose metabolism in patients with diabetes leading to reduced capacity to 
mount the necessary metabolic changes to respond to Mtb may contribute significantly to 
their increase in TB susceptibility. 
In conclusion, our study has cemented glycolysis as a fundamental process that underpins 
the cellular circuitry needed to mount effective host responses to Mtb and promotes it as 
a therapeutic target in TB. In particular, pharmacologic manipulation of enzymes in these 
pathways may generate more robust and effective immune responses and thus open up 
new avenues for host-directed therapies for tuberculosis.
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Supporting Information Figure 1 | Transcriptional Regulation of Glucose Metabolism. (A-B) 
Data are represented as mean scatter plots for gene expression of MCT4 and Sirtuin 5 in LTBI and 
PTB individuals in the South African validation cohort of Berry et al. [13] and in controls and PTB 
patients on 0 m, 2 m or 12 m of treatment with anti-tubercular drugs. Symbols represent individual 
samples and data are shown as means. Means were compared using the Mann-Whitney U test. 
*p<0.05, **p<0.01, ***p<0.001. 
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Supporting Information Figure 2 | Physiology of the Metabolic Response to Mtb Stimulation. 
(A) CD14+ monocytes were stimulated for 24 h with Mtb lysate (n=6) and LPS (n=4) and the 
resulting ECAR and OCR rates were determined using the Seahorse metabolic analyser. Three 
baseline measurements were determined. Data are shown as means ± SEM of n = 4 to 6 from a 
single experiment. Means were compared using the Wilcoxon signed-rank test (*p<0.05).
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Supporting Information Figure 3 | Induction of Glycolysis is Mediated by the AKT-mTOR 
Pathway. (A) CD14+ monocytes pre-incubated with DMSO (vehicle control) or rapamycin (mTOR 
inhibitor) were stimulated with RPMI (R) or Mtb lysate (T) for 2 h. Cell lysates were analysed by 
Western blot for phosphorylation of p70-S6K and actin levels using specific antibodies. Blots from 
two donors are shown. 
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Supporting Information Figure 4 | Regulation of Monocyte-Derived Cytokines by Aerobic 
Glycolysis. (A-D) PBMCs were pre-incubated with DMSO (vehicle control) or (A) 1 mM or 5 mM 2DG, 
(B) 1 nM or 10 nM rapamycin, 100 nM torin, (C) 500 μM AICAR or (D) 50 μM or 500 μM ascorbate or 
for 1 h prior to stimulation with Mtb lysate. TNF-α, IL-1β, IL-6 and IL-10 levels were measured from 
culture supernatants by ELISA.  Data are shown as means ± SEM of n = 6 to 9 pooled from three 
independent experiments. Means were compared using the Wilcoxon signed-rank test (*p<0.05, 
**p<0.01).
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Supporting Information Figure 5 | Effects of Metabolic Pathway Inhibitors on Cell Death. 
(A–E) PBMCs were pre-incubated with DMSO (vehicle control) or (A) 1 mM or 5 mM 2DG, (B) 1 nM 
or 10 nM rapamycin, 100 nM torin, (C) 500 μM AICAR or (D) 50 μM or 500 μM ascorbate or for 1 h 
prior to stimulation with Mtb lysate for 1, 3 or 7 d after which the cells were harvested and stained 
with an Annexin-V / PI stain to determine levels of cell death. Data are shown as means ± SEM of n 
= 4 to 6 pooled from three independent experiments. Means were compared using the Wilcoxon 
signed-rank test. 
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Supporting Information Figure 6 | In vivo Effects of Rapamycin on Ex vivo Splenocyte 
Restimulation. (A–W) C57/BL6 mice were treated with rapamycin or vehicle (mixed PBS/100% 
EtOH) from 1 day prior to aerosol infection until 28 d post-infection. Mice were euthanized. 
Splenocytes were harvested and re-stimulated with Mtb lysate, PPD, PHA or LPS for 6 d after which 
a bead-based immunoassay was performed (A-U). Lung homogenates were harvested and CFUs 
plated and counted after three weeks (W). Data are shown as means ± SEM of n =6 samples from a 
single experiment. Means were compared using the Mann–Whitney U test (*p<0.05).
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ABSTRACT
Microbial stimuli such as lipopolysaccharide (LPS) induce robust metabolic rewiring 
in immune cells, known as the Warburg effect. It is unknown whether this increase in 
glycolysis but decrease in oxidative phosphorylation (OXPHOS) is a general characteristic 
of monocytes that have encountered a pathogen. Using CD14+ monocytes from healthy 
donors we demonstrate that most microbial stimuli increase glycolysis, but only stimulation 
of Toll-like receptor (TLR) 4 with LPS leads to a decrease in OXPHOS. Instead, activation of 
other TLRs, such as TLR2 activation by Pam3CysSK4 (P3C), increases oxygen consumption 
and mitochondrial enzyme activity. Transcriptome and metabolome analysis of monocytes 
stimulated with P3C versus LPS confirmed the divergent metabolic responses between 
both stimuli and revealed significant differences in the TCA cycle, OXPHOS and lipid 
metabolism pathways upon stimulation of monocytes with P3C versus LPS. At a functional 
level, pharmacological inhibition of complex I of the mitochondrial electron transport 
chain diminished cytokine production and phagocytosis in P3C-, but not LPS-stimulated 
monocytes. To summarise, unlike LPS, complex microbial stimuli and the TLR2 ligand 
P3C induce a specific pattern of metabolic rewiring that involves up-regulation of both 
glycolysis and OXPHOS which enable activation of host defence mechanisms like cytokine 
production and phagocytosis.
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INTRODUCTION 
Otto Warburg first described the concept of metabolic rewiring in tumour cells in the 1930s, 
and showed that differentiated cells rely on mitochondrial oxidative phosphorylation 
(OXPHOS) to generate ATP whereas tumour cells switch to aerobic glycolysis under 
normoxic conditions 1. In recent years immunologists have discovered that this metabolic 
shift also underpins the activation and function of immune cells. T-helper cells such as 
activated T
H
1 and T
H
17 cells are characterised by active glycolysis 2, whereas quiescent 
T-cells like regulatory and memory T cells rely on OXPHOS and fatty acid oxidation (FAO) 
for their ATP production 2, 3. Similar parallels can be drawn between polarized macrophages, 
where pro-inflammatory M1 macrophages are highly glycolytic but anti-inflammatory M2 
macrophages rely mainly on OXPHOS and FAO 4, 5.  These metabolic adaptations are thought 
to accommodate various functional outputs. For instance, intracellular metabolites such as 
succinate 6 and itaconate 7 serve not only as TCA cycle intermediates, but are also closely 
linked to cytokine production, macrophage polarization and microbial killing. 
As such, the shift from OXPHOS to glycolysis upon activation, known as the Warburg effect, 
has been adopted as a core paradigm in the field of immunology8. Currently, the field is 
dominated by studies in the murine system which primarily investigate the influence of TLR 
ligands such as LPS on cellular metabolism 4, 7, 9, 10. Few studies have investigated this switch 
in human immune cells 11 and it is unclear whether all microbial stimuli induce the Warburg 
effect. To build on this, we examined whether different microbial stimuli could induce the 
Warburg effect in human monocytes. Whole pathogen lysates were used to represent both 
gram-positive and gram-negative bacteria, whereas TLR4 (LPS) and TLR2 (Pam
3
CysSK
4 
(P3C)) 
ligands were used at different concentrations for mechanistic studies. Additionally, we 
investigated the consequences of metabolic rewiring on two functional outputs: cytokine 
production and phagocytosis. To our surprise we discovered that a shift from OXPHOS to 
glycolysis was only observed in monocytes stimulated with concentrations of 1-100 ng/
mL LPS, but not in monocytes stimulated with P3C or other bacterial lysates. In monocytes 
stimulated with P3C increased OXPHOS was needed for retaining their phagocytic capacity 
and cytokine production. These findings therefore challenge the notion that a shift from 
OXPHOS to glycolysis underlies activation of all immune cells upon microbial stimulation. 
Instead, we propose that each individual stimulus induces a complex set of metabolic 
programs which govern the function of a given immune cell.
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METHODS
Healthy Volunteers
Peripheral blood mononuclear cells (PBMCs) were isolated from blood donated by healthy 
male volunteers after informed consent. Ethical approval was obtained from the CMO 
Arnhem-Nijmegen. 
Isolation of PBMCs and CD14+ Monocytes 
Isolation of PBMCs was performed by differential centrifugation over Ficoll-Paque™ PLUS 
(GE Healthcare Biosciences). Monocytes were separated from the PBMCs by hyper-osmotic 
density gradient centrifugation over Percoll (Sigma-Aldrich), and afterwards washed once 
with PBS. Cells were counted in a Coulter counter (Coulter Electronics). Alternatively, CD14+ 
monocytes were purified from freshly isolated PBMCs using MACS microbeads for positive 
selection, according to the manufacturer’s instructions (Miltenyi Biotec, Germany).
Stimulation Experiments
2 x 105 monocytes per well were used for Seahorse measurements, while 1 x 106 monocytes 
per well monocytes were used for cytokine, RNA, and Western blot analysis. Monocytes were 
cultured in RPMI 1640 (no glucose, Gibco) supplemented with 10 μg/mL gentamicin (Gibco), 
10 mM pyruvate (Gibco), 10 mM HEPES (Sigma-Aldrich), 5.5 mM glucose (Sigma-Aldrich) and 
10% human pool serum and stimulated with either RPMI, 0.1 to 10 μg/mL Pam
3
CysSK
4
 (EMC 
Microcollections, Germany), 0.1 to 100 ng/mL lipopolysaccharide (LPS) from Escherichia 
coli (Sigma-Aldrich), 10 μg/mL poly (I:C) (Invivogen), 5 μg/mL Mycobacterium tuberculosis 
(H37Rv) lysate, 1 x 106 organisms/mL Escherichia coli (ATCC 35218) or 1 x 106 organisms/mL 
Staphylococcus aureus (clinical isolate). Unless stated otherwise, monocytes were stimulated 
with 10 ng/mL LPS or 10 μg/mL P3C for 24 h. 
Monocytes were treated with 2-Deoxyglucose (2DG; Sigma-Aldrich) to block glycolysis, 
with rotenone (Sigma-Aldrich) in combination with antimycin A to block complex I of the 
electron transport chain, with TRIF inhibitory peptide (Pepinh-TRIF, InvivoGen) or control 
peptide (Pepinh-Control, InvivoGen) to inhibit TRIF-signaling, with GW9962 (Sigma-Aldrich) 
to inhibit PPARγ, with rosiglitazone (Sigma-Aldrich) to activate PPARγ or dimethyl itaconate 
(Sigma Aldrich). For experiments related to hypoxia, monocytes were stimulated with LPS 
or P3C for 24 h and then incubated in hypoxic (1 % oxygen) or normoxic (20 % oxygen) 
conditions for 2 h prior to measuring the phagocytic capacity of the monocytes. 
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Cell culture supernatants were collected and stored at −20°C. Cells were lysed in TRIzol 
reagent (Invitrogen) and stored at −80°C until RNA isolation was performed or stored at 
-80°C until processed for Western blot analysis as described below. 
Cytokine Measurements
The production of interleukin (IL)-1β and tumour necrosis factor (TNF)-α were measured by 
commercial ELISA kits (R&D Systems, Minneapolis, MN), IL-6 and IL-10 concentrations were 
measured by ELISA (Sanquin, Amsterdam, Netherlands). 
Lactate Measurements
Lactate was measured from cell culture supernatants after perchloric acid precipitation. The 
resulting supernatants were neutralised with NaOH. An enzymatic assay in which lactate was 
oxidized and the resulting H
2
O
2
 was coupled to the conversion of Amplex® Red reagent to 
fluorescent resorufin by HRP (horseradish peroxidase) was used to determine lactate levels. 
Either 30 μL of lactate standard or 200-fold diluted sample was added to a black 96-well flat-
bottom plate followed by 30 μL of reaction mix which consisted of 0.6 μL of 10 U/mL HRP 
(Sigma-Aldrich), 0.6 μL of 100 U/mL lactate oxidase (Sigma), 0.3 μL of 10 mM Amplex® Red 
reagent (Life Technologies), and 28.5 μL PBS. The assay was incubated for 20 min at room 
temperature and the fluorescence of resorufin (excitation/emission maxima=570/585 nm) 
was measured on a 96-well plate reader (Biotek). 
Extracellular flux analysis
Real-time oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) of 
monocytes were analyzed using an XF-96 Extracellular Flux Analyzer (Seahorse Bioscience). 
In short, basal metabolic rates of monocytes seeded in quintuplicate were determined 
during four consecutive measurements in unbuffered Seahorse medium (8.3 g DMEM 
powder, 0.016 g phenol red and 1.85 g NaCl in 1 L milli-Q, pH set at 7.4 at 37 °C; sterile-filtered) 
containing 5.5 mM glucose and 2 mM L-glutamine. After three basal measurements, three 
consecutive measurements were taken upon the addition of each 1.5 µM oligomycin, 1 mM 
FCCP, and 2 µM antimycin together with 1 µM rotenone. Glucose (20 mM) and pyruvate 
(1 mM) were added together with FCCP to fuel maximal respiration. All compounds used 
during the Seahorse runs were acquired from Sigma. Spare Respiratory Capacity (SRC) was 
determined as absolute increase of OCR after FCCP injection compared to basal OCR. Equal 
cell numbers in the wells were assessed by measuring total DNA content using the Quant-
iT™ dsDNA Assay Kit (Thermofisher Scientific). 96-well plates for Seahorse measurements 
were pre-treated with Corning™ Cell-Tak Cell and Tissue Adhesive.
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Mitochondrial respiratory chain enzyme measurements
Assays for the measurements of the activity of the mitochondrial respiratory chain enzymes 
and citrate synthase were based on previously described methods 32, 33, 34. The assays were 
performed  on a KoneLab autoanalyzer as described before 35.
Western Blotting 
Monocytes were lysed in 100 μL lysis buffer (1M Tris pH 7.4, 0.5M EDTA, 5M NaCl, 10% ND40, 
0.5M NaF, 2.5% sodium deoxycholate, PhosSTOP (Roche) and cOmplete (Roche)). The cell 
homogenate was frozen, thawed and processed for Western blot analysis according to 
the manufacturer’s instructions. Western blotting was carried out using Mini-PROTEAN 
TGX precast Gels (Bio-Rad). Proteins were transferred using the Trans-Blot® Turbo™ system 
(Bio-Rad) according to the manufacturer’s instructions. The following primary antibodies 
were used: actin (Sigma), phospho-AKT (S473) (Cell Signalling), total AKT (Cell Signalling), 
hydroxylated HIF-1α (Cell Signalling), PARP (Cell Signalling) and Caspase-3 (Cell Signalling). 
Unmodified, full scans of the blots can be found in Supplementary Figure 7 and 8.
Phagocytosis assay
For the phagocytosis assay, 150.000 CD14+ monocytes were seeded into a 96-well plate 
and stimulated for 24 h with RPMI, LPS (10 ng/mL) or P3C (10 μg/mL) (4 replicates each). 
Inhibitors (1 μM rotenone, Sigma-Aldrich; 1 mM 2DG, Sigma-Aldrich) were added to the 
cells 30 min prior to the phagocytosis assay. Phagocytosis was assessed using the Vybrant® 
Phagocytosis Assay Kit (Molecular Probes).  
Cell Viability Assessment by Annexin-V Staining
The percentage of cells that underwent early or late apoptosis was determined by labelling 
with annexin V–fluorescein isothiocyanate (FITC, Biovision) and staining with propidium 
iodide (PI, Sigma Aldrich), according to the manufacturer’s instructions. Treated CD14+ were 
gently scraped after incubation with versene solution (Gibco) for 15 min on ice, washed 
with PBS and re-suspended in 200 μL of RPMI. Cells were incubated on ice in the dark with 1 μL 
of Annexin V-FITC for 15 min followed by a 5 min incubation with 1.5 μL of PI. The relative level 
of apoptotic cells was detected by flow cytometry within 1 h, using a FC500 flow cytometer 
(Beckman Coulter) and data were analysed using Kaluza 1.3 software (Beckman Coulter). 
RNA Isolation and qPCRs
RNA was isolated from CD14+ cells using TRIzol reagent (Invitrogen), according to the 
manufacturer’s protocol. RNA was transcribed into complementary DNA by reverse-
transcription using the iScript cDNA synthesis kit (BIORAD). Primer sequences used for 
Quantitative real-time PCR (qPCR) are listed in supplementary Table 1. Power SYBR Green 
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PCR Master Mix (Applied Biosystems) was used for qPCR in an AB Step one plus real-time 
PCR system (Applied Biosystems, Life technologies) or the CFX384 Real-Time PCR Detection 
System (Biorad). qPCR data were normalized to the housekeeping gene human β2M. 
Metabolite Measurements
Three million CD14+ monocytes were seeded in each well of a 6-well plate and stimulated 
for 24 h with RPMI, LPS (10 ng/mL) or P3C (10 μg/mL) (2 replicates each). Dry cell pellets 
were flash frozen and stored at -80°C. Of note, the same samples were used for both 
transcriptomics and metabolomics. Samples were shipped to Metabolon, Inc for processing 
and measurement. 512 compounds of known structural identity were detected. Samples 
were prepared using the automated MicroLab STAR® system from Hamilton Company.  Raw 
data was extracted, peak-identified and QC processed using Metabolon’s hardware and 
software. Peaks were quantified using area-under-the-curve. Metabolite data normalized 
to protein concentration (measured by Bradford assay by Metabolon Inc.) was used for all 
analyses. MetaboAnalyst 3.0 was used to explore and characterise the dataset. Data was 
auto-scaled and an unsupervised analysis using principal component analysis (PCA) was 
performed to determine clustering and separation 36. A heatmap representing the top 25 
metabolites ranked by ANOVA was generated. 
Microarray analysis
RNA was purified from human CD14+ monocytes using TRIzol reagent (Invitrogen) followed 
by an additional round of purification with RNeasy Minikit columns (Qiagen, Venlo, the 
Netherlands). RNA quality was assessed using RNA 6000 nanochips on the Agilent 2100 
bioanalyzer (Agilent Technologies, Amsterdam, the Netherlands). Purified RNA (100 ng) 
was labelled with the Affymetrix WT PLUS reagent kit (Affymetrix, Santa Clara, CA, USA) and 
hybridized to an Affymetrix Human Gene 1.1 ST array plate (Affymetrix, Santa Clara, CA, USA). 
Hybridization, washing and scanning were carried out on an Affymetrix GeneTitan platform 
according to the manufacturer’s instructions. Arrays were normalized using the robust multi 
array average method 37, 38. Probe sets were defined according to Dai et al. 39. In this method 
probes are assigned to Entrez IDs as a unique gene identifier. The p-values were calculated 
using an intensity-based moderated t-statistic (IBMT) 40. The microarray data have been 
submitted to the Gene Expression Omnibus (accession number GSE78699). Expression 
changes in whole blood ex vivo  (GSE55375) 41 and in vivo  (GSE6269) 42 were extracted from 
publically available microarray data sets using the analysis pipeline described above.
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Electron Microscopy
For EM analysis of mitochondria, cells were fixed in 2% glutaraldehyde in 0.1 M phosphate 
buffer (pH 7.4) and were postfixed for 1 h in 1% osmium tetroxide and 1% potassium 
ferrocyanide in 0.1 M cacodylate buffer. After being washed in buffer, cells were dehydrated 
in an ascending series of aqueous ethanol and were subsequently transferred via a mixture 
of propylene oxide and Epon to pure Epon 812 as embedding medium. Ultrathin gray 
sections (60–80 nm) were cut, contrasted with aqueous 2% uranyl acetate, rinsed, and 
counterstained with lead citrate, air dried, and examined in a JEOL JEM1010 electron 
microscope (JEOL, Welwyn Garden City, UK) operating at 80 kV.
Statistics
For normally distributed parametric data the student’s t-test was used. For non-parametric 
data the Wilcoxon signed-rank test was used. 
Data availability 
The data that support the findings of this study are available from the corresponding author 
upon request. Microarray data is publically available through GEO using accession number 
GSE78699.
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RESULTS
LPS uniquely downregulates OXPHOS compared to other bacterial stimuli 
CD14+ human monocytes were stimulated with a panel of commonly used concentrations 
of TLR ligands (LPS or P3C) or whole pathogen lysates (E. coli, S. aureus or M. tuberculosis) for 
24 h to investigate changes in metabolism and cytokine production. Increased extracellular 
acidification rate (ECAR) (Figure 1a) and lactate production (Figure 1b) in response to all 
stimuli suggested a universal increase in glycolysis upon microbial stimulation. This was 
accompanied by changes in gene expression of enzymes in the glycolysis pathway. 
Specifically, expression of the first enzyme of glycolysis, hexokinase 2 (HK2), and the rate 
limiting enzyme, fructose 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 
(PFKFB3), was increased by all stimuli (Figure 1c). Cytokine production (TNFα, IL-6, IL-1β, and 
IL10), a function that has been linked to changes in cellular metabolism 6, was also increased 
by all stimuli (Figure 1d).
Next, we assessed the oxidative capacity of monocytes by measuring oxygen consumption 
rate (OCR) and spare respiratory capacity (SRC). SRC is an indicator of the total mitochondrial 
capacity of a cell, which represents the amount of spare energy available during periods of 
stress 12. As reported earlier 13, LPS lowered basal OCR and SRC of human monocytes. In 
contrast P3C and bacteria lysates increased basal OCR and SRC (Figure 2a, b). Supporting 
these results, LPS decreased the activity of several enzymes in the mitochondrial electron 
transport chain (ETC), whereas P3C increased their activity (Figure 2c). Similarly, microarray 
analysis revealed lower expression levels of genes that comprise the five ETC complexes in 
monocytes stimulated with LPS compared to P3C (Figure 2d). 
Protein levels of classical regulators of energy metabolism, AKT and HIF1α, were equally 
activated after LPS or P3C stimulation (Figure 2e), suggesting that these regulators are 
unlikely to control OXPHOS. Mitochondrial function has recently been suggested to be 
linked to mitochondrial morphology 14. Using electron microscopy, the mitochondria 
appeared to be larger in LPS- compared to P3C-stimulated monocytes (Figure 2f ).
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Figure 1 | Glycolysis is upregulated in human monocytes after stimulation with various 
pathogenic stimuli for 24 h. a–d, ECAR (a), lactate production (b), expression of glycolytic enzymes 
(c) and cytokine production (d) of human monocytes treated with TLR ligands or whole-pathogen 
lysates were measured. All data (means ± s.e.m.) are from two experiments with a total of six to 
eight donors. *P < 0.05, **P < 0.01, ***P < 0.001 (paired two-tailed Student’s t-test).
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Figure 2 | LPS is unique in downregulating OXPHOS in human monocytes. a, Basal OCR and real-
time changes in the OCR of human monocytes stimulated with TLR ligands or whole-pathogen lysates, 
assessed during sequential treatment with oligomycin, carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP) and antimycin A + rotenone. b, Basal OCR and SRC of 
monocytes treated with TLR ligands or whole-pathogen lysates. c, Enzyme activity of mitochondrial 
complexes (C) I–IV (Q, ubiquinone) and citrate synthase (CS) in monocytes stimulated with LPS or 
P3C, normalized to untreated monocytes. d, Gene expression data of mitochondrial complexes I–V of 
monocytes stimulated with LPS or P3C. Expression levels are presented as signal log ratios (SLR), with 
red representing higher and blue lower gene expression in LPS- versus P3C-stimulated monocytes. e, 
Immunoblot of phosphorylated AKT (pAKT), total AKT and hydroxylated HIF-1α in human 
monocytes stimulated with LPS or P3C for 30 or 120 min. R denotes untreated cells. HSP90 served as 
a loading control. f, Mitochondrial morphology analysed by electron microscopy. Data (means ± s.e.m.) 
are from two experiments with a total of six to eight donors (a,b), two experiments with a total of seven 
donors (c), one experiment with five donors (d), a representative experiment with three donors (e) or 
one experiment with one donor (f). *P < 0.05, **P < 0.01 (paired two-tailed Student’s t-test). 
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Figure 2 | LPS is unique in downregulating OXPHOS in human monocytes. a, Basal OCR 
and real-time changes in the OCR of human mo ocytes stimulated with TLR ligands or whole-
pathogen lysates, assessed during sequential treatment with oligomycin, carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP) and antimycin A + rotenone. b, Basal OCR and SRC of 
monocytes treated with TLR ligands or whole-pathogen lysates. c, Enzyme activity of mitochondrial 
complexes (C) I–IV (Q, ubiquinone) and citrate synthase (CS) in monocytes stimulated with LPS or 
P3C, normalized to untreated monocytes. d, Gene expression data of mitochondrial complexes 
I–V of monocytes stimulated with LPS or P3C. Expression levels are presented as signal log ratios 
(SLR), with red representing higher and blu  lower gene expre sion in LPS- v rsus P3C-stimulated 
monocytes. e, Immunoblot of phosphorylated AKT (pAKT), total AKT and hydroxylated HIF-1α in 
human monocytes stimulated with LPS r P3C for 30 or 120 mi . R denotes untreated cells. HSP90 
served as a loading control. f, Mitochondrial morphology analysed by electron microscopy. Data 
(means ± s.e.m.) are from two experiments with a total of six to eight donors (a,b), two experiments 
with a total of seven donors (c), one experiment with five donors (d), a representative experiment 
with three donors (e) or one experiment with one donor (f ). *P < 0.05, **P < 0.01 (paired two-tailed 
Student’s t-test).
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The transcriptome of LPS- vs. P3C-treated monocytes reveals specific 
patterns of metabolic rewiring 
To validate the expression profiles of LPS- and P3C-stimulated monocytes we used a publically 
available data set of ex vivo LPS- or P3C-stimulated whole blood. Principle component 
analysis (PCA) using genes of selected KEGG-derived metabolic pathways revealed a clear 
separation of untreated vs. LPS- vs. P3C-treated cells in both data sets (Figure 3a, b). We 
then compared the expression levels of individual genes in each metabolic pathway and as 
expected observed robust changes in gene expression induced by LPS- or P3C-stimulated 
monocytes (Supplementary Figure 1a). Overall, LPS induced a decrease in expression of 
metabolic genes compared to P3C, most noticeably those part of the TCA cycle, OXPHOS 
and PPAR signalling pathways (Figure 3c, Supplementary Figure 1a). These observations 
were validated in the ex vivo whole blood data set (Figure 3d). 
Of note, a similar PCA analysis performed with publically available expression data of PBMCs 
from individuals with acute E. coli vs. S. aureus infections showed clustering that was not 
as distinct as LPS- vs. P3C-stimulated monocytes (Supplementary Figure 1b). Similarly, the 
metabolic gene expression profiles of LPS- vs. P3C-stimulated monocytes showed little 
overlap with the expression profiles of PBMCs from individuals with acute E. coli vs. S. aureus 
infection (Supplemental Figure 1c). Unlike a pure population of monocytes, PBMCs are a 
heterogeneous mix of circulating immune cells with distinct bio-energetic profiles and 
distribution of respiratory chain proteins 15. 
LPS-treated monocytes displayed a pronounced decrease in the expression of genes 
involved in lipid handling and usage (Fig. 3d and Supplementary Fig. 1a). Many genes in 
this pathway, 
including PPAR-γ and its targets (LPL, FABP4 and PDK4), had lower expression in LPS- versus 
P3C-stimulated monocytes, suggesting that PPAR-γ may regulate the difference in OXPHOS 
between the two stimuli (Fig. 3e). To test this hypothesis, we inhibited PPAR-γ using the 
antagonist GW9662 and found that basal OCR was mostly unaffected (Supplementary Fig. 
2a). GW9662 decreased IL-1β and increased IL-10 levels (Supplementary Fig. 2b). Treatment 
with rosiglitazone, a PPAR-γ agonist, had little effect on OCR and cytokine production in 
LPS- and P3C-stimulated monocytes (Supplementary Fig. 2a,b). Together, these results do 
not implicate PPAR-γ as the primary regulator of the oxidative capacity of P3C-stimulated 
monocytes. Instead, PPAR-γ may be upregulated as a consequence of the higher levels of 
polyunsaturated fatty acids found in monocytes stimulated with P3C compared with LPS 
(Fig. 3f ). These fatty acids would function as natural ligands of PPAR-γ.
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The TIR-domain-containing adapter-inducing interferon-β (TRIF) pathway is specifically 
activated downstream of TLR4, but not TLR2. Therefore, we tested whether Poly(I:C), a TLR3 
ligand which signals exclusively via TRIF, would induce a similar pattern of metabolic rewiring 
to LPS. As with P3C, stimulation with Poly(I:C) increased ECAR and OCR (Supplementary 
Figure 2c), suggesting that TRIF is not involved in the metabolic rewiring of LPS-treated cells. 
Additionally, inhibition of TRIF using an inhibitory peptide did not affect cytokine secretion 
or metabolic gene expression of LPS-treated cells (Supplementary Figure 2d,e). 
LPS has dose-dependent effects on OXPHOS in human monocytes    
The concentrations of 10 ng/mL LPS and 10 µg/mL P3C used in our experiments are most 
commonly applied throughout literature. To test if the differences in regulation of OXPHOS 
were dose-dependent, we stimulated monocytes with a range of LPS (from 0.1 ng/mL 
to 100 ng/mL) or P3C (from 0.1 µg/mL to 10 µg/mL) doses and measured metabolic and 
functional outcomes. Various doses of LPS (1-100 ng/mL) induced greater levels of IL-1β 
(Figure 4a) and other cytokines (Supplementary Figure 3a) compared to P3C, whereas the 
lowest dose of LPS (0.1 ng/mL) was similar to P3C. Basal ECAR was similar for all conditions, 
however OCR and SRC varied across the different doses of LPS but not P3C (Figure 4c). The 
higher doses of LPS (1-100 ng/mL) decreased the oxidative capacity of monocytes whereas 
the lowest dose (0.1 ng/mL) increased OXPHOS similarly to P3C. 
To test if these changes were reflected at a transcriptional level, we measured the 
expression of genes involved in glycolysis (PFKFB3 and GAPDH) and fatty acid metabolism 
(PPARγ, LPL, LIPA, and CPT-1α) (Figure 4d, e). In line with our findings, expression of these 
genes in monocytes stimulated with the low dose of LPS (0.1 ng/mL) was comparable with 
monocytes stimulated with P3C (10 μg/mL), but not 10 ng/mL LPS.  
Lastly, time-dependent differences in OXPHOS were observed between the standard doses 
of 10 ng/mL LPS and 10 μg/mL P3C. 4 h post-treatment with LPS the basal OCR and SRC 
rates of stimulated monocytes were increased (Figure 4f ). With the exception of E. coli, the 
other stimuli had no effect on OCR and SRC 4 h post-stimulation. (Figure 4f ). Glycolysis, as 
measured by ECAR and lactate production, was similar between all stimuli (Supplementary 
Figure 3b, c).
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Figure 3 | Human monocytes stimulated with LPS versus P3C show differential expression 
of metabolic genes. a–d, Microarray analysis of human monocytes stimulated with LPS (10 ng/
ml) or P3C (10 μg/ml) for 24 h (monocytes), and whole blood stimulated with LPS (1 ng/ml) or P3C 
(200 ng/ l) for 24 h (whole blood; data retrieved from Gene Expression Omnibus accession no. 
GSE55375). Shown are PCA plots based on genes from selected KEGG- derived metabolic pathways, 
showing th  percentage of explained variance (expl. var.) (a,b); heat map of genes from selected 
KEGG-derived metabolic pathways in human monocytes. Expression data are presented as the SLR 
of LPS versus P3C. For each pathway, significantly different upregulated (red) or downregulated 
(blue) genes (q < 0.01) are shown (c); and heat map of genes from selected KEGG-derived metabolic 
pathways in human monocytes and whole blood. Expression data are presented as SLR of LPS versus 
P3C. For each pathway, the top 15 most differentially higher (red) or lower (blue) expressed genes in 
LPS- versus P3C-stimulated monocytes are shown. Significantly different regulated genes (q < 0.01) 
are shown in bold (d). e, Relative gene expression of LPS- and P3C-stimulated monocytes measured 
by real-time quantitative PCR. Heat map showing the relative abundance of polyunsaturated fatty 
acids in LPS- versus P3C-stimulated monocytes per donor (A–E). Data (means ± s.e.m.) are from one 
experiment with five donors (a,c,d,f ) or from two experiments with a total of eight donors (e). *P < 
0.05, **P < 0.01; (paired two-tailed Student’s t-test). 
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Differences in expression of genes involved in glycolysis and fatty acid metabolism were less 
pronounced after 4 h compared to 24 h between the two conditions. (Figure 4g, h). These 
transcriptional differences in kinetics were validated in the whole blood data set stimulated 
with LPS vs. P3C (Supplementary Figure 3 d,e).  
Although metabolic rewiring can be dependent on the maturation and activation state of 
cells,  measurement of HLA-DR revealed no differential effect on activation by either 0.1 or 
10 ng/mL LPS or 10 µg/mL P3C (Supplementary Figure 4a,b). P3C-stimulated monocytes 
expressed slightly more CD11c and CD83 compared to LPS. Nevertheless, stimulation with 
0.1 ng/mL LPS and 10 ng/mL LPS led to a similar maturation pattern despite differences 
in OXPHOS, suggesting that the extent of monocyte maturation probably cannot explain 
differences in metabolic rewiring upon LPS- and P3C-stimulation.      
Functional consequences: OXPHOS is needed for phagocytosis, whilst 
cytokine production relies on both OXPHOS and glycolysis in P3C-
stimulated monocytes
We next investigated how cytokine production and phagocytosis are influenced by the 
different metabolic programs induced by LPS or P3C. As described elsewhere 16, inhibition 
of glycolysis with 2DG decreased IL-1β (Figure 4a) and other cytokines (Supplementary 
Figure 5a) in both conditions. Inhibition of OXPHOS using the complex I inhibitor rotenone, 
lowered cytokine production only in P3C-stimulated cells (Figure 4b). This points to a P3C-
specific reliance on OXPHOS for cytokine production. In contrast to Kelly et al. 17, IL-10 levels 
were decreased in rotenone-treated cells after LPS-stimulation (Supplementary Figure 5b.) 
Rotenone did not affect cell death, as assessed by annexinV/PI-staining and measurement 
of cleaved caspase-3 and PARP (Supplementary Figure 5c, d).
Next we determined the phagocytic capacity of stimulated monocytes and found that LPS 
compared to P3C lowered phagocytic rates (Figure 5c). To determine whether OXPHOS 
facilitated the higher phagocytic capacity of P3C- vs. LPS-treated cells, we inhibited complex 
I of the ETC with rotenone. Treatment with rotenone significantly decreased the phagocytic 
capacity of P3C-stimulated monocytes whereas untreated or LPS-treated monocytes were 
unaffected. Nonetheless, lowering of oxygen consumption using hypoxic culture conditions 
(1% vs. 5% of O
2
), had no effects (Supplementary Figure 5e). 2DG also did not affect the 
phagocytic capacity of stimulated monocytes, suggesting that OXPHOS but not glycolysis 
is an important determinant of the phagocytic capacity of human monocytes (Figure 4c).
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Figure 4 Dose- and time-dependent effects on metabolic reprogramming in human monocytes. (a-f) 
IL-1β production (a), basal ECAR (b), basal OCR and SRC (c), and relative gene expression (d-e) of 
human monocytes treated with several doses of LPS and P3C for 24 h. (f-h) Basal OCR and SRC (f) and 
relative gene expression (g-h) of human monocytes treated with TLR ligands or whole pathogen 
lysates for 4 h. Data (mean ± s.e.m.) are from one experiment with five donors (a-e), from two 
experiments with a total of five to six donors (f) and from two experiments with a total of eight 
donors (g-h). * p<0.05, ** p<0.01 (two-tailed t-test) 
 
Figure 4 | Dose- and time-dep ndent metaboli  r wiring in human mon cytes. a–e, IL-1β 
production (a), basal ECAR (b), basal OCR and SRC (c), and relative gene expression (d,e) of human 
monocytes treated with various doses of LPS and P3C for 24 h. f–h, Basal OCR and SRC (f ) and 
relative gene expression (g,h) of human monocytes treated with TLR ligands or whole-pathogen 
lysates for 4 h. Data (means ± s.e.m.) are from one experiment with five donors (a–e), from two 
experiments with a total of five to six donors (f ) or from two experiments with a total of eight 
donors (g,h). *P < 0.05, **P < 0.01; exact p values are also indicated in the graphs (paired two-tailed 
Student’s t-test).
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Metabolite analysis reveals pronounced differences in TCA cycle 
metabolites between LPS- and P3C-stimulated monocytes 
To potentiate our understanding of differences in metabolic rewiring between LPS- and 
P3C-treated monocytes, we measured intracellular levels of over 500 metabolites. PCA 
analysis confirmed a robust separation in metabolic responses upon LPS- and P3C-
stimulation (Figure 5d). A heat map of the top 25 differentially regulated metabolites 
showed increased levels of succinate, citrate and itaconate specifically in LPS-treated cells, 
whereas gulonate levels were highly increased upon P3C stimulation (Figure 5e). These 
findings appear to match the two previously described breaks in the TCA cycle at citrate and 
succinate upon LPS stimulation18, but indicate that these breaks might be absent in P3C-
stimulated monocytes (Figure 5f ). An increase in expression of IRG1, which converts citrate 
to itaconate, in LPS-, but not P3C-stimulated cells further supports these findings (Figure 
5g). Moreover, LPS stimulation decreased the expression of the two TCA cycle enzymes, 
IDH1 and SDH, present after each break in the TCA cycle (Figure 5g). 
As shown above (Figure 5e), itaconate has been reported to accumulate intracellularly in 
LPS-treated mouse macrophages 19. To test if itaconate plays a functional role in cytokine 
production, membrane permeable dimethyl-itaconate was added prior to LPS or P3C 
stimulation. IL-1β, IL6 and IL-10 were all decreased, whereas levels of TNFα were mainly 
unaffected both upon LPS or P3C stimulation (Supplementary Figure 6a). Moreover, dimethyl-
itaconate did not change glycolytic metabolism, as assessed by lactate production, in either 
LPS or P3C-stimulated monocytes(Supplementary Figure 6b). These results highlight the 
importance of intracellular metabolites in the regulation of immune cell function and 
demonstrate their immune-modulatory potential independent of the pathogenic stimulus. 
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levels were highly increased upon P3C stimulation (Fig. 5e). These
ﬁndings appear to match the two previously described breaks in
the TCA cycle at citrate and succinate following LPS stimulation18,
but indicate that these breaks might be absent in P3C-stimulated
monocytes (Fig. 5f). An increase in expression of IRG1, which
converts citrate to itaconate, in LPS- but not in P3C-stimulated
cells further supported these ﬁndings (Fig. 5g). Moreover, LPS
stimulation decreased the expression of two TCA cycle enzymes,
IDH1 and SDH, present after each break in the TCA cycle (Fig. 5g).
As shown above (Fig. 5e), itaconate has been reported to
accumulate intracellularly in LPS-treated mouse macrophages19.
To test whether itaconate plays a functional role in cytokine pro-
duction, membrane-permeable dimethyl itaconate was added
before LPS or P3C stimulation. Levels of IL-1β, IL-6 and IL-10
were all decreased, whereas levels of TNF-α were mainly unaffected
following LPS or P3C stimulation (Supplementary Fig. 6a).
Moreover, dimethyl itaconate did not change glycolytic metabolism,
as assessed by lactate production, in either LPS- or P3C-stimulated
monocytes (Supplementary Fig. 6b). These results highlight the
importance of intracellular metabolites in the regulation of
immune cell function and demonstrate their immunomodulatory
potential independent of the pathogenic stimulus.
Discussion
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Figure 5 | Differential metabolic rewiring of human monocytes stimulated with LPS or P3C leads to functional differences in cytokine production and
phagocytosis. a,b, IL-1β production of monocytes pretreated with 2DG (a) or rotenone (b) for 1 h before addition of LPS or P3C for 24 h. c, Phagocytosis of
monocytes stimulated with LPS or P3C for 24 h and treated with 2DG or rotenone for 30 min before the start of the assay. d, PCA plot based on
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representing higher and blue representing lower abundance. f, Scheme showing the relative abundance of TCA cycle intermediates in monocytes stimulated
with LPS or P3C for 24 h. Units on the y axis are given as relative metabolite levels normalized to cellular protein content. g, Relative expression of genes
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Figure 5 | Differential metabolic rewiring of human monocytes stimulated with LPS or P3C 
leads to functional differences in cytokine production and p agocytosis. a,b, IL-1β production 
of monocytes pretreated with 2DG (a) or rotenone (b) for 1 h before addition of LPS or P3C for 24 h. 
c, Phagocytosis of monocytes stimulated with LPS or P3C for 24 h and treated with 2DG or rotenone 
f r 30 min before the start of the assay. d, PCA plot based on intracellular metabolites. e, Heatmap 
of the top 25 metabolites most differentially regulated in monocytes stimulated with LPS or P3C for 
24 h, with red representing higher and blue representing lower abundance. f, Scheme showing the 
relative abundance of TCA cycle intermediates in monocytes stimulated with LPS or P3C for 24 h. 
Units on the y axis are given s relative metabolite levels normalized to cellular protein cont nt. g, 
Relative expression of genes involved in regulating levels of TCA cycle intermediates. Data (means ± 
s.e.m.) are fr m two xperiments with a t tal of five d nors (a–c) or from one experiment with five 
donors (d–g). *P < 0.05, **P < 0.01 (paired two-tailed Student’s t-test).
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DISCUSSION
Evidence acquired mostly from in vitro stimulations of myeloid cells with LPS has pinpointed 
an increase in glycolysis and decrease in OXPHOS as characteristic for activated pro-
inflammatory innate immune cells 20. Our study recapitulates these findings in human 
monocytes exposed to LPS, but also demonstrates that a decrease in OXPHOS upon 
activation of myeloid cells is not an universal response to pathogenic stimuli. Furthermore, 
we link different metabolic routes adopted by human monocytes upon microbial 
stimulation to host defence functions like cytokine release and phagocytosis.   
Increased glucose utilisation upon activation with TLR-ligands or bacterial stimuli has 
previously been demonstrated 9 and has led to the identification of various upstream 
regulators of glycolysis, including AKT and HIF1α 6. Our studies confirm these findings in 
human monocytes 6, as inhibition of glycolysis with 2DG reduced IL-1β production after 
stimulation with LPS or P3C. Although some conflicting results in murine dendritic cells 9 
versus macrophages 6 have been reported, in human monocytes 2DG also decreased TNF-α, 
IL-6 and IL-10 production. Together with higher glycolytic rates, LPS-stimulated monocytes 
displayed decreased OXPHOS and metabolic flexibility. In contrast, stimulation with P3C or 
lysates from E. coli, S. aureus or M. tuberculosis resulted in increased or unaltered OXPHOS 
and metabolic flexibility. Thus, the classical Warburg effect induced by LPS is not a universal 
prerequisite for pro-inflammatory cytokine responses. 
Pathogen-specific metabolic rewiring may fuel different functional outputs. In this study 
we show that the phagocytic capacity of human monocytes is related to their oxidative 
capacity. LPS-stimulation lowered OXPHOS as well as the phagocytic capacity of monocytes 
in comparison to P3C-stimulation. Similarly, inhibition of complex I of the ETC with rotenone 
decreased the phagocytic capacity of P3C-stimulated monocytes. Phagocytosis is an 
energy demanding process 21 and OXPHOS unlike glycolysis is characterised by a high ATP 
yield. Thus, OXPHOS seems to be more capable of supporting the bio-energetic demands 
of phagocytosis. Interestingly, the phagocytic capacity of monocytes was unaffected by 
short-term hypoxia which, whilst activating HIF1α, may not result in complete inhibition of 
mitochondrial respiration.
Previous studies have shown that macrophages are dependent on several metabolic 
pathways for phagocytosis 22, 23, making it likely that other pathways such as FAO contribute 
to phagocytosis as well.  Similarly as seen for phagocytosis, inhibition of OXPHOS decreased 
cytokine production from P3C- but not LPS-stimulated monocytes, further emphasizing 
that different stimuli may use convergent or redundant metabolic pathways to execute 
their inflammatory functions. 
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We attempted to delineate the differences in OXPHOS between LPS- and P3C-stimulated 
monocytes in several ways. Firstly, we examined the contribution of TRIF signalling, since 
both stimuli induce MyD88-signalling, whereas only LPS has been shown to activate TRIF. 
Poly(I:C), a TLR3 ligand exclusively recruiting TRIF 24, increased the oxidative capacity of 
monocytes, thus making it unlikely that signalling via TRIF contributes to the LPS-induced 
decrease in OXPHOS. Secondly, we looked at PPARγ, which has been shown to promote 
OXPHOS, stimulate mitochondrial biogenesis in mouse macrophages 25 and has been linked 
to the regulation of phagocytosis in human macrophages 26. Although expression of PPARγ 
was greater in P3C- than LPS-stimulated cells, stimulation or inhibition of PPARγ did not affect 
OXPHOS or the cytokine production of LPS- nor P3C-stimulated monocytes. It is more likely 
that the activation of PPARγ by P3C is a consequence of stimulation rather than responsible 
for P3C-induced metabolic rewiring. Thirdly, mitochondrial morphology was visualized. A 
recent study linked changes in mitochondrial morphology to the metabolic differences 
observed between glycolytic T-effector (TE) cells and OXPHOS-dependent T-memory (TM) 
cells. Mitochondrial fusion in TM cells favoured OXPHOS and FAO, whereas fission in TE 
cells lead to loosening of the cristae which resulted in less efficient transport of electrons 
through the ETC and in turn promoted glycolysis as an alternative fuel source 27. Electron 
microscopy revealed larger mitochondria after LPS stimulation, suggesting that changes 
in mitochondrial morphology might contribute to differences in OXPHOS and metabolic 
rewiring upon LPS- vs. P3C-stimulation. Lastly, metabolome analysis was executed and 
revealed increased presence of metabolites that have been shown to accumulate upon a 
broken TCA cycle in LPS-stimulated murine macrophages 6, 7 in LPS- but not P3C-stimulated 
human monocytes. These metabolites, such as citrate, succinate and itaconate, have been 
identified as important regulators of intracellular metabolism and inflammatory activation. 
For example, excess citrate is transported into the cytosol where it is converted into acetyl-
CoA for fatty acid synthesis, and to oxaloacetate which promotes NO-production that can 
inhibit components of the mitochondrial ETC via nitrosylation 28. These metabolites may 
thus serve to maintain the reduced respiratory capacity of LPS-stimulated monocytes. 
Itaconate treatment of LPS-stimulated mouse macrophages has been shown to dampen the 
inflammatory response by modulating mitochondrial respiration 29. Likewise, pretreatment 
of monocytes with itaconate lowered cytokine release not only in LPS- but also in P3C-
stimulated cells, demonstrating that itaconate can modulate the inflammatory response of 
human monocytes irrespective of the stimulus. The modulatory effects of itaconate may be 
relevant in septic patients, where IRG1, the enzyme responsible for itaconate production, 
was found to be highly up-regulated in their PBMCs 30. Furthemore itaconate plays a key 
role in LPS-induced tolerance in mouse macrophages 30. 
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Additionally, we have identified gulonate to be specifically induced in P3C-stimulated 
monocytes. Gulonate is part of the glucuronic acid pathway, an alternative pathway for 
the oxidation of glucose that produces activated UDP-glucuronate. Gulonate is ultimately 
converted to D-xylulose-5-phosphate that enters the pentose phosphate pathway. 
Therefore, gulonate and gulonate-derived metabolites may represent an alternative 
pathway to oxidize glucose in P3C-treated cells. Specific metabolites that accumulate in 
P3C-treated cells, including gulonate, may preserve OXPHOS through as yet unidentified 
mechanisms.
Although LPS and P3C are often used as a model for gram-negative bacteria (like E. coli) and 
gram-positive bacteria (like S. aureus) respectively, ex vivo stimulations of human monocytes 
with either LPS, E. coli, P3C or S. aureus led to varied metabolic profiles. In the case of LPS, 
a low dose (0.1 ng/mL) induced similar metabolic changes to P3C, whereas higher doses 
led to the characteristic decrease in OXPHOS. This suggests that differences in signalling 
strength rather than qualitative signalling differences between LPS and P3C explain the 
divergent metabolic phenotype. Of much interest however are the parallels of low dose 
LPS (0.1 ng/mL) with acute in vivo infections of E. coli and of high dose LPS (1-100 ng/
mL) with sepsis which has recently been characterised by defects in OXPHOS and energy 
metabolism in leukocytes 31. Concentrations above 0.1 ng/mL of LPS seem to cross a certain 
signalling threshold at which not only is glycolysis increased, but OXPHOS is also reduced to 
maintain ATP production. These dose-related effects therefore emphasize the complexity of 
intracellular metabolic adaptations and the importance of selecting representative in vitro 
models for disease.  
This study highlights the complexity of metabolic rewiring in activated human immune 
cells and demonstrates the importance of understanding pathogen-specific metabolic 
reprogramming. We propose that each pathogen induces a highly specific metabolic 
program in human innate immune cells, thereby determining the functional output of the 
cells. Whilst some functional outputs, e.g. cytokine release, may be relatively similar, the 
underlying metabolic routes may vary significantly. Targeting metabolic routes to alleviate 
inflammatory conditions or improve antimicrobial host defence thus holds therapeutic 
promise, yet tailor-made approaches are warranted.
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Supplementary Figure 1 | Microarray analysis of the following datasets: human monocytes 
stimulated with LPS (10 ng/mL) or P3C (10 μg/mL) for 24 h (ex vivo: monocytes), or PBMCs isolated 
from patients with an E. coli or S. aureus infection (in vivo: PBMCs; data retrieved from GSE6269). 
(a) Heat map of genes from selected KEGG-derived metabolic pathways in the ex vivo monocyte 
dataset. Expression data are presented as signal log ratio (SLR) of LPS vs. P3C, LPS vs. RPMI or P3C 
vs. RPMI. For each pathway significantly different regulated genes (q<0.01) are shown. Genes with 
a SLR>1.5 or SLR<-1.5 are highlighted in bold. (b) PCA plot of the in vivo PBMC dataset based on 
genes part of selected KEGG-derived metabolic pathways. (c) Heat map of genes of selected KEGG-
derived metabolic pathways. Expression data are presented as signal log ratio (SLR) of LPS vs. P3C or 
E. coli vs. S. aureus. For each pathway the top fifteen most differentially higher (red) and lower (blue) 
expressed genes in LPS- vs. P3C- stimulated monocytes are shown. 
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Supplementary Figure 2 | (a) Basal oxygen consumption rate (OCR) of human monocytes 
pretreated with the PPARγ-inhibitor GW9662 for 1 h before addition of LPS or P3C for 24 h. (b) 
Cytokine production of human monocytes pretreated with GW9662 or the PPARγ-activator 
rosiglitazone for 1 h before addition of LPS or P3C for 24 h. (c) Basal extracellular acidification rate 
(ECAR), OCR and spare respiratory capacity (SRC) of human monocytes treated with various TLR 
ligands for 24 h. (d, e) Cytokine production (d) and gene expression (e) of  human monocytes 
pretreated with either a TRIF-specific inhibitory peptide or a control peptide for 1 h before addition 
of LPS or P3C for 24 h. Data (mean ± s.e.m.) are from one experiment with five donors (a), one 
experiment with three to five donors (b), two experiments with a total of eight donors (c) or one 
experiment with three donors (d, e). * p<0.05, ** p<0.01 (paired two-tailed t-test). 
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measured by ECAR and lactate production, was similar between all stimuli (Supplementary 
Figure 3b, c).  
 
Figure 3 | Human monocytes stimulated with LPS versus P3C show differential expression of 
metabolic genes. a–d, Microarray analysis of human monocytes stimulated with LPS (10 ng/ml) or 
P3C (10 μg/ml) for 24 h (monocytes), and whole blood stimulated with LPS (1 ng/ml) or P3C (200 
ng/ml) for 24 h (whole blood; data retrieved from Gene Expression Omnibus accession no. GSE55375). 
Shown are PCA plots based on genes from selected KEGG- derived metabolic pathways, showing the 
percentage of explained variance (expl. var.) (a,b); heat map of genes from selected KEGG-derived 
metabolic pathways in human monocytes. Expression data are presented as the SLR of LPS versus P3C. 
For each pathway, significantly different upregulated (red) or downregulated (blue) genes (q < 0.01) 
are shown (c); and heat map of genes from selected KEGG-derived metabolic pathways in human 
monocytes and whole blood. Expression data are presented as SLR of LPS versus P3C. For each 
pathway, the top 15 most differentially higher (red) or lower (blue) expressed genes in LPS- versus 
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Supplementary Figure 3 | (a) Cytokine production of human monocytes treated with several 
doses of LPS and P3C for 24 h. (b) Basal extracellular acidification rate (ECAR) and lactate production 
of human monocytes stimulated with TLR ligands or whole pathogen lysates for 4 h. (c) Basal 
oxygen consumption rate (OCR) and real-time changes in OCR of human monocytes stimulated 
with TLR ligands or whole pathogen lysates for 4 h, assessed during the sequential treatment with 
oligomycin, FCCP and antimycin A/rotenone. (d, e) Microarray analysis of the following datasets: 
human monoc tes sti ulated with LPS (10 ng/mL) or P3C (10 μg/mL) for 24 h (ex vi o: monocytes), 
and whole blood stimulated with LPS (1 ng/mL) or P3C (200 ng/mL) for 1-24 h (ex vivo: whole 
blood; data retrieved from GSE55375). (d) PCA plot of the whole blood dataset based on genes 
part of selected KEGG-derived metabolic pathways. (e) Heat map of genes part of selected KEGG-
derived metabolic pathways. Expression data are presented as signal log ratio (SLR) of LPS vs. P3C. 
For each pathway the top fifteen most differentially increased (red) or decreased (blue) genes in 
LPS- vs. P3C-stimulated monocytes are shown. Data (mean ± s.e.m.) are from one experiment with 
five donors (a) or from two experiments with a total of five to six donors (b-c). * p<0.05, ** p<0.01 
(paired two-tailed t-test). 
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Supplementary Figure 4 | Maturation markers present on human monocytes stimulated with 
LPS or P3C for 24 h. (a) Representative flow cytometry plots from one donor. (b) Mean fluorescent 
intensity (MFI) representing the presence of maturation markers in monocytes of three donors. 
Data (mean ± s.e.m.) are from one experiment with three donors. 
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Supplementary Figure 5 | (a, b) Cytokine production of monocytes pretreated with either 
2-Deoxyglucose (2DG) (a) or rotenone (b) for 1 h before addition of LPS or P3C for 24 h. (c, d) 
Cell death in monocytes pretreated with rotenone for 1 h prior to addition of LPS or P3C for 24 
h, assessed by annexinV-PI-staining (c) and Western blot for PARP and cleaved caspase-3 (d). (e) 
Phagocytic capacity of monocytes stimulated with LPS or P3C for 24 h and held under normoxic 
or hypoxic conditions for 2 h prior to the start of the assay. Data (mean ± s.e.m.) are from two 
experiments with a total of five donors (a-b), or one experiment with three donors (c-e). * p<0.05, 
** p<0.01 (paired two-tailed t-test). 
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Supplementary Figure 6 | Cytokine (a) and lactate (b) production of human monocytes pretreated 
with dimethyl itaconate (DI) for 1 h before addition of LPS or P3C for 24 h. Data (mean ± s.e.m.) are 
from one experiment with three donors. * p<0.05, ** p<0.01 (paired two-tailed t-test). 
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Supplementary Figure 7 | Original scans and figures of Western blot images used in Figure 2e. The 
box indicates the relevant samples. 
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Supplementary Figure 8 | Original scans and figures of Western blot images used in Supplementary 
Figure 5d. The box indicates the relevant samples.
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Supplementary Table 1 | Primer sequences used to examine gene expression levels by RT-qPCR.
3’ primer 5’ primer
B2M ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
CD36 GTGCTGTCCTGGCTGTGTTT TCACTTCCTGTGGATTTTGC
CPT1α TCCAGTTGGCTTATCGTGGTG TCCAGAGTCCGATTGATTTTTGC
FABP4 CAGGAAAGTCAAGAGCACCAT GCATTCCACCACCAGTTTATC
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC
HK2 TGCCACCAGACTAAACTAGACG CCCGTGCCCACAATGAGAC
IDH1 GGAAAAGCTCGGACCTACCC CGCTCACAAGCTCAGACTCA
IRG1 GTTCCTGGGAACCACTACGG GATGTCTGGCTGACCCCAAA
LIPA CCCACGTTTGCACTCATGTC CCCAGTCAAAGGCTTGAAACTT
LPL CATTCCCGGAGTAGCAGAGT GGCCACAAGTTTTGGCACC
PDK4 GGAGCATTTCTCGCGCTACA ACAGGCAATTCTTGTCGCAAA
PFKFB3 ATTGCGGTTTTCGATGCCAC GCCACAACTGTAGGGTCGT
SDHa TGCCATCCACTACATGACGG GCTCTGTCCACCAAATGCAC
PPARγ ATTGACCCAGAAAGCGATTCC TCTTCCATTACGGAGAGATCCAC
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ABSTRACT
Cellular metabolism can influence host immune responses to Mycobacterium tuberculosis 
(Mtb). Using a systems approach, differential expression of 292 metabolic genes involved 
in glycolysis, glutathione, pyrimidine and inositol phosphate pathways was evident at the 
site of a human tuberculin skin test challenge in patients with active tuberculosis infection. 
For 28 metabolic genes, we identified single nucleotide polymorphisms (SNPs) that were 
trans-acting for in vitro cytokine responses to Mtb stimulation, including glutathione and 
pyrimidine metabolism genes that alter production of Th1 and Th17 cytokines. Our findings 
identify novel therapeutic targets in host metabolism that may shape protective immunity 
to Mtb infection.
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INTRODUCTION
The activity of many cellular metabolic pathways can impact the host immune response to 
infections [1]. Individual metabolic pathways have been implicated in anti-mycobacterial 
responses: glutathione enhances IL-12 and IFN-γ secretion following Mtb stimulation [2]; 
tryptophan catabolism is involved in Mtb-induced production of IL-1β and IL-23 [3] and 
control of Mtb growth [4]; and a shift towards aerobic glycolysis in Mtb infected macrophages 
regulates IL-1β production [5,6]. However, as metabolic reactions are intrinsically inter-
dependent, the challenge lies in determining the relative roles of these and other pathways 
during in vivo Mtb infection.
Our group has made use of the human tuberculin skin test (TST) challenge model to 
faithfully reflect the inflammatory changes that occur at the site of tuberculosis (TB) disease, 
characterising the tissue immunological pathways induced early after mycobacterial 
antigen exposure [7]. However, to date, no studies have explored the metabolic changes 
and their functional consequences on downstream cytokine responses in such a model. 
Quantitative cytokine production in response to mycobacterial stimulation has been 
associated with genetic polymorphisms [8]. These cytokine quantitative trait loci (cQTLs) 
provide a functional insight into how genetics influences an inflammatory response, and 
in turn identify critical pathways that may be amenable to host-directed therapy [8]. In this 
study, we use the TST model to test the hypothesis that differential tissue expression of 
genes involved in regulating metabolic pathways can directly influence cytokine production 
following Mtb stimulation. In turn, our findings provide putative mechanistic links between 
the activity of cellular metabolic pathways and immune effector functions. 
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METHODS
Transcriptomic Data Analysis 
Transcriptomic data from TST and blood of patient with active TB were derived from datasets 
E-MTAB-3254 and E-MTAB-3260 (https://www.ebi.ac.uk/arrayexpress/).  Transcriptomes 
from human Mtb-infected and healthy lymph nodes (LN) were derived from dataset 
E-GEOD-63548. We used the KEGG pathway database (http://www.genome.jp/kegg/
pathway.html) to derive 33 pathways associated with human metabolism, yielding a list 
of 1422 metabolic genes containing no duplicate genes and no annotation to the original 
pathways (Tables S1 & S2). Differential gene expression and pathway enrichment analyses, 
as well as Venn diagram, and network plots generation were performed as previously 
described [7] (Supplementary Methods for more details)
SNP extraction and cQTL mapping
Single nucleotide polymorphisms (SNPs) within metabolic genes were identified as 
described in Supplementary Methods. SNPs were then mapped (p<0.05 cut-off ) for cQTLs in 
the 500FG cohort. This cohort consists of 500 healthy individuals of Dutch European ancestry 
from the Human Functional Genomics Project (www.humanfunctionalgenomics.org), from 
which peripheral blood mononuclear cells (PBMC) or macrophages have been stimulated 
by heat-killed Mtb and the secretion of IFN-γ, IL-17, IL-22 (7 days post-stimulation) and IL-
1β, IL-6 and TNFα (24hr post-stimulation) measured, as previously described [8]. To identify 
cQTLs, raw cytokine levels were first log transformed then mapped to genotype data using 
a linear regression model with age and gender as covariates. P values were obtained using 
linear regression analysis of cytokine on genotype data, as previously described [8]. 
Metabolite reporter analysis
Reporter metabolite analysis [9] was performed in Matlab using the RAVEN Toolbox (http://
biomet-toolbox.org/index.php?page=downtools-raven) and the human genome-scale 
metabolic reconstruction network HMR 2.00 provided in Human Protein Atlas (http://www.
metabolicatlas.org/downloads/hmr) (see Supplementary Methods).
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RESULTS
Metabolic gene expression at the site of TST. 
We have previously demonstrated that the transcriptional response at the site of TST is 
characterised by upregulation of 1725 genes that closely reflect changes seen in dissected 
human TB granuloma relative to healthy lung tissue [8]. We extend these findings by 
demonstrating that the TST signature is enriched within Mtb-infected relative to healthy 
LN (Figure 1A), confirming that the TST transcriptional responses mirrors pathology seen at 
established sites of human TB disease. 
Using the KEGG database for annotations of metabolic pathways, we assessed the 
expression of metabolic genes at the site of TST challenge in patients with active TB disease. 
292 significant gene changes were observed when comparing gene expression between 
the site of tuberculin or saline injection (Figure S1 and Table S3). To relate these changes in 
tissue with those in blood we assessed metabolic gene expression in the peripheral blood 
transcriptome of patients with active TB compared to healthy volunteers. Changes in tissue 
and blood showed a remarkable lack of concordance, driven largely by the paucity (only 9) 
of differential expression of metabolic genes in the blood compartment (Figure 1B & Figure 
S2 & Table S4).. This demonstrated that the TST challenge model provides greater molecular 
resolution to identify host differential metabolic gene expression to mycobacterial infection 
than the blood compartment [7].
Given the interconnected relationship between multiple metabolic pathways, we generated 
a network depicting the ten most enriched KEGG annotated metabolic pathways based 
on the 292 differentially expressed metabolic genes (Figure 1C). As expected, TST induced 
changes in multiple inter-linked metabolic pathways. These included not only several 
previously described pathways such as glycolysis and glutathione metabolism, but also 
others such as inositol phosphate metabolism and specific amino acid metabolic pathways 
not previously associated with TB [1,2]. Since differentially expressed genes within the 
same metabolic pathway were both up- or down-regulated (Figure S3), we evaluated 
which metabolites in these pathways were most affected using Reporter Metabolite 
analysis, identifying those metabolites in the human metabolic network around which 
the most transcriptional change occurs. [10]. The model predicted changes in several 
key metabolites between TST vs saline, including 1,3-bisphospho-D-glycerate (glycolysis), 
L-formylkynurenine (tryptophan metabolism), 1-phosphatidyl-1D-myo-inositol-3,4-
bisphosphate and glutathione (Figure 1D). Therefore, the model predicts that gene 
expression changes in the TST alter the concentration of several bioactive metabolites in 
multiple pathways, and that this has the potential to impact the nature of the host immune 
response to mycobacterial antigen exposure. 
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Metabolite P value Strength Associated Metabolic Pathway
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Figure	1:	Metabolic	pathways	enriched	in	TST	responses	relative	to	saline	injection.
(A)	Expression	of	TST	signature	in	Mtb	infected	lymph	nodes	(LN)	relative	to	healthy	LN.	Each	dot	
represents	one	sample.		Horizontal	lines	represent	median	value	expression	.	*	p<0.0001	by	
Mann-Whitney	test.	(B)	Pairwise	comparison	of	292	genes	differentially	expressed	in	TST	relative	
to	saline	injection	relative	to	the	expression	difference	between	the	blood	of	patients	with	active	
TB	and	healthy	volunteers	(HV).	r2 =	Spearman’s	rank	correlation	coefficient,	CoV	=	covariance.	
(C)	The	top	ten most	statistically	enriched	KEGG	metabolic	pathways	are	represented	in	a	
network	plot,	in	which	the	edges	indicate	associations	between	genes	(yellow	nodes)	and	named	
pathways	(blue	nodes),	and	the	node	size	is	proportional	to	the	respective	pathway	enrichment	–
log10	p	value	enrichment	statistic.	(D)	Reporter	metabolites	with	differentially	expressed	in	TST	
compared	to	saline	injection.	Metabolites	selected	for	known	association	with	metabolic	
pathways	and	ranked	by	increasing	p	value.
0.0057
0.0057
0.0072
0.0075
0.0077
0.0089
0.0097
0.0128
0.0128
0.0128
-4 0 4 8
-4
0
4
8
F o ld  c h a n g e  in  s k in
T S T  v s  s a lin e  ( lo g 2 )
F
o
ld
 c
h
a
n
g
e
 i
n
 b
lo
o
d
a
c
ti
v
e
 T
B
 v
s
 H
V
 (
lo
g
2
)
r 2  =  0 .0 3 8
C o V  =  0 .0 1 9
M
tb
 in
fe
c t
e d
 L
N
H e
a l
th
y  
L N
6 .0
6 .5
7 .0
7 .5
T
S
T
 s
ig
n
a
tu
re
 g
e
o
m
e
a
n
 e
x
p
re
s
s
io
n
(l
o
g
2
)
*
Figure 1 | Meta lic pathways enriched in TST responses relative to saline injection. 
(A) Expression of TST signature in Mtb infected lymph nodes (LN) relative to healthy LN. Each dot 
represents one sample.  Horizontal lines represent median value expression . * p<0.0001 by Mann-
Whitney test. (B) Pairwise comparison of 292 genes differentially expressed in TST relative to saline 
injection relative to the expression difference between the blood of patients with active TB and 
healthy volunteers (HV). r2 = Spearman’s rank correlation coefficient, CoV = covariance. (C) The 
top ten m st statistically enriched KEGG metabolic pathways are r presented in a network plot, in 
which the edges indicate associations between genes (yellow nodes) and named pathways (blue 
nodes), and the node size is proportional to the respective pathway enrichment –log10 p value 
enrichment statistic. (D) Reporter metabolites with differentially expressed in TST compared to 
saline injection. Metabolites selected for known association with metabolic pathways and ranked 
by increasing p value.
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Mapping metabolic gene cQTLs to Mtb-induced cytokine production
Next, we sought to test the hypothesis that metabolic changes in the tissue environment 
influence Mtb-induced cytokine production. We used natural genetic variation to identify 
putative cis-acting SNPs for metabolic genes and tested whether they might be trans-
acting SNPs for cytokine responses. We identified metabolic genes differentially expressed 
in the TST and assessed their impact on cytokine secretion following Mtb lysate-stimulation 
in a cohort of 500 healthy individuals. First, we used genotypes extracted from the 1000 
Genomes Project to identify 16061 SNPs from the 109 metabolic genes that comprised 
the 10 most enriched metabolic pathways in the TST (Figure 1C). We then assessed which 
of these SNPs were associated with variable cytokine secretion, generating 2376 putative 
cQTLs. To reduce multiple testing false positives, we focused on SNPs that were both 
present within the mRNA coding region of the gene of interest and influence the same 
gene’s transcription (i.e. metabolic gene SNPs that were cis-eQTLs).
This analysis generated 47 cQTL SNPs from 28 metabolic genes (Figures 2A-B & Table S5). 
Of these genes, the most over-represented metabolic pathways included the glutathione, 
glycolysis, inositol phosphate metabolism and pyrimidine pathways (Figure 2C). Many 
amino acid metabolism pathways were also observed (Figure 2C), and ALDH3A2, ALDH3A1, 
LDHA and IL4I1 were the most frequent constituent genes from these pathways (Figure 2C). 
Glutathione & pyrimidine metabolism predominantly influenced the secretion of IFN-γ & IL-
17: 7 of 15 (47%) cQTLs that regulated IFN-γ secretion and 4 of 7 (57%) cQTLs that regulated 
IL-17 secretion were derived from genes assigned to glutathione or pyrimidine metabolic 
pathways, whereas no cQTLs from these pathways influenced cytokine secretion by 
macrophages (Figure 2B). In contrast, genes involved in glycolysis, amino acid and inositol 
phosphate metabolism acted as cQTLs more ubiquitously, influencing the secretion of both 
T cell and myeloid cell derived cytokines (IL-1β, IL-6, IL-22 and TNFα) (Figure 2B). 
Finally, in order to explore the physiological relevance of the 28 metabolic genes that can act 
as cQTLs, we compared their gene expression in Mtb-infected LN with the transcriptional 
changes seen at the site of TST (Figure 2D). This revealed the expression between these 
tissues to be highly correlated, indicating that these metabolic genes have the potential to 
also exert cQTL activity at the site of human TB disease, thus shaping the local inflammatory 
response to Mtb infection.
14997-lachmandas-layout.indd   173 12/10/2017   12:18
174
Chapter 7
B
Figure	2:	Identification	of	cQTLs	within	metabolic	genes	differentially	expressed	in	a	TST.
(A) Box	plots	showing	the	association	of	SNP	genotypes	with	Mtb-induced	cytokine	levels.	The	
length	of	the	box	is	the	interquartile	range	and	the	whiskers	indicate	the	range	of	1.5	× the	length	
of	the	box	from	either	end	of	the	box.	P	values	were	obtained	using	linear	regression	analysis	of	
cytokine	on	genotype	data.	(B)	Heatmap	of	all	47	cQTL	SNPs	and	their	relationship	to	cytokine	
secretion	following	PBMC	or	macrophage	(Mfs)	stimulation	with	Mtb	lysate.	(C)	Number	of	cQTL	
genes	comprising	each	of	the	represented	metabolic	pathways,	and	number	of	genes	representing	
amino	acid	metabolism	pathways.	(D)	Gene	expression	of	28	metabolic	genes	with	cQTL	SNPs	in	
TST	relative	to	saline	compared	to	the	expression	in	Mtb	infected	lymph	nodes	(LN)	relative	to	
healthy	LN.	r2 =	Spearman’s	rank	correlation	coefficient
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GSTM3 Glutathione	Metabolism
GSTM3 Glutathione	Metabolism
INPP4A Inositol	Phosphate	Metabolism
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Figure 2 | Identifi ti n of cQTLs within metabolic genes differ ntially expressed in a TST. 
Box plots showing the association of SNP genotypes with Mtb-induced cytokine levels. The length 
of the box is the interquartile range and the whiskers indicate the range of 1.5 × the length of 
the box from either end of the box. P values were obtained using linear regression analysis of 
cytokine on genotype data. (B) Heatmap of all 47 cQTL SNPs and their relationship to cytokine 
secretion following PBMC or macrophage (Mfs) stimulation with Mtb lysate. (C) Number of cQTL 
genes comprising each of the represented metabolic pathways, and number of genes representing 
amino acid metabolism pathways. (D) Gene expression of 28 metabolic genes with cQTL SNPs in 
TST relative to saline compared to the expression in Mtb infected lymph nodes (LN) relative to 
healthy LN. r2 = Spearman’s rank correlation coefficient
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DISCUSSION
Putative roles for individual metabolic pathways shaping the host response to Mtb infection 
have been proposed [2,3,5], but their relative contribution in a multicellular tissue infection 
setting has not been investigated. We took a systems approach using the human in vivo 
TST challenge model, revealing gene expression changes in multiple metabolic pathways 
that in turn predict enrichment of several bioactive metabolites. Furthermore, we show 
that genetic polymorphisms in these differentially expressed metabolic genes control Mtb 
induced cytokine production.
We have previously shown that the inflammatory response to TST challenge closely reflects 
the immunopathological changes in human TB disease [7], and have now extended 
these observations to Mtb-infected LN. Importantly, the quantitatively smaller changes in 
metabolic gene expression in the blood of patients with active TB illustrate the importance 
of studying metabolism in the tissue setting. We observed differential gene expression of 
multiple pathways, including glycolysis, glutathione, pyrimidine and inositol phosphate 
metabolism. However, to determine whether the changes in the metabolic environment 
after Mtb infection can directly influence the ensuing immune responses, we used the 
500FG cohort to map SNPs in metabolic genes that affect cytokine secretion [8]. The 
expression of these genes was highly correlated between the site of TST challenge and 
human Mtb-infected LN, underlying that these novel metabolic gene cQTLs are likely to 
have functional consequences on the immune response in human TB disease.
Our analyses re-affirm previous observations that changes in glycolysis and glutathione 
metabolism can influence cytokine secretion following Mtb stimulation [2,5], whilst 
identifying new roles for pyrimidine and inositol phosphate metabolism, as well as 
several amino acid pathways. Pyrimidine metabolism has recently been associated with 
regulating inflammasome activity and cytokine secretion in the blood of older individuals 
[11]. We demonstrate that genes which regulate pyrimidine and glutathione metabolism 
predominantly impact the secretion of T cell derived cytokines IFN-γ and IL-17. In this way, 
our novel functional genomics approach has revealed that therapeutic manipulation of 
pyrimidine and glutathione pathways may influence Th1 and Th17 polarisation, and thus 
the balance between protection and pathology in Mtb-infected tissues [12]. 
In contrast, we demonstrate that differentially expressed genes involved in amino acid and 
inositol phosphate metabolism impact a wider array of cytokines, including those secreted 
from myeloid cells. Phosphatidylinositol is synthesised from glucose-6-phosphate in two 
steps, and is the backbone of signal transduction components such as IP3 and Akt [6]. This 
may explain the observed association between polymorphisms in genes of this pathway 
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(INPP4A, INPP5D and PIK3C2G) and secretion of a larger range of cytokines, including IFN-γ, 
IL-22, IL-6 and IL-1β. Of the cQTL genes involved in amino acid metabolism, ALDH3A2 and 
ALDH3A1 play key roles in detoxification and lipid peroxidation [13], whereas IL4I1 
expression is predominantly in the lysosomal antigen processing compartment [14], 
suggesting that alteration in macrophage amino acid metabolism may impact on 
intracellular survival of Mtb. 
Our study has some limitations. Firstly, we restricted our cQTL analyses to SNPs that were 
also cis-eQTLs to limit multiple testing errors, thus likely missing other functionally relevant 
cQTLs that may act in trans via other genes. Equally, identification of SNPs that were eQTLs 
was limited to databases that probed blood and tissues not infected with Mtb, possibly 
missing other functionally relevant SNPs in the context of Mtb infection. Finally, the effector 
cytokines studied for cQTL analysis were restricted to the manually selected panel available 
in the 500FG database, introducing bias into the breadth of immunological effector 
functions exerted by metabolic gene SNPs.
In summary, this study made a comprehensive assessment of the human tissue metabolic 
transcriptional response to in vivo mycobacterial antigenic stimulation. A number of 
known and novel metabolic pathways were differentially expressed, and genetic variation 
in identified genes affected cytokine responses to Mtb. Therefore, our systems approach 
revealed a new layer of complexity to the host anti-mycobacterial response and provide 
support for host-directed strategies targeting cellular metabolism, such as the regulation 
of glycolysis by metformin [15]. Furthermore, our approach combining transcriptomics and 
functional genomics illustrates a pipeline that can be used to identify novel and clinically 
relevant pathways in the context of other infectious diseases. 
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ALDH3A1 play key roles in detoxification and lipid peroxidation [13], whereas IL4I1 
expression is predominantly in the lysosomal antigen processing compartment [14], 
suggesting that alteration in macrophage amino acid metabolism may impact on 
intracellular survival of Mtb. 
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also cis-eQTLs to limit multiple testing errors, thus likely missing other functionally relevant 
cQTLs that may act in trans via other genes. Equally, identification of SNPs that were eQTLs 
was limited to databases that probed blood and tissues not infected with Mtb, possibly 
missing other functionally relevant SNPs in the context of Mtb infection. Finally, the effector 
cytokines studied for cQTL analysis were restricted to the manually selected panel available 
in the 500FG database, introducing bias into the breadth of immunological effector 
functions exerted by metabolic gene SNPs.
In summary, this study made a comprehensive assessment of the human tissue metabolic 
transcriptional response to in vivo mycobacterial antigenic stimulation. A number of 
known and novel metabolic pathways were differentially expressed, and genetic variation 
in identified genes affected cytokine responses to Mtb. Therefore, our systems approach 
revealed a new layer of complexity to the host anti-mycobacterial response and provide 
support for host-directed strategies targeting cellular metabolism, such as the regulation 
of glycolysis by metformin [15]. Furthermore, our approach combining transcriptomics and 
functional genomics illustrates a pipeline that can be used to identify novel and clinically 
relevant pathways in the context of other infectious diseases. 
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SUPPLEMENTARY MATERIAL
Transcriptomic data analysis
Transcriptomic data from TST and blood of patient with active TB were derived from datasets 
E-MTAB-3254 and E-MTAB-3260 (https://www.ebi.ac.uk/arrayexpress/).  This comprised 
16 individuals with active TB disease who underwent both TST skin biopsy and blood 
transcriptome profiling. We also included 8 individuals with active TB who received saline 
skin injection as a comparator for the TST transcriptomic response. Additionally, the blood 
transcriptome of 8 healthy volunteers was analysed to assess the transcriptomic changes in 
the blood of the patients with active TB. Transcriptomes from human Mtb-infected (n=22) 
and healthy lymph nodes (LN) (n=4) were derived from dataset E-GEOD-63548.
For all datasets, probe identifiers were converted to gene symbols using platform annotations 
provided with each dataset. Datasets were sorted alphabetically by gene symbol, and 
duplicate genes were removed using Microsoft Excel duplicate remover function. Significant 
differences in metabolic gene expression between groups was performed by unpaired 
t-test with alpha p<0.01 and Bonferroni correction for multiple testing in Multi-Experiment 
Viewer software (http://www.tm4.org/). Pathway enrichment using InnateDB online tool 
was performed on the resulting gene list (http://innatedb.com/). Genes contributing to the 
10 most enriched KEGG metabolic pathways were put forward for SNP and QTL analyses. 
Network plots were generated using Gephi v0.8.2 (https://gephi.org/), and Venn diagrams 
were constructed using BioVenn tool (http://www.cmbi.ru.nl/cdd/biovenn/). 
SNP extraction and cQTL mapping
Single nucleotide polymorphisms (SNPs) within metabolic genes were identified from the 
publicly available variation database dbSNP using the NCBI Variation Viewer tool (www.
ncbi.nlm.nih.gov/variation/view). SNPs located 250 kb upstream and downstream of the 
genes of interest with minor allele frequency ≥ 0.05 were extracted using the GRCh38.p7 
assembly. Linkage disequilibrium (LD) SNP pruning using genotypes extracted from 1000 
Genomes Project for Europeans (http://www.internationalgenome.org/home) based on 
pairwise genotypic correlation was performed using plink v1.07 (http://zzz.bwh.harvard.
edu/plink/dataman.shtml) and one of a pair of SNPs was removed if the LD was greater 
than 0.5. LD-pruned SNPs as well as any other functional SNP (missense variants) that were 
removed due to high LD were then mapped (p<0.05 cut-off ) for cQTLs in the 500FG cohort. 
To reduce multiple testing false positives, the putative cQTLs were further refined to include 
only SNPs that both were present within the coding region of the gene of interest (https://
genome.ucsc.edu/) and had eQTL activity for the encoded gene (http://www.gtexportal.
org/home/).
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Metabolite reporter analysis
Reporter metabolite analysis [9] was performed in Matlab using the RAVEN Toolbox (http://
biomet-toolbox.org/index.php?page=downtools-raven) and the human genome-scale 
metabolic reconstruction network HMR 2.00 provided in Human Protein Atlas (http://
www.metabolicatlas.org/downloads/hmr). The algorithm represents the input network as 
a bipartite undirected graph where both enzymes and metabolites form nodes and the 
interactions between them represent edges. The model calculates an enrichment score for 
each metabolite in the graph based on the normalized differential expression data of its 
neighbouring enzymes seen in Table S3.
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Figure S1 | Metabolic gene expression in TST. Frequency distribution of fold increases 
and decreases in metabolic gene transcript in TST compared to saline injections. 
Figure S2 | Differential metabolic gene expression in tissue and blood. Venn diagram 
identifying the number of metabolic genes differentially expressed between TST and saline 
skin injection (red) and between the blood of patients with active TB disease and healthy 
volunteers (HV) (blue). 
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Figure S3 | Metabolic genes assigned to individual pathways show both increased 
and decreased enrichment in the TST. Bar graphs representing gene expression of 
select metabolic genes in TST and saline groups. Data represented as mean ± SEM from 24 
patients with active TB who received a TST (n=16) or saline (n=8) injection. **** p<0.0001 
(Mann Whiteney test). 
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Supplementary Table 1 | KEGG database pathways associated with human metabolism
KEGG pathway number KEGG pathway annotation
path:hsa00250 Alanine, aspartate and glutamate metabolism
path:hsa04152 AMPK signaling pathway
path:hsa00330 Arginine and proline metabolism
path:hsa04024 cAMP signaling pathway
path:hsa00020 Citrate cycle (TCA cycle)
path:hsa00270 Cysteine and methionine metabolism
path:hsa00472 D-Arginine and D-ornithine metabolism
path:hsa00471 D-Glutamine and D-glutamate metabolism
path:hsa00061 Fatty acid biosynthesis
path:hsa00071 Fatty acid degradation
path:hsa04727 GABAergic synapse
path:hsa00480 Glutathione metabolism
path:hsa00260 Glycine, serine and threonine metabolism
path:hsa00010 Glycolysis / Gluconeogenesis
path:hsa04066 HIF-1 signaling pathway
path:hsa00340 Histidine metabolism
path:hsa00310 Lysine degradation
path:hsa04150 mTOR signaling pathway
path:hsa00190 Oxidative phosphorylation
path:hsa04115 p53 signaling pathway
path:hsa00030 Pentose phosphate pathway
path:hsa00360 Phenylalanine metabolism
path:hsa00400 Phenylalanine, tyrosine and tryptophan biosynthesis
path:hsa04070 Phosphatidylinositol signaling system
path:hsa04151 PI3K-Akt signaling pathway
path:hsa03320 PPAR signaling pathway
path:hsa00240 Pyrimidine metabolism
path:hsa00620 Pyruvate metabolism
path:hsa00380 Tryptophan metabolism
path:hsa00350 Tyrosine metabolism
path:hsa00280 Valine, leucine and isoleucine degradation
path:hsa01040 Biosynthesis of unsaturated fatty acids
path:hsa00062 Fatty acid elongation
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Supplementary Table 2 | Genes annotated to human metabolic pathways by KEGG database.
AACS,AADAT,AANAT,AASS,ABAT,ABCC4,ACAA1,ACAA2,ACACA,ACACB,ACAD8,ACADL,ACADM,ACADS,ACADSB,ACADVL,ACAT1,ACAT2,A-
CLY,ACMSD,ACO1,ACO2,ACOT1,ACOT12,ACOT2,ACOT4,ACOT7,ACOX1,ACOX2,ACOX3,ACSBG1,ACSBG2,ACSF3,ACSL1,ACSL3,ACSL4,ACSL5,ACSL6,
ACSS1,ACSS2,ACY1,ACYP1,ACYP2,ADCY1,ADCY10,ADCY2,ADCY3,ADCY4,ADCY5,ADCY6,ADCY7,ADCY8,ADCY9,ADCYAP1R1,ADH1A,ADH1B,ADH-
1C,ADH4,ADH5,ADH6,ADH7,ADI1,ADIPOQ,ADIPOR1,ADIPOR2,ADORA1,ADORA2A,ADPGK,ADRA1A,ADRB1,ADRB2,ADSL,ADSS,ADSSL1,AFMID,AGMAT,AGX-
T,AGXT2,AHCY,AHCYL1,AHCYL2,AK9,AKR1A1,AKT1,AKT1S1,AKT2,AKT3,ALAS1,ALAS2,ALDH18A1,ALDH1A3,ALDH1B1,ALDH2,ALDH3A1,ALDH3A2,ALDH-
3B1,ALDH3B2,ALDH4A1,ALDH5A1,ALDH6A1,ALDH7A1,ALDH9A1,ALDOA,ALDOB,ALDOC,AMD1,AMDHD1,AMH,AMT,ANGPT1,ANGPT2,ANGPT4,ANGPTL4
,ANPEP,AOC1,AOC2,AOC3,AOX1,APAF1,APIP,APOA1,APOA2,APOC3,AQP7,ARAP3,ARG1,ARG2,ASH1L,ASL,ASMT,ASNS,ASPA,ASS1,ATF2,ATF4,ATF6B,ATM,AT-
P12A,ATP1A1,ATP1A2,ATP1A3,ATP1A4,ATP1B1,ATP1B2,ATP1B3,ATP1B4,ATP2A2,ATP2B1,ATP2B2,ATP2B3,ATP2B4,ATP4A,ATP4B,ATP5A1,ATP5B,ATP5C1,ATP5D,AT-
P5E,ATP5F1,ATP5G1,ATP5G2,ATP5G3,ATP5H,ATP5I,ATP5J,ATP5J2,ATP5L,ATP5O,ATP6AP1,ATP6V0A1,ATP6V0A2,ATP6V0A4,ATP6V0B,ATP6V0C,ATP6V0D1,ATP-
6V0D2,ATP6V0E1,ATP6V0E2,ATP6V1A,ATP6V1B1,ATP6V1B2,ATP6V1C1,ATP6V1C2,ATP6V1D,ATP6V1E1,ATP6V1E2,ATP6V1F,ATP6V1G1,ATP6V1G2,ATP6V1G3,AT-
P6V1H,ATR,AUH,AZIN2,BAAT,BAD,BAI1,BAX,BBC3,BBOX1,BCAT1,BCAT2,BCKDHA,BCKDHB,BCL2,BCL2L1,BCL2L11,BDNF,BHMT,BPGM,BRAF,BRCA1,C8orf44SGK3,-
CAB39,CAB39L,CACNA1A,CACNA1B,CACNA1C,CACNA1D,CACNA1F,CACNA1S,CAD,CALM1,CALM2,CALM3,CALML3,CALML5,CALML6,CAMK2A,CAMK2B,CAMK2D,-
CAMK2G,CAMK4,CAMKK1,CAMKK2,CANT1,CARNS1,CASP3,CASP8,CASP9,CAT,CBS,CCBL1,CCBL2,CCNA1,CCNA2,CCNB1,CCNB2,
CCNB3,CCND1,CCND2,CCND3,CCNE1,CCNE2,CCNG1,CCNG2,CD19,CD36,CD82,CDA,CDC37,CDIPT,CDK1,CDK2,CDK4,CDK6,CDKN1A,CDKN1B,CDKN2A,C-
DO1,CDS1,CDS2,CFTR,CHAD,CHDH,CHEK1,CHEK2,CHRM1,CHRM2,CHUK,CKB,CKM,CKMT1A,CKMT1B,CKMT2,CMPK1,CMPK2,CNDP1,CNDP2,CNGA1,CN-
GA2,CNGA3,CNGA4,CNGB1,CNGB3,COL11A1,COL11A2,COL1A2,COL24A1,COL27A1,COL2A1,COL3A1,COL4A1,COL4A2,COL4A3,COL4A4,COL4A5,CO-
L4A6,COL5A1,COL5A2,COL5A3,COL6A1,COL6A3,COL6A5,COL6A6,COLGALT1,COLGALT2,COMP,COMT,COX10,COX11,COX15,COX17,COX4I1,COX4I2,COX-
5A,COX5B,COX6A1,COX6A2,COX6B1,COX6B2,COX6C,COX7A1,COX7A2L,COX7B,COX7B2,COX7C,COX8A,COX8C,CPS1,CPT1A,CPT1B,CPT1C,CPT2,CREB1,CRE-
B3,CREB3L1,CREB3L2,CREB3L3,CREB3L4,CREB5,CREBBP,CRTC2,CS,CSF1,CSF1R,CSF3,CSF3R,CSH1,CSH2,CTH,CTPS1,CTPS2,CUL2,CYBB,CYC1,CYP1A1,CYP1A2,-
CYP1B1,CYP27A1,CYP4A11,CYP4A22,CYP7A1,CYP8B1,DAO,DBH,DBI,DBT,DCK,DCT,DCTD,DCTPP1,DDB2,DDC,DDIT4,DDO,DERA,DGKA,DGKB,DGKD,DGKE,DGK-
G,DGKH,DGKI,DGKQ,DGKZ,DHODH,DLAT,DLD,DLST,DMGDH,DNMT1,DNMT3A,DNMT3B,DOT1L,DPYD,DPYS,DRD1,DRD2,DTYMK,DUT,ECHS1,ECI1,ECI2,EDN1,ED-
NRA,EEF2,EEF2K,EFNA1,EFNA2,EFNA3,EFNA4,EFNA5,EGF,EGFR,EGLN1,EGLN2,EGLN3,EHHADH,EHMT1,EHMT2,EI24,EIF4B,EIF4E,EIF4E1B,EIF4E2,EIF4EBP1,ELAVL1,E
LOVL1,ELOVL2,ELOVL3,ELOVL4,ELOVL5,ELOVL6,ELOVL7,ENO1,ENO2,ENO3,ENOPH1,ENTPD1,ENTPD3,ENTPD4,ENTPD5,ENTPD8,EP300,EPHA2,EPO,EPOR,ERBB2,-
F2R,FABP1,FABP2,FABP3,FABP4,FABP5,FABP6,FABP7,FADS1,FADS2,FAH,FAHD1,FAS,FASLG,FASN,FBP1,FBP2,FFAR2,FGF1,FGF10,FGF11,FGF12,FGF13,FGF14,FGF16,F-
GF17,FGF18,FGF19,FGF2,FGF20,FGF21,FGF22,FGF3,FGF4,FGF5,FGF6,FGF7,FGF8,FGF9,
FGFR1,FGFR2,FGFR3,FGFR4,FH,FIGF,FLT1,FLT4,FN1,FOLH1,FOS,FOXO1,FOXO3,FSHB,FTCD,FXYD1,FXYD2,G6PC,G6PC2,G6PC3,G6PD,GABARAP,GA-
BARAPL1,GABARAPL2,GABBR2,GABRA1,GABRA2,GABRA3,GABRA4,GABRA5,GABRA6,GABRB1,GABRB3,GABRD,GABRE,GABRG1,GABRG3,GABRP,GA-
BRQ,GABRR1,GABRR2,GABRR3,GAD1,GAD2,GADD45A,GADD45B,GADD45G,GALM,GAMT,GAPDH,GAPDHS,GATM,GCAT,GCDH,GCK,GCLC,GCLM,GCSH,G-
FPT1,GFPT2,GGCT,GGT1,GGT5,GGT6,GGT7,GH2,GHR,GHRL,GHSR,GIPR,GK,GK2,GLDC,GLI1,GLI3,GLO1,GLP1R,GLS,GLS2,GLUD1,GLUD2,GLUL,GLY-
AT,GLYCTK,GNAI1,GNAI2,GNAI3,GNAO1,GNAS,GNB1,GNB2,GNB3,GNB4,GNG10,GNG11,GNG13,GNG2,GNG3,GNG4,GNG5,GNG7,GNG8,GNGT1,GNGT2
,GNMT,GOT1,GOT2,GPHN,GPI,GPR119,GPT,GPT2,GPX1,GPX2,GPX3,GPX4,GPX5,GPX6,GPX7,GPX8,GRHPR,GRIA2,GRIA3,GRIN1,GRIN2B,GRIN2C,GRIN2D,GRI-
N3A,GRIN3B,GSK3B,GSR,GSS,GSTA1,GSTA2,GSTA3,GSTA4,GSTA5,GSTK1,GSTM1,GSTM2,GSTM3,GSTM4,GSTM5,GSTO1,GSTO2,GSTP1,GSTT1,GSTT2,GSTT2B,GSTZ1,
GTSE1,GYS1,GYS2,H6PD,HAAO,HADH,HADHA,HADHB,HAGH,HAGHL,HAL,HAP1,HCAR1,HCAR2,HCAR3,HCN2,HCN4,HDC,HGD,HGF,HHIP,HIBADH,HIBCH,HIF1A,H-
K1,HK2,HK3,HKDC1,HMGCL,HMGCR,HMGCS1,HMGCS2,HMOX1,HNF4A,HNMT,HOGA1,HPD,HRAS,HSD17B10,HSD17B12,HSP90AA1,HSP90AB1,HSP90B1,HTR1
A,HTR1B,HTR1D,HTR1E,HTR1F,HTR4,HTR6,HYKK,IBSP,IDH1,IDH2,IDH3A,IDH3B,IDH3G,IDO1,IDO2,IFNA10,IFNA13,IFNA14,IFNA16,IFNA17,IFNA4,IFNA8,IFNAR1,IF-
NAR2,IFNG,IFNGR1,IFNGR2,IGF1,IGF1R,IGFBP3,IKBKB,IKBKG,IL2,IL2RA,IL3RA,IL4,IL4I1,IL4R,IL6,IL6R,IL7,IL7R,ILK,IMPA1,IMPA2,IMPAD1,INMT,INPP1,INPP4A,INPP4B,INP-
P5A,INPP5B,INPP5D,INPP5E,INPP5J,INPP5K,
INPPL1,INS,IPPK,IRS1,IRS2,IRS4,ITGA1,ITGA10,ITGA11,ITGA2,ITGA2B,ITGA3,ITGA4,ITGA5,ITGA7,ITGA8,ITGA9,ITGAV,ITGB1,ITGB3,ITGB4,ITGB5,ITG-
B6,ITGB7,ITGB8,ITPA,ITPK1,ITPKA,ITPKB,ITPKC,ITPR1,ITPR2,ITPR3,IVD,JAK1,JAK2,JAK3,JUN,KCNJ6,KDR,KIT,KITLG,KMO,KMT2A,KMT2B,KMT2C,K-
MT2D,KMT2E,KRAS,KYNU,L3HYPDH,LAMA1,LAMA2,LAMA3,LAMA4,LAMA5,LAMB1,LAMB2,LAMB3,LAMB4,LAMC1,LAMC2,LAMC3,LAP3,LD-
HA,LDHAL6A,LDHAL6B,LDHB,LDHC,LDHD,LEP,LEPR,LHPP,LIPE,LPAR1,LPAR2,LPAR3,LPAR4,LPAR5,LPL,LTBR,MAOA,MAOB,MAP2K1,MAP2K2,MAP-
3K7,MAPK1,MAPK10,MAPK3,MAPK8,MAPK9,MAT1A,MAT2A,MAT2B,MCAT,MCCC1,MCCC2,MCEE,MCL1,MDH1,MDH2,MDM2,MDM4,ME1,ME2,ME3,-
MECR,MGST1,MGST2,MGST3,MIF,MKNK1,MKNK2,MLLT4,MLST8,MLYCD,MMP1,MPST,MRI1,MTAP,MT-ATP6,MT-ATP8,MT-CO1,MT-CO2,MT-CO3,MTCP1,MT
-CYB,MTM1,MT-ND1,MT-ND2,MT-ND3,MT-ND4,MT-ND4L,MT-ND5,MT-ND6,MTOR,MTR,MUT,MYB,MYC,MYL9,NAGS,NAT8L,NDUFA1,NDUFA10,NDUFA11,NDUFA12,N-
DUFA13,NDUFA2,NDUFA3,NDUFA4,NDUFA4L2,NDUFA5,NDUFA6,NDUFA7,NDUFA8,NDUFA9,NDUFAB1,NDUFB1,NDUFB10,NDUFB11,NDUFB2,NDUFB3,NDUFB4,N-
DUFB5,NDUFB6,NDUFB7,NDUFB8,NDUFB9,NDUFC1,NDUFC2,NDUFC2-KCTD14,NDUFS1,NDUFS2,NDUFS3,NDUFS4,NDUFS5,NDUFS6,NDUFS7,NDUFS8,NDUFV1,N-
DUFV2,NDUFV3,NFATC1,NFKB1,NFKBIA,NGF,NGFR,NIT2,NME1,NME1-NME2,NME2,NME3,NME4,NME5,NME6,NME7,NOS1,NOS2,NOS3,NOX1,NOX3,NPPA,NPY,N-
R1H3,NRAS,NSD1,NSF,NT5C,NT5C1A,NT5C1B,NT5C1B-RDH14,NT5C2,NT5C3A,NT5C3B,NT5E,NT5M,NUDT2,OAT,OCRL,ODC1,OGDH,OGDHL,OLAH,OLR1,OPLAH,O-
RAI1,OSM,OSMR,OTC,OXCT1,OXCT2,OXSM,OXTR,P4HA1,P4HA2,P4HA3,PAH,PAK1,PC,PCCA,PCCB,PCK1,PCK2,PDE3A,PDE3B,PDE4A,PDE4B,PDE4C,PDE4D,
PDGFB,PDGFC,PDGFD,PDGFRA,PDGFRB,PDHA1,PDHA2,PDHB,PDK1,PDPK1,PECR,PERP,PFKFB1,PFKFB2,PFKFB3,PFKFB4,PFKL,PFKM,PFKP,P-
GAM1,PGAM2,PGAM4,PGD,PGF,PGK1,PGK2,PGLS,PGM1,PGM2,PHGDH,PHLPP1,PHLPP2,PHYKPL,PI4K2A,PI4K2B,PI4KA,PI4KB,PIDD1,PIK3AP1,PIK-
3C2A,PIK3C2B,PIK3C2G,PIK3C3,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIK3R1,PIK3R2,PIK3R3,PIK3R5,PIKFYVE,PIP4K2A,PIP4K2B,PIP4K2C,PIP5K1A,PIP5K1B,PIP-
5K1C,PIPOX,PKLR,PKM,PKN1,PKN2,PKN3,PLCB1,PLCB2,PLCB3,PLCB4,PLCD1,PLCD3,PLCD4,PLCE1,PLCG1,PLCG2,PLCL1,PLCZ1,PLD1,PLD2,PLIN1,PLN,-
PLOD1,PLOD2,PLOD3,PLTP,PMAIP1,PNMT,PNP,PNPT1,POLA1,POLA2,POLD1,POLD2,POLD3,POLD4,POLE,POLE2,POLE3,PO
LE4,POLR1A,POLR1B,POLR1C,POLR1D,POLR1E,POLR2A,POLR2B,POLR2C,POLR2D,POLR2E,POLR2F,POLR2G,POLR2H,POLR2I,POLR2J,POLR2J2,POLR2J3,POLR2K,POL-
R2L,POLR3A,POLR3B,POLR3C,POLR3D,POLR3E,POLR3F,POLR3G,POLR3GL,POLR3H,POLR3K,PPA1,PPA2,PPARA,PPARD,PPARG,PPARGC1A,PPAT,PPM1D,PPP1CA,PPP1C-
B,PPP1CC,PPP1R12A,PPP1R1B,PPP2CA,PPP2CB,PPP2R1A,PPP2R1B,PPP2R2A,PPP2R2B,PPP2R2C,PPP2R2D,PPP2R3A,PPP2R3B,PPP2R3C,PPP2R5A,PPP2R5B,PPP2R5
C,PPP2R5D,PPP2R5E,PPT1,PPT2,PRDX6,PRIM1,PRIM2,PRKAA1,PRKAA2,PRKAB1,PRKAB2,PRKACA,PRKACB,PRKACG,PRKAG1,PRKAG2,PRKAG3,PRKCA,PRKCB,PRKC-
G,PRKCZ,PRKX,PRL,PRLR,PRODH,PRODH2,PRPS1,PRPS1L1,PRPS2,PSAT1,PSPH,PTCH1,PTEN,PTGER2,PTGER3,PTK2,PTPLA,PTPLB,PYCR1,PYCR2,PYCRL,RAB10,RAB11B,
RAB14,RAB2A,RAB8A,RAC1,RAC2,RAC3,RAF1,RAP1A,RAP1B,RAPGEF3,RAPGEF4,RBKS,RBL2,RBX1,RCHY1,RELA,RELN,RFWD2,RGN,RHEB,RHOA,RICTOR,RIMKLA,RIM-
KLB,ROCK1,ROCK2,RPE,RPEL1,RPIA,RPRM,RPS6,RPS6KA1,RPS6KA2,RPS6KA3,RPS6KA6,RPS6KB1,RPS6KB2,RPTOR,RRAGA,RRAGB,RRAGC,RRAGD,RRAS,RRAS2,RRM1,R-
RM2,RRM2B,RXRA,RXRB,RXRG,RYR2,SARDH,SAT1,
SAT2,SCD,SCD5,SCP2,SDHA,SDHB,SDHC,SDHD,SDS,SDSL,SERPINB5,SERPINE1,SESN1,SESN2,SESN3,SETD1A,SETD1B,SETD2,SETD7,SET-
D8,SETDB1,SETDB2,SETMAR,SFN,SGK1,SGK2,SGK3,SHISA5,SHMT1,SHMT2,SIAH1,SIRT1,SLC12A5,SLC27A1,SLC27A2,SLC27A4,SLC27A5,SL-
C27A6,SLC2A1,SLC2A4,SLC32A1,SLC38A1,SLC38A2,SLC38A3,SLC38A5,SLC6A1,SLC6A11,SLC6A13,SLC9A1,SMOX,SMS,SORBS1,SOS1,SOS2,SOX-
9,SRC,SREBF1,SRM,SRR,STAT3,STEAP3,STK11,STRADA,STRADB,SUCLA2,SUCLG1,SUCLG2,SUCNR1,SUV39H1,SUV39H2,SUV420H1,SU-
V420H2,SYK,SYNJ1,SYNJ2,TALDO1,TAT,TBC1D1,TCEB1,TCEB2,TCIRG1,TCL1A,TCL1B,TDO2,TECR,TEK,TF,TFRC,TH,THBS1,THBS2,THBS3,THBS4,TH
EM4,TIAM1,TIMP1,TK1,TK2,TKT,TKTL1,TKTL2,TLR2,TLR4,TMLHE,TNC,TNF,TNFRSF10B,TNN,TNNI3,TNR,TNXB,TP53,TP53AIP1,TP53I3,TP73,TPH1,TPH2,TPI1,T-
PO,TRAK2,TSC2,TSHR,TST,TWISTNB,TXNDC12,TXNRD1,TXNRD2,TXNRD3,TYMP,TYMS,TYR,TYRP1,UBC,UCK1,UCK2,UCKL1,UCP1,ULK1,ULK2,ULK3,UMPS,UPB1,UP-
P1,UPP2,UPRT,UQCR10,UQCR11,UQCRB,UQCRC1,UQCRC2,UQCRFS1,UQCRH,UQCRQ,UROC1,VAV1,VAV2,VAV3,VEGFA,VEGFB,VEGFC,VHL,VIPR2,VTN,VWF,WHSC1,WH-
SC1L1,YWHAB,YWHAE,YWHAG,YWHAH,YWHAQ,YWHAZ,ZMAT3,ZNRD1
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Supplementary Table 3 | Metabolic genes differentially expressed in TST relative to saline 
skin injection.
Gene FC Gene FC Gene FC Gene FC Gene FC Gene FC
IDO1 7.143 INPP5D 1.768 SGK1 1.168 RAP1B 0.846 COX4I2 -0.507 LAMB2 -1.233
IL4I1 6.139 PPA1 1.741 MCL1 1.165 BAX 0.836 NOS1 -0.509 EFNA4 -1.245
MMP1 4.952 GSTO1 1.717 IL6R 1.156 INPP4A 0.834 POLR2K -0.524 ENTPD3 -1.262
IL6 4.552 CDKN1A 1.708 ACOT4 1.154 RELA 0.829 ORAI1 -0.539 GGT6 -1.267
IL7R 4.380 PFKP 1.685 STAT3 1.144 ITGA1 0.828 PRLR -0.540 RAPGEF4 -1.290
CYBB 4.046 HIF1A 1.680 GNG10 1.116 GNG5 0.814 PGAM2 -0.575 ALDH5A1 -1.324
LAP3 3.968 GPX1 1.676 JAK3 1.114 ENTPD4 0.812 PPP1CB -0.628 ITGB5 -1.371
TIMP1 3.887 PIP4K2A 1.625 EGLN2 1.105 RRAGC 0.811 ATP6V0A1 -0.655 IGF1R -1.386
TLR2 3.848 ACSL4 1.608 MAP2K1 1.104 ADSL 0.807 PTCH1 -0.658 TECR -1.394
ANGPTL4 3.782 ENO1 1.596 NRAS 1.096 PRPS1 0.805 PLCD3 -0.658 RAC3 -1.426
OSM 3.654 INPP1 1.588 RAP1A 1.074 CDS2 0.799 EIF4B -0.703 FASN -1.426
CSF3 3.491 PGK1 1.588 ALAS1 1.069 AGMAT 0.796 LHPP -0.733 CAT -1.442
IDO2 3.431 IFNGR2 1.585 HK3 1.069 BPGM 0.785 ITPR3 -0.758 ALDH4A1 -1.449
TNF 3.216 OSMR 1.574 ODC1 1.062 GADD45G 0.781 PTPLB -0.762 GNAI1 -1.484
IL2RA 3.113 PDE3B 1.567 MAT2B 1.058 POLR3K 0.768 MUT -0.809 SHMT1 -1.518
KYNU 3.058 BCL2L11 1.550 ILK 1.045 UCK2 0.762 GPHN -0.819 MAOA -1.518
RAC2 2.988 TNFRSF10B 1.545 CREB5 1.042 CMPK2 0.759 OCRL -0.823 MPST -1.532
IFNG 2.962 ITGB7 1.543 VAV2 1.040 IDH2 0.749 ULK2 -0.842 ULK1 -1.593
TNC 2.954 LDHA 1.519 ATP6V1C1 1.026 RHOA 0.749 EEF2 -0.843 PIK3C2G -1.604
UPP1 2.897 AKT1S1 1.507 TP53I3 1.024 ATP5G3 0.746 DDB2 -0.859 GAMT -1.641
FBP1 2.865 ADCY7 1.501 TFRC 1.021 FLT1 0.744 PRKCZ -0.865 ACOX1 -1.666
PLCB2 2.788 COL4A2 1.458 IFNAR2 1.020 DCK 0.735 GCSH -0.881 GSTM1 -1.669
VAV1 2.769 GADD45B 1.450 PKN1 0.977 SDHB 0.734 EFNA5 -0.886 TYR -1.719
GGT5 2.724 PIK3CG 1.448 RPS6KA1 0.975 CREB3 0.732 NME3 -0.889 RXRA -1.733
TCL1A 2.644 ADPGK 1.442 PRPS1L1 0.972 EIF4EBP1 0.726 INPP5K -0.915 ERBB2 -1.744
PDE4B 2.541 SHISA5 1.434 KDR 0.967 ASL 0.706 ITPKB -0.950 COL4A6 -1.786
SDSL 2.484 MAOB 1.431 POLE4 0.958 ACLY 0.695 ME1 -0.955 ALDH3A2 -1.815
SAT1 2.476 NFKBIA 1.398 GSTK1 0.956 IDH3A 0.690 ULK3 -0.969 ATP1A2 -1.994
IL4R 2.469 SUCNR1 1.393 IFNGR1 0.946 RAB8A 0.689 GSTA5 -0.974 COL4A5 -1.999
PGF 2.453 SLC27A2 1.354 CASP9 0.946 NDUFB3 0.685 ALDH6A1 -0.978 ACSBG1 -2.024
PTGER2 2.429 NFKB1 1.335 NT5E 0.943 ABCC4 0.680 SLC27A1 -0.993 GSTA3 -2.053
TCIRG1 2.426 GNGT2 1.330 NOS3 0.942 CAMKK2 0.660 ACAT1 -0.996 IRS2 -2.067
THBS1 2.321 PRKCB 1.328 PGAM4 0.937 DGKG 0.634 PPA2 -1.004 CALML5 -2.076
IL3RA 2.304 MKNK1 1.325 ATP6V0E1 0.934 APAF1 0.628 TIAM1 -1.020 PSAT1 -2.178
JAK2 2.301 ME2 1.309 GPI 0.932 ATP6V1G1 0.615 ATP6V1E2 -1.024 CHRM1 -2.328
GLUL 2.297 JUN 1.308 CASP3 0.932 CAB39 0.606 PFKM -1.046 DCT -2.443
GALM 2.276 PLCG2 1.299 ALDOA 0.930 MCCC2 0.603 RRM1 -1.052 EEF2K -2.447
ACSL5 2.251 SRC 1.292 POLR3D 0.923 PYCR2 0.553 GABARAPL2 -1.055 GSTM3 -2.459
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Gene FC Gene FC Gene FC Gene FC Gene FC Gene FC
ANPEP 2.231 PGD 1.250 PPP2R1B 0.920 SMS 0.553 CDS1 -1.058 PHGDH -2.625
FAS 2.156 IMPA1 1.249 CASP8 0.899 G6PC3 0.544 CDK6 -1.066 LAMB4 -2.860
ITGA4 2.118 SYK 1.243 NT5C2 0.892 COX10 0.527 MCEE -1.072 TYRP1 -3.211
FASLG 2.093 CCND3 1.217 CANT1 0.887 CD19 0.524 DNMT3B -1.093 ARG1 -3.613
GFPT2 2.083 PPP2R3C 1.216 POLA2 0.876 ATF4 0.516 GLI3 -1.095   
CSF3R 1.965 NAGS 1.214 IMPAD1 0.870 OXTR 0.509 PDGFC -1.117   
COL4A1 1.937 PIK3AP1 1.207 PLOD3 0.869 CUL2 0.458 PRKAB2 -1.124   
CSF1R 1.929 ITGA5 1.203 NDUFV2 0.865 COX8A 0.453 AHCYL2 -1.132   
DPYD 1.894 ITGB6 1.196 IKBKG 0.862 EIF4E2 0.382 PIK3C2B -1.157   
GNAI2 1.893 GAPDH 1.192 DGKD 0.861 MLST8 -0.368 PPT2 -1.169   
CCND2 1.818 ATP6V1B2 1.183 PGAM1 0.857 RPS6KB1 -0.378 INPP5A -1.183   
PIK3CD 1.781 CNDP2 1.172 AKR1A1 0.854 GSTA2 -0.477 ELOVL6 -1.198   
FC = Fold change TST vs saline (log2)
Supplementary Table 4 | Metabolic genes differentially expressed in blood of patients with 
active TB disease relative to blood of healthy volunteers.
Gene Fold change  active TB - healthy volunteers (log2)
ACSL4 0.722
DPYD 0.720
ATP6V1E1 0.598
ATP2B4 0.485
TH -0.528
ACYP1 -0.584
NDUFV1 -0.595
POLR3A -0.611
IFNA4 -0.870
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ABSTRACT
Metformin, the most widely administered diabetes drug has been proposed as a candidate 
for host directed therapy for tuberculosis although little is known about its effects on human 
host responses to Mycobacterium tuberculosis. 
In this study metformin was added to PBMCs isolated from healthy non-diabetic volunteers 
in vitro. It enhanced cellular metabolic processes whilst inhibiting the mTOR targets of p70-
S6K and 4E-BP1. The net result was a decrease in proliferation, cytokine responses and an 
increase in phagocytosis. In healthy subjects in vivo metformin intake induced significant 
transcriptional and functional changes. RNAseq and western blot analysis revealed 
transcriptional down-regulation of oxidative phosphorylation, mTOR signaling and/
or type I IFN pathways whilst phagocytosis and ROS genes were increased. Functionally, 
metformin lowered inflammatory cytokine production of TNF-α (-58%), IFN-γ (-47%) and 
IL-1β (-20%) whilst inducing anti-mycobacterial processes such as phagocytosis (by 1.5 to 
2 fold) and ROS production (+20%). These results show that in humans metformin has a 
range of potentially beneficial effects on cellular metabolism, immune function and gene-
transcription involved in innate host responses to M. tuberculosis. This study thus underlines 
the importance of cellular metabolism for host immunity and supports a role for metformin 
as host-directed therapy for tuberculosis. 
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INTRODUCTION
Metformin, a diabetes drug, has been proposed as a candidate for host directed therapy 
(HDT) in tuberculosis1. Diabetes itself increases susceptibility to tuberculosis2 and worsens 
tuberculosis outcome3. The mechanisms behind this increase in susceptibility are unclear 
and a role for diabetes drugs could be envisioned. In particular metformin is anti-
inflammatory and inhibits pathways such as mTOR signalling that are important in the host 
defence to M. tuberculosis4. 
Nonetheless, studies in mice and epidemiological data on metformin usage suggest 
that metformin has beneficial therapeutic effects in the context of tuberculosis disease1. 
Proposed mechanisms include an increase in mitochondrial ROS and enhanced killing 
but so far none of these have been investigated in healthy humans. The mechanism of 
action behind metformin’s effects are not clearly defined as metformin acts through 
several pathways including mitochondrial complex I inhibition, an increase in AMP/ATP 
levels, decreased glucagon and mTOR signaling and an increase in AMPK signaling5. Lastly 
it is challenging to study the effects of metformin in patients with diabetes as multiple 
characteristics of diabetes such as hyperglycaemia, dyslipidaemia, vitamin D deficiency and 
oxidative stress may all affect cellular immune responses to M. tuberculosis.6 
To specifically study the effect of metformin in humans, in this study we first characterised 
metformin’s effects on human immune responses to M. tuberculosis in vitro and then 
validated these findings in vivo by administration of metformin to healthy volunteers 
without diabetes. We examined a broad range of transcriptional changes in whole blood 
and isolated immune cells and functional responses including cytokine production, 
production of reactive oxygen species (ROS), phagocytosis and M. tuberculosis killing. 
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METHODS
Study subjects
In vitro experiments were performed with peripheral blood mononuclear cells (PBMCs) 
isolated from buffy coats obtained from healthy volunteers (Sanquin Blood bank, Nijmegen, 
The Netherlands). As donations were anonymous, no tuberculosis skin tests or IFN-γ release 
assay was performed. The incidence of tuberculosis in the Dutch population is extremely 
low (1.5/100,000), and Bacillus Calmette-Guérin (BCG) vaccination is not part of the routine 
vaccination program. To study the in-vivo effect of metformin, 12 male healthy non-obese 
volunteers who took no medication and had no kidney function loss or metabolic disorder, 
were asked to take metformin in increasing doses starting at 1 x 500 mg tablet once a 
day and ending with 2 x 500 mg tablets twice a day. Blood was drawn at two baseline 
time points: 1 d before and immediately before metformin intake, and again immediately 
after, 3 d after and 2 weeks after the last dose of metformin. Experiments were conducted 
according to the principles expressed in the Declaration of Helsinki. Both for the in-vitro 
(NL32357.091.10) and healthy volunteers (NL47793.091.14) studies ethical approval was 
granted by the Arnhem-Nijmegen Ethical Committee. As validation EDTA blood from 10 
healthy young subjects given metformin (500 mg day 1-2) increasing to 1000 mg (day 3-8) 
was examined as part of a pharmacokinetic study (NL53534.091.15).
In-vitro studies
Cellular isolation and differentiation. Isolation of PBMCs was performed by differential 
centrifugation over Ficoll-Paque™ PLUS (GE Healthcare Biosciences). CD14+ monocytes were 
purified from isolated PBMCs using MACS microbeads for positive selection, according to the 
manufacturer’s instructions (Miltenyi Biotec). To generate macrophages, 3 x 107 PBMCs were 
incubated at 37°C in petri dishes (Corning) for 1 h. Non–adherent cells were then washed 
away using warm PBS three times. The remaining adherent monocytes were differentiated 
into M1 or M2 macrophages in 10% human pooled serum and 5 ng/mL GM-CSF (R&D 
Systems) or 50 ng/mL M-CSF (R&D Systems) respectively for 6 d. Media containing growth 
factors and serum were refreshed on day 3 of differentiation. At 6 d post differentiation, 
adherent macrophages were harvested using Versene Solution (Thermo Fisher Scientific). 
All cell types were re-suspended in RPMI+ (RPMI 1640 (Gibco) supplemented with 10 μg/
mL gentamicin (Lonza), 10 mM L-glutamine (Life Technologies), and 10mM pyruvate (Life 
Technologies). Cells were counted in a Coulter counter (Coulter Electronics) and adjusted to 
5 x 106 PBMCs/mL, 1 x 106 CD14+ monocytes/mL or 1 × 106 macrophages/mL.  
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Cytokine production. 100 μL of PBMCs, CD14+ monocytes or 75 μL of M1 / M2 macrophages 
were stimulated in RPMI+ with or without 1 - 5 μg/mL Mycobacterium tuberculosis strain 
H37Rv (M. tuberculosis) lysate, in the presence or absence of 3 – 3000 μM Metformin (Sigma-
Aldrich) for 4 h, 24 h or with 10% pooled human serum for 7 days. Cell culture supernatants 
were collected and stored at −20°C. Cytokines in culture supernatants were measured by 
commercial ELISA kits: interleukin (IL)-1β, tumour necrosis factor (TNF)-α, IL-17A, IL-22 (R&D 
Systems) and IL-6, interferon gamma (IFN-γ) and IL-10 (Sanquin). 
Cellular proliferation. Proliferation of PBMCs was measured using the CFSE kit (BioLegend) 
according to the instructions described by the manufacturer. Briefly, PBMCs were re-
suspended at a density of 10 x 106 cells/mL in PBS and labelled by adding CFSE in a 1: 1 ratio 
at a final concentration of 1.25 µM. The suspension was mixed gently and incubated for 5 
min at 37°C. An equal volume of 100% human pooled serum was added and incubated 
for 3 min at room temperature. Cells were washed twice in RPMI supplemented with 10% 
human pooled serum and re-suspended to a concentration of 5 x 106 PBMCs/mL in RPMI+. An 
unlabelled cell fraction and a labelled cell fraction were measured by flow cytometry on day 
0 to determine staining efficacy. Labelled cells were stimulated for 6 d with M. tuberculosis 
lysate in the presence or absence of 300 µM metformin. On day 6, cells were stained with 
anti-CD4 (PE-Cy5 conjugated, ITK Diagnostics BV) and measured by flow cytometry. The 
percentage of proliferated CD4+ cells was calculated as percentage of all CD4+ cells.
Metabolic measurements. Lactate was measured from stored cell culture supernatants using 
a coupled enzymatic assay in which lactate was oxidised and the resulting H
2
O
2
 was coupled 
to the conversion of Amplex® Red reagent to fluorescent resorufin by HRP (horseradish 
peroxidase)7. Measurement of the NAD+/NADH redox ratio was adapted from Zhu et al8. 
Glucose consumption was measured according to the manufacturer’s instructions using 
the Amplex® Red Glucose/Glucose Oxidase Assay Kit (Life Technologies). 
Western Blot Measurements. Pellets of 5 x 106 PBMCs per condition were lysed in 100 μL lysis 
buffer (1M Tris pH 7.4, 0.5M EDTA, 5M NaCl, 10% ND40, 0.5M NaF, 2.5% sodium deoxycholate, 
PhosSTOP (Roche) and cOmplete (Roche)). The cell homogenate was frozen, thawed and 
processed for Western blot analysis according to the manufacturer’s instructions. Western 
blotting was carried out using Mini-PROTEAN TGX precast Gels (Bio-Rad). Proteins were 
transferred using the Trans-Blot® Turbo™ system (Bio-Rad) according to the manufacturer’s 
instructions. Blots were incubated overnight at 4°C with actin at 1:1000, phospho-AMPK 
(T172) (p-AMPK) at 1:500, phospho p70 S6K (T389) (p-p70 S6K) at 1:500, phospho-4EBP1 
(T37/460) (p-4EBP1) at 1:1000, phospho-P38 (T180/Y182) (p-P38) at 1:1000, total-P38 at 
1:000 or phospho-AKT (S473) (p-AKT) at 1:1000. Actin was bought from Sigma and all other 
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antibodies from Cell Signalling. Secondary antibody used was swine anti-rabbit at 1:5000 
(Dako). SuperSignal West Femto Substrate (Thermo Fisher Scientific) or ECL (Bio-Rad) were 
used for visualisation of proteins. 
Reactive Oxygen Species Measurements. 100 μL of whole blood diluted 100x in Hanks’ buffered 
salt solution (HBSS) or 50 μL of a total of 2.5 x 105 PBMCs together with 50 μL of HBSS was 
added in quadruplicate to each well of a white 96-well assay plate (Corning). Cells were 
incubated with 50 μL of 1 mg/mL serum-opsonized zymosan, 50 μL of 10 μg/mL serum-
opsonised M. tuberculosis lysate or 50 μL of 100% human pooled serum as control. 50 μL of 
145 μg/mL luminol (Sigma) was added, and chemiluminescence was measured every 142 
s for 1 h. Opsonized zymosan particles were prepared by incubation of zymosan derived 
from Saccharomyces cerevisiae (Sigma-Aldrich) in pooled human serum for 30 min at 37°C, 
after which the particles were washed twice in PBS and re-suspended in PBS. Opsonised M. 
tuberculosis lysate was prepared by incubation of lysate in 100% human pooled serum for 1 
h prior to making aliquots and freezing. 
Phagocytosis. pHrodo® Green Zymosan Bioparticles® Conjugate (Thermo Fisher Scientific) 
was used to measure the rate of phagocytosis. The pH-sensitive molecular probes are almost 
non-fluorescent in a neutral environment, but the dye lights up when the pH decreases in 
the lysosome. So the amount of emitted fluorescence is a relative measure for the rate 
of phagocytosis. One vial of pHrodo particles was dissolved in 2 mL RPMI and sonicated 
for 5 min.  For in-vitro measurements, 5 x 105 PBMCs were incubated for 24 h at 37°C in a 
flat bottom black plate with RPMI or 1000 μM metformin. The supernatant was removed 
and 100 μl  RPMI (cells only control) or pH rodo suspension was added to each well in 
duplicate and incubated for 2 h in a non-CO2 elevated incubator at 37°C before measuring 
fluorescence. For the trial volunteers, peripheral blood leukocytes were isolated by lysis of 
erythrocytes using hypotonic lysis buffer (155 mM NH4Cl, 10 mM KHCO3). After isolation, 
the cells were rested for 30 min at 37°C in a black 96-wells plate, after which RPMI (cells only 
control) or pH rodo suspension was added to each well in duplicate and incubated for 2 h 
in a non-CO2 elevated incubator at 37°C before measuring fluorescence. Fluorescence was 
measured at an excitation of 486 nm and an emission rate of 528 nm.
M. tuberculosis cellular infection. Frozen mycobacteria, H37Rv, were thawed, washed and re-
suspended in antibiotic-free RPMI 1640 with 10% fetal bovine serum (FBS) and were used 
to infect 3 x 106 PBMCs in 15 mL falcon tubes with a multiplicity of infection (MOI) of 5. 
The infected cells were incubated at 37°C with 5% CO2 for 3 h. After this time, cells were 
washed two times with antibiotic-free medium by centrifuging at 800 rpm. The infected 
cells were counted and seeded in triplicate for 3, 24, or 48 h.  At predetermined time points 
after infection, the infected cells were washed once with PBS and then lysed with 200 mL 
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of PBS with 1% SDS. Various dilutions of this lysate were plated on Middlebrook 7H11 agar 
supplemented with 10% oleic acid–albumin– dextrose–catalase (OADC, Difco Laboratories), 
in triplicate. Agar plates were incubated at 37°C for 3 weeks, after which colonies were 
counted visually. CFUs obtained from two or three dilutions were used to calculate the total 
number of CFU per mL. 
Cellular Viability. To examine early or late apoptosis, 5 x 105 treated PBMCs were washed with 
PBS, re-suspended in 200 μL of RPMI and incubated on ice in the dark with 1 μL of Annexin V-FITC 
(FITC, Biovision) for 15 min followed by a 5 min incubation with 1.5 μL of propidium-iodide 
(PI, Sigma Aldrich). The relative level of apoptotic cells was detected by flow cytometry 
within 1 h, using a FC500 flow cytometer (Beckman Coulter) and data were analysed using 
Kaluza 1.3 software (Beckman Coulter). 
Transcriptomics 
Whole blood was captured in Paxgene tubes and stimulated PBMCs or CD14+ monocytes 
were lysed in TRIzol reagent (Invitrogen) or RNAprotect (Qiagen) and stored at −80°C until 
RNA isolation was performed. RNA was isolated from purified CD14+ cells using TRIzol 
reagent (Invitrogen), from whole blood samples using the PAXgene blood miRNA kit 
(Qiagen) and from cultured PBMC samples using the RNeasy Mini Kit (Qiagen) following 
the manufacturers’ protocols. RNA was transcribed into complementary DNA by reverse-
transcription using either the iScript cDNA synthesis kit (BIORAD) or the Superscript IV 
VILO (Invitrogen). Primer sequences used for Quantitative real-time PCR (qPCR) are listed 
in Supplementary Table 1. Power SYBR Green PCR Master Mix (Applied Biosystems, Life 
technologies) was used for qPCR in an AB Step one plus or 7500 Fast real-time PCR system 
(Applied Biosystems) or the CFX384 Real-Time PCR Detection System (Biorad). qPCR data 
were normalized to the housekeeping gene human β2M or HuP0. 
For RNA-sequencing, RNA was quantified using Nanodrop ND1000 spectrophotometer 
and quality assured using an Agilent 2100 Bioanalyzer. RNA from the whole blood Paxgene 
samples was depleted of globin transcripts using GLOBINclear TM (Invitrogen). Whole blood 
samples were processed using the Ribo-Zero TruSeq stranded total RNA library preparation 
method (Illumina) whereas cultured PBMC RNA samples were processed using the TruSeq 
stranded mRNA library prep kit (Illumina). All samples were sequenced on a NextSeq500, 
generating ~36-45M million 43bp paired-end reads per sample. FASTQ sequence files were 
aligned to the human genome version Human_g1k_v37 using STARAligner9 and aligned 
reads which overlapped with 63,677 genome features were counted using HTSeq-count 
with annotation version Homo_sapiens.GRCh37.75.gtf10. Differentially expressed genes 
were calculated using the DESeq2 package11 in Bioconductor, with false discovery rate 
correction applied for multiple testing. Gene set analyses were performed using the Stouffer 
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method in the Piano R package12  with the MSigDB Hallmark gene sets database13. as well 
as the KEGG pathways database. The RNA Seq study was approved by the LSHTM Research 
Ethics Committee (#11968).
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RESULTS 
In-vitro effects of metformin on cellular metabolism and cytokine production. 
When added to PBMCs metformin decreased the levels of the downstream mTOR targets, 
phospho-p70S6K and phospho-4EBP1 whilst increasing its known molecular target: AMPK 
(Fig. 1a). Both lactate production and glucose consumption were increased in M. tuberculosis 
stimulated PBMCs in the presence of metformin (Fig. 1b and 1c) whilst the NAD+/NADH 
ratio was decreased (Fig. 1d).  
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Figure 1 | Metformin alters mTOR signaling axis whilst maintaining glucose regulatory 
effects. (a)Western blots of PBMCs stimulated with M. tuberculosis lysate for 2 h in the presence 
or absence of 1000 µM metformin (Met). Data are from two individual experiments. (b) NAD+/
NADH fold change of Mtb stimulated vs unstimulated PBMCs in the presence or absence of 1000 
µM metformin for 24 h, 48 h, or 7 d. Data (mean ± s.e.m.) are from two experiments with a total 
of six donors. (c,d) Lactate production and glucose consumption from PBMCs stimulated with M. 
tuberculosis lysate in the presence or absence of 1000 µM metformin for 24 h, 48 h, or 7 d. Data 
(mean ± s.e.m.) are from three experiments with a total of nine donors. (d) * p<0.05, ** p<0.01 
(Wilcoxon matched-pairs signed rank test). 
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At both therapeutic (10 – 220 µM) and experimental concentrations 14 metformin showed 
clear effects on cytokine production. It significantly decreased M. tuberculosis induced 
TNF-α, IL-1β, IFN-γ and IL-17 production from PBMCs (Fig. 2a), IL-1β, IL-6 and IL-10 from M1 
and M2 monocyte derived human macrophages (Fig. 2b) and TNF-α, IL-1 β and IL-10 from 
CD14+ monocytes (Supplementary Fig. 1a). At a transcriptional level, metformin inhibited 
expression of IL-18, IL-23 p19 and TGF- β1 (Fig. 2c). The minimal effect of metformin on 
cellular proliferation (Fig. 2d) is unlikely to account for the strong effects on cytokine 
production (Figure 2e). Metformin at the doses tested also had no significant effect on 
cellular viability (Supplementary Fig. 1b). 
Effect of metformin on immune phenotype and transcriptomics in healthy 
subjects
We next examined the effect of metformin in healthy subjects. Blood was drawn at several 
time-points before and after metformin intake (Fig. 3a). We first examined changes in AMPK 
activation in PBMCs (Fig. 3b and Supplementary Fig. 2a). As expected, phospho-AMPK 
was significantly increased in both un-stimulated and M. tuberculosis lysate stimulated 
conditions after metformin intake (Td6 vs Td0) (Fig. 3c and 3d). 
Next, RNA-Seq analysis of whole blood samples collected before and after 5 days of 
metformin intake was performed. Using an unbiased approach, no significant effects 
were seen on individual genes (Supplementary Fig. 2b), but at a biological pathway level 
metformin induced consistent changes (Fig. 3e). Significant down-regulation of oxidative 
phosphorylation (OXPHOS) and ribosome pathways whereas significant up-regulation of 
endocytosis/phagocytosis, MAPK and chemokine signaling pathways was observed. Similar 
results were obtained when a second analysis platform, GAGE15, was used (data not shown). 
In PBMCs isolated from subjects before and after (Td6) metformin intake, metformin 
significantly affected gene transcription, both in stimulated and unstimulated cells, with 
approximately 800 genes differentially expressed (Supplementary Fig. 2c). In gene set 
analysis of unstimulated PBMC, metformin led to upregulation of genes involved in mitosis 
and down-regulation of genes involved in OXPHOS, adipogenesis and myc targets (Fig. 
3f ). In M. tuberculosis stimulated cells, metformin suppressed genes involved in cytokine 
signalling such as IFN-α, IFN-γ and TNF-α, OXPHOS and mTORC related genes (Figure 3f ).
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Figure 2: Metformin affects the cytokine landscape of human cells responding toM. tuberculosis stimulation.
Cytokine production from (a) human PBMCs stimulated with M. tuberculosis lysate in the presence or absence of 3 –
3000 µM of metformin after 24 h (TNF-α, IL-6, IL-1β and IL-10) or after 7 d ( IFN-!, IL-17 or IL-22) in the presence of
10% pooled human serum and (b) from M1 and M2 macrophages stimulated M. tuberculosis lysate in the presence
or absence of 300 & 3000 µM of metformin after 24 h. (c) Gene expression of cytokines from CD14+ monocytes
stimulated with M. tuberculosis lysate in the presence or absence of 3000 µM of metformin after 4 h (IL-18 and TGF-
β1) or after 24 h (IL-23 p19 subunit and IL-12 p35 subunit). (d) % of CD4+ T cell proliferation in PBMCs stimulated
with M. tuberculosis lysate in the presence or absence of 300 µM metformin for 6 d. CFSE dye was used to track
generations. (e) Radial graph is representative of fold changes between M. tuberculosis lysate stimulated in the
presence of 3000 of µM metformin relative to M. tuberculosis lysate stimulation alone. The axis represents the
degree of fold change. Less than 1 is a decrease in responses and is indicated by projection towards the centre of
the radius. For a-c and e all data (mean ± s.e.m.) are from three experiments with a total of six to thirteen donors.
For d data are (mean ± s.e.m.) from four experiments with a total of seven donors. * p<0.05, ** p<0.01 (Wilcoxon
matched-pairs signed rank test for 2a-c and Paired t test for 2d ).
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Figure 2 | Metformin affects the cytokine landscape of human cells responding to M. 
tuberculosis stimulation.  Cytokine production from (a) human PBMCs stimulated with M. 
tubercul sis lysate in the presence or absence of 3 – 3000 µM of metformin after 24  (TNF-α, IL-6, 
IL-1β and IL-10) or after 7 d ( IFN-γ, IL-17 or IL-22) in the presenc  of 10% po led human serum and 
(b) from M1 and M2 macrophages stimulated M. tuberculosis lysate in the presence or absence of 
300 & 3000 µM of metformin after 24 h. (c) Gene expression of cytokines from CD14+ monocytes 
stimulated with M. tuberculosis lysate in th  presence or absence f 3000 µM of metformin after 
4 h (IL-18 and TGF-β1) or after 24 h (IL-23 p19 subunit and IL-12 p35 subunit). (d) % of CD4+ T c ll 
proliferation in PBMCs stimulated with M. tuberculosis lysate in the presence or absence of 300 µM 
metformin for 6 d. CFSE dye was used to track generations. (e) Radial graph is representative of 
fold chang s b tween M. tuberculosis lysate stimulated in the presence of 3 00 of µM metformin 
relative to M. tuberculosi  lysate stimulation alone. The axis represents the degree of fold change. 
Less than 1 is a decrease in responses and is indicated by projection towards the centre of the 
radius. For a-c and e all data (mean ± s.e.m.) are from three experiments with a total of six to thirteen 
donors. For d data are (mean ± s.e.m.) from four experiments with a total of seven donors. * p<0.05, 
** p<0.01 (Wilcoxon matched-pairs signed rank test for 1a-c and Paired t test for 1d ). 
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Figure 3: Global effects of metformin in healthy human volunteers
(a) Healthy volunteers (n =11) received an increasing dose of metformin for five consecutive days. Blood was drawn twice
pre-(TdB) and several times post-metformin treatment.
(b) Western blot analysis of p-AMPK levels in lysates of PBMCs stimulated for 2 h RPMI (-) or M. tuberculosis lysate (+)
from healthy volunteers before and after metformin intake.
(c) Quantitative relative band intensity analysis of p-AMPK between pre- (Td0) and post-metformin (Td6) periods for RPMI
andM. tuberculosis lysate stimulation. * p<0.05, ** p<0.01 (Paired t test ).
(d) Fold change in p-AMPK levels between pre- (Td0) and post-metformin (Td6) periods for RPMI and M. tuberculosis
lysate stimulation. * p<0.05, ** p<0.01 (Paired t test ). All western blot data (mean ± s.e.m.) are representative of a
total of eight donors presented in figure 3b and supplementary figure 2a.
(e) Gene set analysis showing KEGG pathways which were differentially expressed in ex vivo blood samples following
metformin administration. The bar length indicates the magnitude of the change of the gene set. Data were analyzed
using the Piano R package, and pathways with adjusted P<0.01 are shown.
(f) Hallmark gene set enrichment and network analysis, showing gene sets up- (red) or down- (blue) regulated following
metformin administration in PBMCs in either resting state or stimulated withM. tuberculosis lysate for 4 h.
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Figure 3 | Global effects of metformin in healthy human volunteers. (a) Healthy volunteers (n 
=11) recei ed an increasing dose of metformin for five consecutive days. Blood was drawn twi  
pre-(TdB) and s v ral times post-metformin treatment. (b) Western blot analysis of p-AMPK levels 
in lysates of PBMCs stimulated for 2 h RPMI (-) or M. tuberculosis lysate (+) from healthy volunteers 
before and after metformin intake. (c) Quantitative relative band intensity analysis of p-AMPK 
between pre- (Td0) and post-metformin (Td6) eriods for RPMI and M. tuberculosis lysate stimulation.  
* p<0.05, ** p<0.01 (Paired t test ).  (d) Fold change in p-AMPK levels between pre- (Td0) and post-
metformin (Td6) periods for RPMI and M. tuberculosis lysate stimulation.  * p<0.05, ** p<0.01 (Paired 
t test ). All western blot data (me n ± s.e.m.) ar  repres t tiv  of a total of eight donors presented 
in figure 3b and supplementary figure 2a. (e) Gene set analysis showing KEGG pathways which 
were differentially expressed in ex vivo blood samples following metformin administration. The bar 
length ind c tes the magnitude of the change of the gene set.  Data were analyzed using the 
Piano R package, and pathways with adjusted P<0.01 are shown. (f )Hallmark gene set enrichment 
and network analysis, showing gene sets up- (red) or down- (blue) regulated following metformin 
administration in PBMCs in either resting state or stimulated with M. tuberculosis lysate for 4 h.
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Each gene ontology (GO) group in the identified gene sets was investigated, and the 
“response to type 1 interferon” GO set showed the most markedly reduced expression 
following metformin administration in M. tuberculosis lysate-stimulated cultures 
(Supplementary Fig. 2D). Within this GO, the expression of eight genes (Interferon-induced 
protein with tetratricopeptide repeats (IFIT) 1, IFIT 2 and IFIT 3, 2’-5’-oligoadenylate synthase 
(OAS) 1, OAS2 and OAS3, MX dynamin like GTPase (MX) 1 and radical S-adenosyl methionine 
domain containing 2 (RSAD2)) was more than two-fold reduced following metformin 
administration in cells stimulated with M. tuberculosis for 4 hours (Fig. 4a.). Thus the type 1 
interferon response was blocked by metformin. This effect was diminished by 24 hours as 
shown by qRT-PCR (Fig. 4a). Additionally, after metformin intake (Td6) a significant decrease 
in TNF-α, IL-1β, IL-6, IFN-γ and IL-17 release in response to stimulation was found (Fig. 4b). 
This effect was sustained significantly for TNF-α and insignificantly for IL-1β, IFN-γ and IL-22 
up to 21 days post metformin intake. 
The MAPK, AKT and mTOR pathways are known to strongly influence cytokine production. 
So we measured the levels of p-P38 and total-P38 (Fig. 4c and Supplementary Fig. 3a), a 
member of the MAPK family, p-AKT and p-4EBP1, a representative of the mTOR pathway 
(Fig. 4d and Supplementary Fig. 3b), in cell lysates taken pre- and post-metformin intake. 
An overall decrease in all three targets were observed. Quantitative band intensity analysis 
showed that the ratio of p-P38 to total-P38 and the levels of p-AKT were significantly 
reduced by metformin (Fig. 4e and 4f ). Similarly, metformin reduced p-4EBP1 levels 
however significance was not achieved (Fig. 4g). Effects at an individual level can be seen in 
Supplementary Figures 3c (p-P38/total-P38), 3d (p-AKT) and 3e (p-4EBP1). 
Effects of metformin on cellular phenotype 
Metformin showed mixed effects on the number, relative distribution and activation of 
immune cells. In whole blood, metformin led to a transient increase in total white blood 
cells (WBC) and neutrophils (Fig. 5a), but the relative percentage of cell types (monocytes, 
lymphocytes, neutrophils, eosinophils and basophils) did not change over time (Fig. 5b). In 
PBMCs, we observed a sustained increase in the relative percentage of monocytes and a 
decrease in the proportion of lymphocytes (Fig 5c).
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Figure 4: Metformin intake in healthy volunteers affects cytokine production via P38 and AKT inhibition.
(a) Expression of eight genes in the “response to type 1 interferon” Gene Ontology group in PBMC stimulated
with M. tuberculosis lysate in vitro for 4 or 24 h, before and after in vivo metformin administration in 11
healthy volunteers. Expression measured by RNA-Seq (4hr) and qRT-PCR (4 and 24hr).
(b) Cytokine production from isolated PBMCs stimulated with M. tuberculosis lysate 24 h (TNF-α, IL-6, IL-1β
and IL-10) or after 7 d ( IFN-!, IL-17 or IL-22) in the presence of 10% pooled human serum before and after
metformin intake.
(c) Western blot analysis of p-38 and Total p38 and (d) p-AKT and p-4EBP1 levels in lysates of PBMCs
stimulated for 2 h RPMI (-) or M. tuberculosis lysate (+) from healthy volunteers before and after metformin
intake. Data are representative of four of eight measured donors from the trial.
(e-g) Fold change in p-38/Total p38 levels, p-AKT or p-4EBP1 between pre- (Td0) and post-metformin (Td6)
periods for RPMI and M. tuberculosis lysate stimulation.
* p<0.05, ** p<0.01 (Paired t test ). All western blot data (mean ± s.e.m.) are representative of a total of eight
donors presented in figure 4c or 4d and supplementary figures 3a or 3b respectively.
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Figure 4 | Metformin intake in healthy volunteers affects cytokine production via P38 
and AKT inhibition. (a) Expression of eight genes in the “response to type 1 interferon” Gene 
Ontology group in PBMC stimulated with M. tuberculosis lysate in vitro for 4 or 24 h, before and 
after in vivo metformin administration in 11 healthy volunteers. Expression measured by RNA-Seq 
(4hr) and qRT-PCR (4 and 24hr). (b) Cytokine production from isolated PBMCs stimulated with M. 
tuberculosis lysate 24 h (TNF-α, IL-6, IL-1β and IL-10) or after 7 d ( IFN-γ, IL-17 or IL-22) in the presence 
of 10% pooled human serum before and after metformin intake. (c) Western blot analysis of p-38 
and Total p38  and (d) p-AKT and p-4EBP1 levels in lysates of PBMCs stimulated for 2 h RPMI (-) 
or M. tuberculosis lysate (+) from healthy volunteers before and after metformin intake. Data are 
representative of four of eight measured donors from the trial. (e-g) Fold change in p-38/Total p38 
levels, p-AKT or p-4EBP1 between pre- (Td0) and post-metformin (Td6) periods for RPMI and M. 
tuberculosis lysate stimulation. * p<0.05, ** p<0.01 (Paired t test ). All western blot data (mean ± 
s.e.m.) are representative of a total of eight donors presented in figure 4c or 4d and supplementary 
figures 3a or 3b respectively. 
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Figure 5 | Metformin intake in healthy volunteers alters the blood cellular composition 
landscape. Analysis of leukocyte counts plotted (a) as raw cell counts for whole blood, (b) as 
percentage of total counts for whole blood and (c) as percentage of total counts for isolated PBMCs. 
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The effect of metformin on ROS production, phagocytosis and 
mycobacterial killing. 
Next we examined the effect of metformin on another host defence mechanism namely, 
ROS production. In whole blood a strong and significant increase in ROS production 
was detected immediately post metformin treatment (Fig. 6a), spontaneously and upon 
stimulation with M. tuberculosis lysate and zymosan. No increase in ROS was observed from 
PBMCs (Supplementary Fig. 4a). In line with increased ROS production in whole blood, 
genes involved in ROS production such as NADPH Oxidase 2 (cybb), p22-PHOX (cyba), RAC1 
and particularly for ROS production in neutrophils p47-PHOX (ncf1), p67-PHOX (ncf2) and 
p40-PHOX (ncf4) were strongly upregulated in blood after metformin intake (Fig. 6b).
Another key host defence strategy is the phagocytosis of mycobacteria. Whole blood 
RNAseq analysis revealed that metformin upregulated genes involved in endocytosis such 
as receptors (RTKs and GPCR), regulators of clathrin-mediated pit formation (AP2) and 
clathrin uncoating (Hsp70) and regulators of intracellular vesicular trafficking (Arfs, ArgGAPs 
and ArfGEFs) (Figure 6c). To validate these findings, we examined phagocytosis in a second 
group of healthy subjects taking metformin. In line with the transcriptional findings, 
metformin increased phagocytosis of zymosan labelled beads in whole blood (Fig. 6d). In-
vitro pretreated PBMCs also showed upregulated phagocytosis (Supplementary Fig. 4b). 
Finally, mycobacterial viability was examined in cryo-preserved PBMCs isolated from subjects 
before and after metformin intake. No significant difference was seen in mycobacterial 
outgrowth at different time points after infection (Fig. 6e and Supplementary Figure 4c).
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Figure 6: Metformin intake in healthy volunteers increases anti-mycobacterial defence mechanisms.
(a) ROS production as measured by luminol-reaction from whole blood from pre- and post-metformin treated
volunteers unstimulated (RPMI) or stimulated with M. tuberculosis lysate (Mtb) or zymosan. Data are
representative of 11 individual donors. Bars representing the fold-change of Td6, Td9 or Td21 over TdB for
each individual donor are superimposed with grey dots representing the mean ± s.e.m.
(b) Expression of six genes encoding key NADPH oxidase proteins for ROS production were assessed in ex vivo
blood by RNA-Seq before and after administration of metformin in the healthy volunteers. * p<0.05, **
p<0.01 (Wilcoxon matched-pairs signed rank test).
(c) Representation of KEGG endocytosis pathway. Net difference in gene expression of phagocytosis related
genes in whole blood before and after metformin intake. Blue indicates a down-regulation whilst red
indicates an up-regulation.
(d) Net phagocytosis of pHrodo conjugates in a validation trial where healthy volunteers were given metformin
for eight days and blood was drawn before (Td1) and after the trial (Td8). Lysed blood was incubated with the
pH rodo suspension for 2 h in a non-CO2 elevated incubator at 37°C before measuring fluorescence
(e) Yield of colony forming units (CFUs) of H37Rv from infected PBMCs obtained before and after metformin
intake.
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Figure  | Metformin intake in healthy volunteers increases anti-mycob cterial defence 
mechanisms. (a) ROS production as measured by luminol-reaction from whole blood from pre- 
and post-metformin treated volunteers unstimulated (RPMI) or stimulated with M. tuberculosis 
lysate (Mtb) or zymosan. Data are representative of 11 individual donors. Bars representing the fold-
change of Td6, Td9 or Td21 ver TdB for each individual d nor are s perimposed with gr y d ts 
representing the mean ± s.e.m. (b) Expression f six genes e coding key NADPH oxidase proteins 
for ROS production were assessed in ex vivo blood by RNA-Seq before and after administration of 
metformin in the healthy volunteers. * p<0.05, ** p<0.01 (Wilcoxon matched-pairs signed rank test). 
(c) Represent tion of KEGG endocytosis pathway. Net difference in gene expression of phagocytosis 
related genes in wh le bl od before and after metformin intake. Blue indicates a dow -regulation 
whilst red indicates an up-regulation. (d) Net phagocytosis of pHrodo conjugates in a validation trial 
where healthy volunteers were given metformin for eight days and blood was drawn before (Td1) 
and after the trial (Td8). Lysed blood was incubated with the pH rodo suspension for 2 h in a non-
CO2 elevated incubator at 37°C before measuring fluorescence. (e) Yield of colony forming units 
(CFUs) of H37Rv from infected PBMCs obtained before and after metformin intake. 
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DISCUSSION
Metformin is the most widely used diabetes drug worldwide. It has been proposed for 
adjunctive TB treatment although its effects in humans are not wholly characterised. In 
this study we examine for the first time the detailed effects of metformin on the immune 
responses of healthy individuals before and after metformin intake. We found significant 
changes in several host defence mechanisms. Specifically, a decrease in cytokine production 
and an increase in ROS production and phagocytic capacity was found. These changes were 
mediated by several mechanisms including inhibition of the type 1 interferon pathway, a 
decrease in AKT and P38 signalling and an increase in AMPK signalling. 
Both in vitro and in vivo a strong effect of metformin on inflammatory cytokine signalling 
was observed. Notably metformin inhibited the type I interferon response by blocking the 
interferon-stimulated genes IFIT1, IFIT2 and IFIT3 which, amongst other activities, regulate 
inflammatory cytokine mRNA stability, cell proliferation and apoptosis16. Neutrophil driven 
- type 1 interferon signalling, including upregulated IFIT1, IFIT2, IFIT3, OAS1, OAS2, OAS3, 
RSAD2 and MX1 gene expression in blood17, has been identified as a signature of active 
tuberculosis disease18. Inhibiting this pathway using an arachidonic acid metabolism 
modulator namely, zileuton, has been shown to have protective effects against tuberculosis 
in mice19. Our data show that metformin too has the capacity to down-regulate the 
type-1 interferon pathway and thus sheds light onto a novel mechanism through which 
metformin’s protective effects might be mediated.  
ROS production and phagocytosis were increased by metformin. The increase in ROS did not 
correlate with an increase in white blood cell counts or neutrophil counts (Supplementary 
Fig. 5a and 5b) whereas phagocytosis correlated with an increase in WBC counts but not 
neutrophil counts (Supplementary Fig. 5c). The lack of strong correlations suggests that 
the observed effects are intrinsically mediated by metformin. This is supported by the 
accompanying transcriptional changes observed in both ROS and phagocytosis related 
genes and the increase in phagocytosis induced by metformin in vitro. Mechanistically, 
AMPK activation has been linked to phagocytosis activity as pharmacologic20, 21 or genetic 
ablation22, 23 of AMPK subunits negatively influences phagocytosis. As this is the first 
exploratory study of the effects of metformin on immune function in vivo it would be 
of future interest to examine the phagocytic capacity of antigen presenting cells such as 
macrophages and dendritic cells post metformin treatment.  
In this study, the mycobacterial killing capacity of PBMCs before and after metformin 
treatment remained unchanged. This is in contrast to a recent publication which showed 
that human monocyte derived macrophages pre-treated with metformin displayed 
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enhances mycobacterial killing1. There are several explanations for this discordance in 
results. Firstly, PBMCs before and after metformin intake were cryo-preserved and later 
thawed for infection assays. This process may have resulted in a loss of the ‘metformin’ 
phenotype. Secondly, metformin was not directly present in culture, which suggests that 
activation of the mycobacterial killing machinery may require near constant metformin 
exposure. Lastly, it is likely that a different cell type such as neutrophils, macrophages or a 
systemic model encompassing all the above changes in cytokine, phagocytosis and ROS 
production is needed to see the proposed anti-mycobacterial effects of metformin.
Metformin is put forward as a candidate for host-directed therapy in TB but some caution 
is advised. In contrast to TB, in a model of candidemia metformin resulted in increased 
lethality24. Secondly, it is still unknown if simultaneous administration of tuberculosis drugs 
and metformin will lead to harmful drug-drug interactions or more toxicity. Metformin is a 
substrate for human organic cation transporters (OCT) and multidrug and toxin extrusion 
proteins (MATEs)25. Rifampicin, a first-line anti-tuberculosis drug, increases the expression 
of OCT1 and increases metformin transport into the liver leading to an enhanced glucose-
lowering effect in healthy individuals26. Rifampicin also induces OCT2 which increases 
metformin renal clearance. Ethambutol – another first line drug - potently inhibits OCT1, 
OCT2 and more weakly OCT3 suggesting that significant drug-drug interactions may 
take place in situations of co-administration27. Interestingly an in vitro study specifically 
examining the drug-drug interactions between metformin and tuberculosis drugs found 
that only moxifloxacin was a potent inhibitor of metformin transport25. In vivo human 
studies exploring the relationship between tuberculosis drugs and metformin will be key in 
advancing metformin as adjunctive tuberculosis therapy. 
Besides metformin, other anti-diabetes drugs may also impact host response to M. 
tuberculosis. Glibenclamide, a sulfonylurea derivate, has been reported to reduce mortality 
due to mellioidosis by reducing the hyper-inflammation that leads to sepsis 28, 29. In vitro, 
glibenclamide reduces pro-inflammatory cytokine production in response to M. tuberculosis 
stimulation (Supplementary Fig. 5d). Similarly, thiazolidinediones, another class of diabetes 
drugs, have been linked with reduced risk for development of sepsis30. 
In summary we have learned that metformin dampens the pathological inflammatory 
responses associated with TB lung lesions and disease severity. Simultaneously, it enhances 
anti-mycobacterial processes such as ROS and phagocytosis which promote bacterial 
clearance. These data thus provide in vivo and human based evidence to support metformin 
as a candidate for adjunctive therapy in tuberculosis and to be tested in fittingly designed 
clinical trials.  
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SUPPLEMENTARY MATERIAL 
Supplementary Figure 1
a
b
THIS	WORK	IS	CONFIDENTIAL
Supplementary	Figure	1:	Metformin	affects	the	cytokine	landscape	of	human	cells	responding	to	M.	tuberculosis	
stimulation.	 Cytokine	production	from	(a)	CD14+	monocytes	stimulated	with	M.	tuberculosis	lysate	in	the	presence	
or	absence	of	3000	µM	of	metformin	after	24	h	(TNF-α,	IL-6,	IL-1β	and	IL-10).	All	data	(mean	± s.e.m.)	are	from	two	to	
three	experiments	with	a	total	of	six	donors.	*	p<0.05,	**	p<0.01	(Wilcoxon	matched-pairs	signed	rank	test	).	(b)	
PBMCs	were	pre-incubated	with	stimulated	with	M.	tuberculosis	lysate	in	the	presence	or	absence	of	3	- 3000	µM	of	
metformin	for	1,	3	or	7	d.	Cells	were	harvested	and	stained	with	an	Annexin-V	/	PI	stain	to	determine	levels	of	cell	
death.		Data	are	represented	as	%	means	± SEM	(n	=	4–6).	
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Supplementary Figure 1 | Metformin affects the cytokine landscape of human cells 
responding to M. tuberculosis stimulation. Cytokine production from (a) CD14+ monocytes 
stimulated wi h M. tubercul sis lysate in the presence or absence of 3000 µM of metformin aft r 24 
h (TNF-α, IL-6, IL-1β and IL-10). All data (mean ± s.e.m.) are from two to three xperiments with a 
total of six donors. * p<0.05, ** p<0.01 (Wilcoxon matched-pairs signed rank test ). (b) PBMCs were 
pre-incubated with stimulated with M. tuberculosis lysate in the presence or absence of 3 - 3000 
µM of metformin for 1, 3 or 7 d. Cells were harvested and stained with an Annexin-V / PI stain to 
determine levels of cell death.  Data are represented as % means ± SEM (n = 4–6). 
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Supplementary	Figure	2:	Differential	gene	expression	following	metformin	administration.	(a)	
Western	blot	analysis	of	p-AMPK	and	Actin	in	lysates	of	PBMCs	stimulated	for	2	h	RPMI	(-)	or	M.	
tuberculosis	lysate	(+)	from	healthy	volunteers	before	and	after	metformin	intake.	Data	are	
representative	of	the	remaining	four	of	eight	donors	in	the	trial	presented	in	figure	3b.	
b)	Ex	vivo	paxgene RNA	samples	from	11	healthy	donors	were	analysed	before	and	after	metformin	
administration	for	5	days.	(c)	PBMC	samples	from	the	11	donors	taken	before	or	after	5	d	metformin	
were	cultured	in	the	absence	or	presence	of	M.	tuberculosis	lysate	for	four	hours:	the	data	for	both	
conditions	are	combined.	For	b)	and	c)	data	shown	are	mean	expression	for	each	individual	gene,	and	
genes	shown	in	purple	were	significantly	differently	expressed	(FDR<0.05).	d)		Adjusted	p	values	for	
differential	expression	of	genes	in	the	GO	set	‘type	1	interferon’	compared	to	all	the	adjusted	p	values,	
and	to	the‘	GO	regulation	of	dopamine	metabolic	processes’	pathway.	
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Supplementary Figure 2 | Differential gene expression following etfor in ad inistration. 
(a) Western blot analysis of p-AMPK and Actin in lysates of PB Cs sti ulated for 2 h RP I (-) or 
M. tuberculosis lysate (+) from healthy volunteers before and after metformin intake. Data are 
representative of the remaining four of eight donors in the trial presented in figure 3b. (b) Ex 
vivo paxgene RNA samples from 11 healthy donors were analysed before and after metfor in 
administration for 5 days. (c) PBMC samples from the 11 donors taken before or after 5 d metformin 
were cultured in the absence or presence of M. tuberculosis lysate for four h rs: the data for both 
conditions are combined. For b) and c) data shown are mean expression for each individual gene, 
and genes shown in purple were significantly differently expressed (FDR<0.05). d)  Adjusted p values 
for differential expression of enes i  t   s t ‘type 1 interferon’ compared to all the adjusted p 
values, and to the‘ GO regulation of dopamine metabolic processes’ pathway. 
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Supplementary Figure 3 | Activation levels of p-38, p-AKT and p-4EBP1 before and after 
metformin intake. Western blot analysis of (a) p-38 and Total p38  and (b) p-AKT and p-4EBP1 levels 
in lysates of PBMCs stimulated for 2 h RPMI (-) or M. tuberculosis lysate (+) from healthy volunteers 
before and after metformin intake. Data are representative of the remaining four of eight donors 
from the trial. Fold change in (c) p-p38/Total p38 (d) p-AKT and (e) p-4EBP1 levels between pre- 
(Td0) and post-metformin (Td6) periods for RPMI and M. tuberculosis lysate stimulation.  * p<0.05, 
** p<0.01 (Paired t test ). All western blot data (mean ± s.e.m.) are representative of a total of eight 
donors presented in figures 4c and 4d and supplementary figures 3a and 3b respectively. 
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Supplementary Figure 4 | Effects of metformin on host defence mechanisms. (a) ROS 
production as measured by luminol-reaction from PBMCs from pre- and post-metformin treated 
volunteers unstimulated (RPMI) or stimulated with M. tuberculosis lysate (Mtb) or zymosan. (b) Net 
phagocytosis of pHrodo conjugates by PBMCs untreated (RPMI) or treated with metformin for 24 h 
prior to incubation with pHrodo conjugates for 2 hr. (c) Percentage change (%) in colony forming 
units (CFU) between 24 h or 48 h and 3 h of infection of PBMCs from pre- and post-metformin 
treated volunteers infected with mycobacteria.
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Supplementary Figure 5 | Discussion. Pearson correlation of (a) ROS with white blood cell 
counts (WBC), (b) ROS with neutrophil counts or (c) Phagocytosis with WBC or neutrophil counts.  
Significance and R coefficient indicated in table below each graph. ** p<0.01 (d) Production of IL-
1β or TNF-α in response to M. tuberculosis lysate in the presence of a dose range (ng/mL) of three 
diabetes drugs, namely Glibenclamide (Glib), Glimeperide (Glim) or Pioglitazone. 
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Supplementary Table 1 | Primer Sequences
Gene Figure Forward Reverse
IL-18 1C 5’ - TGTCGCAGGAATAAAGATGGCT - ‘3 5’ - CCTTGGTCAATGAAGAGAACTTGGT - ‘3
IL-23 subunit 
p19
1C 5’ - CTCAGGGACAACAGTCAGTTC - ‘3 5’ - ACAGGGCTATCAGGGAGC - ‘3
IL12 subunit 
p35
1C 5’ - CCTTGCACTTCTGAAGAGATTGA - ‘3 5’ - ACAGGGCCATCATAAAAGAGGT - ‘3
TGF- β1 1C 5’ - CAATTCCTGGCGATACCTCAG - ‘3 5’ - GCACAACTCCGGTGACATCAA - ‘3
IFIT1 4A 5’ - TGCGATCTCTGCCTATCGCC - 3’ 5’ - TGGATTTAAGCGGACAGCCTGC - 3’
IFIT2 4A 5’ -TAGGACACGCTGTGGCTCATCT - 3’ 5’ - GAGCATGGAGGCTGGCAAGAA - 3’
IFIT3 4A 5’ - AACTGGGCCGCCTGCTAAGG - 3’ 5’ - TCTGGGACTGGAGCTGACTGC - 3’
OAS1 4A 5’ - GCCTCATCCGCCTAGTCAAGC - 3’ 5’ - CATGCTCCCTCGCTCCCAAG - 3’
OAS2 4A 5’ - GCTCCCGGCCCACCAAACTA - 3’ 5’ - GACCCCTTTGGCTTCAGTTTCCT - 3’
OAS3 4A 5’ - AGCTGGTCACCCAGTACCGC - 3’ 5’ - GGATGATAGGCCTGGGCTTCTG - 3’
MX1 4A 5’ - CCGACACGAGTTCCACAAATGG 5’ - CCTGGCAGCTCTCTACCACGA - 3’
RSAD2 4A 5’ - TTGTGCTGCCCCTTGAGGAA - 3’ 5’ - CCCAGGTATTCTCCCCGGTCT - 3’
B2M 1C 5’ - ATGAGTATGCCTGCCGTGTG - 3’ 5’ - CCAAATGCGGCATCTTCAAA - 3’
HuP0 4A 5’ - GCTTCCTGGAGGGTGTCC -3’ 5’ - GGACTCGTTTGTACCCGTTG -3
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The impact of diabetes on susceptibility to 
tuberculosis
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SUMMARY
Tuberculosis has co-evolved with humans and its eradication has proven to be a formidable 
challenge. Roughly 15% of all TB cases are attributable to diabetes1, with diabetes itself 
projected to rise by 55% in the next 25 years2. As diabetes threatens global tuberculosis 
control, a better understanding of the mechanisms underlying the effects of diabetes on 
tuberculosis susceptibility and outcome is greatly needed. 
Patients with diabetes mellitus type II are characterised by several physiological changes 
that include but are not limited to hyperglycaemia, hyperinsulinemia, dyslipidaemia, 
hyperuricemia and an altered microbiota. It is not known which of these factors influence 
susceptibility to tuberculosis. To this end I investigated the effects of three factors, namely in 
vitro hyperglycaemia, in vivo hyperglycaemia, and products of the gut microbiome which 
may contribute to increased susceptibility of diabetes patients to TB. 
Hyperglycaemia has often been correlated with changes in the immune system 3, 4, 5, 6 but few 
studies exploring the role of hyperglycaemia in TB infection have been performed. Therefore, 
in Chapter 2 I examined for the first time whether high glucose concentrations could affect 
host defences to M. tuberculosis in vitro. A mild increase in pro-inflammatory cytokines 
when using high glucose cultures was observed. However, phagocytosis and the ability 
of macrophages to control tuberculosis infection was unaffected. These results suggest 
that short term hyperglycaemic cultures do not strongly affect the immune response and 
clearance of mycobacteria. Following this study, we questioned whether chronic, rather 
than acute hyperglycaemia could modulate host defences to mycobacteria. Therefore, 
in Chapter 3 we recruited a cohort of 20 T1DM males with chronic hyperglycaemia, no 
medication except regular insulin, and no serious secondary complications. In response 
to M. tuberculosis stimulation we found a defect in the IL-1β, Il-6 and IFN-γ signalling 
pathways in T1DM patients compared to matched healthy controls. These changes were 
not explained by physiological factors in serum such as plasma glucose levels, changes in 
cellular metabolism or changes in pattern recognition receptors. 
Looking at susceptibility from another angle we turned to an emerging area of research in 
diabetes: the study of the gut microbiome. Cohort studies have shown that patients with 
T2DM have a distinct change in their gut microbiota7, 8, 9. In particular, profound changes 
in their composition of SCFA have been described where physiological levels of butyrate-
producing bacteria such as Roseburia7, 8 and Faecalibacterium prausnitzi7 are decreased 
whereas Bacteroides7, 9 and Escherichia coli are increased7. To determine whether SCFA 
could modulate host responses to mycobacteria in Chapter 4 we examined the effects of 
butyrate on cytokine production in response to M. tuberculosis stimulation. We found that 
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minute but physiologically relevant plasma concentrations of butyrate lowered levels of 
inflammatory cytokines via transcriptional upregulation of IL-10. Subsequent blockade of 
IL-10 inhibited the anti-inflammatory effects of butyrate.
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DISCUSSION
With the help of these and other recently published in vitro and in vivo studies, we can 
begin to answer the following question: Are there specific factors or mechanisms that 
increase susceptibility of diabetes patients to tuberculosis?
The role of hyperglycaemia on cytokine responses to M. tuberculosis
Epidemiological studies have provided evidence for a strong link between hyperglycaemia 
(HbA1c > 7%), glycaemia control and the risk of TB10, 11. In fact, one of the studies demonstrated 
a linear relationship between fasting plasma glucose and risk of tuberculosis10.  In line with 
this an in vivo mouse model of TB and T2DM showed that mice with chronic  but not acute 
diabetes were susceptible to TB infection 12. This confirms our observations that in vitro 
acute hyperglycaemia does not affect the immune response to tuberculosis. In vivo we 
showed that PBMCs from T1DM patients produced less IL-1β, IL-6 and IFN-γ, although these 
changes were not correlated with HbA1c or plasma glucose levels. This lack of correlation 
with hyperglycaemia prompted us to test correlations with insulin or T1DM duration, 
however no correlations were found. Other factors such as cholesterol and triglycerides 
levels were unchanged. A limitation of our study from Chapter 3 is represented by the small 
cohort (n= 20) compared to the large epidemiological cohort (n= >120,000) described 
above. Therefore, subtle associations between glucose and cytokine responses may not be 
detectable. 
Interestingly, a series of studies by Kumar et al. show that patients with both active TB and 
T2DM produce more Th1 and Th17 cytokine13, 14, 15, whereas patients with both latent TB 
(LTB) and T2DM produce less pro-inflammatory cytokines16. Cytokine changes in the Kumar 
et al. studies correlated with hyperglycaemia levels only during concomitant TB-DM14 but 
not LTB-DM16. This suggests that correlations with hyperglycaemia are only evident once 
disease is established. 
If this is true, how would hyperglycaemia alter host immune response mechanisms? 
A variety of studies suggest that epigenetics may be a root cause. Firstly, glucose has been 
shown to cause persistent epigenetic changes in the promoter of the NF-kB subunit p65 
leading to gene expression changes for pro-inflammatory cytokines17. Secondly, a study 
by Martinez et al. has shown that T-cells from hyperglycaemic mice have more condensed 
chromatin compared to healthy mice which supports transcription and pro-inflammatory 
cytokine production18. Lastly in support of these studies, Prada-Medina et al. have shown 
that TB-DM patients are characterised by transcriptional changes in epigenetic regulatory 
pathways13. Thus, a future study of the epigenome of naïve and mycobacteria stimulated 
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cells from patients with TB, TB-DM, DM only and healthy controls would allow us to delineate 
the possible role of epigenetics and hyperglycaemia in the enhanced susceptibility of DM 
patients to TB. 
The gut microbiome
The composition of the gut microbiota can influence host immune responses. Patients with 
diabetes have a decrease in the number of butyrate producing bacteria7, 8. Butyrate has 
been shown to reduce secretion of pro-inflammatory cytokines. In diabetes a decrease in 
butyrate suggests that this control system is tipped in favour of inflammation. Our study 
shows that at physiologically relevant concentrations butyrate can ameliorate the immune 
response to TB, thus bringing potential therapeutic value to butyrate supplementation. In 
the case of concomitant TB-DM, butyrate could be used to curb excessive inflammation 
and pathology. Butyrate has also been shown to improve insulin sensitivity and supress 
weight gain in obese and diabetic mice19, 20. Thus, if excessive inflammation contributes to 
susceptibility then attenuation of inflammation using butyrate may improve outcome and 
treatment efficacy in patients with both TB and DM. Alternatively, drugs or small molecules 
with similar properties to butyrate should be explored. 
Potential other mechanisms
Another common characteristic of T2DM is high triglyceride or lipid levels. Peyron et al. 
have shown that virulent mycobacteria can induce the formation of ‘foamy’ lipid laden 
macrophages that have a reduced capacity to phagocytose or kill mycobacteria21. In their 
study M. tuberculosis-containing phagosomes merged with lipid bodies within the cell 
suggesting that excess fats may represent a reservoir of fuel for survival and ultimately 
another mechanism for susceptibility. Diabetes is also characterised by an increase in 
oxidative stress. Lagman et al.22 and Tan et al.23 have shown that type 2 diabetes patients have 
lower levels of the antioxidant glutathione (GSH) which when restored in vitro enhances 
mycobacterial killing. Another potential susceptibility factor, namely Vitamin D influences 
the immune responses to tuberculosis24, 25. Patients with TB, DM or TB-DM all present with 
reduced levels of Vitamin D26, 27. Moreover, Chaudhary et al. reported that the prevalence of 
severe vitamin D deficiency was higher in people with TB-DM (45%) as compared with only 
TB (26.66%), only diabetes (17.39%) or healthy controls (7.69%)26. This decrease in Vitamin D 
may contribute to the excess inflammation and disease severity observed in patients with 
TB-DM. 
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A concluding picture on the factors influencing TB susceptibility in DM 
patients
In the first part of this thesis I evaluated the effects of hyperglycaemia on the immune 
response to M. tuberculosis. I found that hyperglycaemia does not have a strong effect in 
vitro. In vivo patients with T1DM have reduced IL-1B signalling, but this is not correlated with 
hyperglycaemia. Using butyrate, I have shown that short chain fatty acids can modulate the 
immune response to M. tuberculosis via IL-10. 
My work and the published studies described above suggest that there is no single clear 
cut susceptibility factor. It appears that a multitude of factors converge to create a niche 
environment in which mycobacteria can evade clearance, reactivate and push the host 
immune system into over drive (Figure 1). Attempts to understand the precise molecular 
mechanisms behind each of these factors are ongoing. In the meantime, clinical strategies 
that reduce the levels of hyperglycaemia, insulin resistance, triglycerides and other factors 
in TB-DM are recommended. In light of the excess inflammation that characterises TB-DM 
drugs that limit inflammation should be considered. 
Last but not least the ongoing global TANDEM study, under which this thesis falls, will reveal 
more details on biomarkers, geographic specific differences and the influence of genetics 
on TB-DM 28. It is with such concerted effort that we as scientists might have a fighting 
chance against the potential resurgence in TB.
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Figure 1 | Overview of factors with potential to influence the susceptibility of diabetes 
patients to tuberculosis. It is hypothesized that the immune response of a patient with diabetes to 
M. tuberculosis is strongly influenced by biological and physiological factors such as dyslipidaemia, 
insulin resistance, hyperglycaemia and genetics. In the early stages of infection insufficient innate 
immune responses such as poor recognition29, low phagocytic activity3, reduced myeloid cell 
frequencies30 and a decrease in the release of cytotoxic molecules31 may prevent early clearance 
of mycobacteria. Impaired antigen processing and presentation may further delay the immune 
response. In fact, a study in mice showed that IFN-γ producing T cells appeared later in the thoracic 
lymph nodes of diabetic mice when compared to control mice12.  The T-cell profile of patients with 
diabetes and tuberculosis is also altered32. For example in these patients, CD8+ T cells produce 
increased amounts of pro-inflammatory cytokines but reduced levels of cytotoxic molecules31. 
Granulomas form to wall of infectious or foreign substances that the body cannot eliminate. It is 
likely that a greater influx of neutrophils33 and increased production of pro-inflammatory cytokines 
or factors such as VEGF34 and matrix metalloproteinases (MMPs) could lead to the formation of 
a necrotic core. This would promote increased bacterial persistence12, 35, growth and eventual 
dissemination. These factors could converge to form a granuloma that suffers from excessive 
pathology and poor bacterial control potentially leading to bacterial dissemination.
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Cellular metabolism of immune cells and host 
defence to tuberculosis
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SUMMARY
Mounting an immune response to an invading pathogen requires more energy. Recent 
technological advances have led to an explosion of studies that seek to understand the 
metabolic processes that underpin the cellular activation, differentiation and function 
of immune cells. In particular, the processes of glycolysis and OXPHOS have come under 
the spotlight and they have been shown to drive host responses to stimulation with TLR 
ligands36, 37.
In Chapter 5 we characterised the changes in glucose metabolism that take place during M. 
tuberculosis stimulation. We showed that glucose metabolism is increased in the circulating 
blood cells of patients with active tuberculosis and that it tapers back down to normal after 
treatment. We replicated this in vitro and demonstrated that the activation of glycolysis took 
place via the TLR2 – AKT – mTOR axis. Inhibition of any of these axes using pharmacological 
inhibitors or genetic knockouts led to an in vitro and in vivo decrease in immune responses 
to tuberculosis thereby confirming the importance of glycolysis in the immune response 
to M. tuberculosis. 
The Warburg effect, which describes a switch from OXPHOS to glycolysis, has been adopted 
as a core paradigm in the field of immune metabolism It primarily describes the rewiring of 
cellular metabolism in myeloid cells upon stimulation, with LPS as the model stimulus36, 38. 
In Chapter 6 we investigated whether this switch also takes place in the context of other 
stimuli and looked for the functional importance of OXPHOS. To our surprise, we discovered 
that LPS was unique in downregulating OXPHOS, whilst all other stimuli including the TLR2 
ligand Pam3Cys, E. coli, M. tuberculosis and S. aureus increased OXPHOS. Further investigation 
revealed that the dose of LPS influenced cellular OXPHOS rates and that OXPHOS is 
functionally linked to the process of phagocytosis. 
Glycolysis and OXPHOS, however, are just two of many metabolic pathways. Therefore, 
in Chapter 7 we used a human tissue infection model39 to perform a systems analysis of 
the most differentially regulated metabolic pathways during M. tuberculosis infection. This 
yielded a 292-gene signature from which the relative importance of each gene was tested 
using cytokine-QTL analysis. Next, we used this gene set to examine the influence of genetic 
variation in metabolic genes on cytokine production in response to M. tuberculosis. It 
confirmed the importance of several metabolic pathways such as the glycolysis, tryptophan 
and glutathione pathways which have previously been linked to tuberculosis. It also 
highlighted several undescribed pathways such as the pyrimidine and inositol-phosphate 
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metabolic pathways in the context of TB. Through this approach, we have identified 
several previously unknown metabolic genes that are at the crossroads between cellular 
metabolism and the immune system, and as such represent relevant therapeutic targets. 
An important question that arose from the work above was the therapeutic potential of this 
data. To answer that we turned to a recent study that put forward metformin, the most widely 
administered diabetes drug, as an adjunctive therapy for tuberculosis40. In Chapter 8 we 
investigated the immune modulating effects of metformin in a group of healthy volunteers 
taking metformin for five days. This study revealed a profound change in the transcriptional 
and cellular landscape of metformin with a specific decrease in pro-inflammatory cytokines 
and increase in ROS and phagocytosis. Mechanistically, inhibition of the MAPK and AKT axes 
was observed whereas AMPK and glycolysis were increased. Although no direct influence 
on killing was seen ex vivo, it is likely that a systemic model encompassing all the above 
changes is needed to see the anti-mycobacterial effects of metformin. This study supports 
the possibility of metformin as adjunctive therapy for tuberculosis but also highlights the 
caution with which this should be done.
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DISCUSSION
Based on these chapters the following question arises: How does cellular metabolism 
influence individual host defence mechanisms against M. tuberculosis infection?
Some of the mechanisms employed in response to M. tuberculosis include (but are not 
limited to) cytokine production, ROS formation, phagocytosis, autophagy and antigen 
presentation. Only a couple of these mechanisms have had the metabolic pathways that 
control them identified. For instance, M. tuberculosis upregulates aerobic glycolysis, a process 
that controls cytokine production41 and the clearance of mycobacteria from infected 
macrophages42. Similarly, the activity of enzymes controlling the mitochondrial process 
of OXPHOS is also increased. In the context of TLR2 stimulation, OXPHOS is important 
for phagocytosis. As mycobacteria signal strongly through TLR2 we can extrapolate that 
OXPHOS is likely to control the phagocytosis of exogenous mycobacteria too. 
Studies by other groups have shown that tryptophan metabolism in M. tuberculosis infected 
macrophages promotes IL-1β and IL-23 synthesis43, 44 and increasing glutathione levels can 
enhance Th1 responses to M. tuberculosis infected PBMCs45. Our systems analysis using a 
human model of mycobacterial tissue infection confirmed a role for a number of these 
pathways and identified the pyrimidine and inositol phosphate pathways as additional 
contributors to the host response to mycobacteria. Although the functions that these 
pathways control are currently unknown, pyrimidine metabolism has been associated with 
regulating inflammasome activity46 and inositol phosphate metabolism is responsible for 
generating the backbone of the M. tuberculosis related signal transduction components IP3 
and AKT41. 
Last but not least, other studies of immune cells have shown that:
• Glycolysis also supports antigen presentation in dendritic cells37
• The TCA cycle facilitates production of immunomodulatory metabolites like citrate 
(proliferation)47, itaconate (bactericidal)48 and succinate (cytokine production)49. 
• The pentose phosphate pathway supports ROS production47 and 
• Amino acid metabolism supports proliferation50 and T effector cell function51.
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To conclude
In this thesis, I have shown that glycolysis is important for M. tuberculosis induced cytokine 
responses via the AKT-mTOR pathway. I have then showed that LPS is unique in down-
regulating OXPHOS whilst other stimuli upregulate OXPHOS. I showed that OXPHOS plays 
a role in phagocytosis. Using a systems biology approach, I then identified pyrimidine 
metabolism and inositol phosphate signalling as novel and important metabolic pathways 
in the host response to M. tuberculosis. Lastly, I have provided evidence supporting the 
concept that metformin, a diabetes drug, is a candidate for host-directed therapy in 
tuberculosis. 
Future studies should focus on the specificity of these pathways during M. tuberculosis 
infection and should include other TB relevant host defence functions such as autophagy 
and ROS production.  To date, nearly all M. tuberculosis related metabolism studies are 
based on gene expression data which do not account for changes in enzyme activity and 
substrate availability. Our systems analysis above identified several key genes that controlled 
amino acid metabolism. Using more advanced techniques, such as metabolomics and flux 
analyses of infected cells, will help us to identify exactly which amino acids are important 
during infection. With improved techniques and representative infection models we will be 
able to investigate how these and other pathways play a role in controlling host defences 
to M. tuberculosis.
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As this thesis comes to a close the final question I ask myself is the following: Can we 
harness discoveries in the field of immune-metabolism to improve the outcome of TB 
patients regardless of DM status?
Current tuberculosis treatment time ranges from a standard 9-month regimen anywhere 
up to 24 months for drug resistant TB, making this one of the longest treatment regimens 
that exists for any bacterial disease.  Failure is still common in part due to side effects, drug 
toxicity, poor adherence and increasing drug resistance. The lack of new TB drug classes 
since the 1970s has blunted progress in improving treatment time and tackling drug 
resistance52. Additionally, antibiotics themselves do not deal with the inflammation, tissue 
damage and paradoxical responses (IRIS) that encompass the host response. These points 
in fact lay down a strong case for a novel approach to treating tuberculosis and in particular 
for host directed therapy (HDT) combination therapy where both pathogen and host are 
targeted.
Recent papers in this thesis and elsewhere have linked host cell metabolism to inflammation 
and, in the case of M. tuberculosis, bacterial clearance. Metabolism modulating drugs are used 
to treat many diseases. Thus, never before have we had such a large repository of candidate 
FDA approved drugs for putative adjunctive TB therapy. Identification of candidates must 
be done systematically. Firstly, the aim of metabolism-based HDT would be to reduce 
tissue damage and excess inflammation whilst improving bacterial clearance. Secondly, as 
researchers we need to improve our knowledge of which host immune functions, important 
for defence against TB, are controlled metabolically and by which pathways. 
Metformin
To begin, metformin stands at the forefront of candidate HDT drugs. It is FDA-approved, 
widely used among patients with diabetes and increases glycolysis whilst inhibiting mTOR. 
This results in a decrease in inflammation and increase in mycobactericidal processes such 
as ROS production, autophagy and phagocytosis. The process of autophagy, a potentially 
protective mechanism against tuberculosis, is activated by metformin and AICAR, another 
AMPK activator, and is negatively correlated with mTOR activity. Clinically approved drugs 
like sirolimus and rapamycin enhance autophagy but also inhibit mTOR and inflammation. 
However, their potent immune suppressing properties and drug-drug interaction may 
prevent them from being used as HDT.
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Statins
Statins are cholesterol-lowering drugs which in several studies have been shown to reduce 
the mycobacterial burden in mice 53, 54, 55. Clinically, familial hypercholesterolemia (FH) patients 
on atorvastatin controlled M. tuberculosis infection better than matched healthy controls54. 
Mechanistically, a reduction in cholesterol via the HMG-CoA –mevalonate pathway was 
suggested to improve phagosome maturation and autophagy. Nonetheless, evidence also 
suggests that low cholesterol levels are a risk factor for tuberculosis. Cholesterol-depleted 
mouse macrophages decrease their ability to phagocytose mycobacteria 56, whilst the 
acute phase response in tuberculosis patients is characterised with low serum cholesterol57. 
Additionally, a cholesterol-rich diet during treatment accelerated the rate of sputum 
sterilisation in new hospitalised cases of pulmonary tuberculosis58. An important aspect of 
HDT is the pharmacokinetics of drugs. Human studies have shown that rifampicin greatly 
decreases the plasma concentrations of simvastatin59 (and its combination with isoniazid, 
an anti-tuberculosis drug, may increase the risk of myopathy and rhabdomyloysis60. 
Overall, statins are promising HDT candidates as they reduce high cholesterol levels and 
improve anti-mycobactericidal activities whilst decreasing cellular inflammation. Their use 
in tuberculosis treatment may be limited to specific patient groups with high cholesterol 
levels such as T2DM patients or persons at risk for cardiovascular disease. 
Drugs modulating arachidonic acid metabolism
Last but not least arachidonic acid metabolism has been in the spotlight for tuberculosis 
in recent years. Prostaglandin E2 (PGE2), a metabolite of arachidonic acid, has been shown 
to limit the excessive anti-inflammatory effects of type I interferon signalling, a core 
signature of pulmonary TB patients61. Therapeutically zileuton, a clinically approved drug for 
asthma, works by tipping arachidonic acid metabolism in the direction of increased PGE2 
production. This protects mice from disease61 and establishes yet another potential avenue 
for HDT in tuberculosis. 
Covering every mode of potential metabolism-related HDT is the foreground for future 
research and Figure 2 is an illustration summarising the possible avenues. 
The figure highlights several FDA-approved or research drugs at different stages of clinical 
development that could potentially be repurposed for HDT in tuberculosis by targeting 
metabolic and / or immune mechanisms. Targeting these pathways for HDT should be high 
on the agenda of HDT specialists and clinicians looking for improved TB therapeutics. 
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Finally, despite decades of attempts on eradication, tuberculosis remains a global threat. 
Using novel but efficient strategies, like HDT, and close monitoring of high risk groups, like 
patients with diabetes, we as researchers can continue to work towards the goal of full TB 
elimination by 2050.
Figure 2 | FDA-approved or research drugs with HDT potential for tuberculosis. The figure 
highlights several drugs in different stages of clinical development with potential for HDT in 
tuberculosis. The drugs mainly target metabolic and / or immune modulatory pathways. Some of 
these include inflammation-related pathways, tryptophan metabolism, cellular energy metabolism 
pathways mediated by mTOR or AMPK, NAD+ / NADH metabolism and cholesterol metabolism. 
Exploring these pathways for their HDT potential should be high on the agenda of HDT specialists 
and clinicians looking for improved TB therapeutics. 
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TUBERCULOSE
Tuberculose (TB) is een infectieziekte, die veroorzaakt wordt door de bacterie Mycobacterium 
tuberculosis (M. tuberculosis), en heeft zich ontwikkeld tot een zeer moeilijk uitroeibare 
ziekte. In 2015 alleen al zijn er 1.8 miljoen mensen overleden aan TB en kregen er 10.4 
miljoen mensen de ziekte TB. Volgens de WHO komt 60% van alle ziektegevallen voor in 
slechts zes landen: India, Indonesië, China, Nigeria, Pakistan en Zuid-Afrika.
Deel 1: Tuberculose en Diabetes
Het is bekend dat het hebben van diabetes in 15% van de tuberculose gevallen een rol 
speelt. In 2015 waren er 415 miljoen mensen met diabetes, en de verwachting is dat dit zal 
oplopen naar 642 miljoen in 2040. Omdat diabetes een rol speelt in tuberculose, heeft deze 
stijging in diabetes ook invloed op het aantal TB gevallen, en is het belangrijk om te weten 
hoe dit werkt, wat de mechanismen zijn en hoe we dit kunnen voorkomen. Dit is wat ik in 
het eerste gedeelte van mijn thesis beschrijf. 
In hoofdstuk 2 heb ik gekeken naar de effecten van hoge glucose waarden (hyperglycemie) 
op de immuun respons tegen M. tuberculosis. Ik beschrijf dat hyperglycemie niets verandert 
aan de immuun reactie tegen M. tuberculosis, want er is geen verschil op het gebied van 
cytokine productie en in de capaciteit om M. tuberculosis te doden (bacteriële klaring). In 
hoofdstuk 3 beschrijf ik dat patiënten met type 1 diabetes een verminderde interleukine 
(IL) 1 beta productie hebben, alhoewel dit niet toe te schrijven is aan hyperglycemie. Tot 
slot heb ik in hoofdstuk 4 laten zien dat butyraat, een zogenoemde korte keten vetzuur, 
en andere vergelijkbare metabolieten in de darmen een sterke invloed kunnen hebben op 
de immuun respons tegen M. tuberculosis via IL-10. 
Het werk in deze thesis, maar ook het werk van anderen, suggereert dat er geen eenvoudige 
manier is om de relatie tussen diabetes en tuberculose uit te leggen. Er is niet één specifieke 
factor die de twee ziekten met elkaar verbindt. Het lijkt erop dat een combinatie van factoren 
zoals hyperglycemie, maar ook oxidatieve stress en een verminderde immuunreactie, samen 
een milieu creëren waarin mycobacteriën makkelijk het immuunsysteem ontsnappen, 
maar ook (hyper)activeren (Hoofdstuk 9, figuur 1). Studies naar de precieze moleculaire 
mechanismen achter elk van deze factoren zijn momenteel gaande. Ondertussen wordt 
in de kliniek aangeraden om hyperglycemie, insuline resistentie, triglyceriden en andere 
factoren in TB-diabetes te verlagen. Gezien de ernstige inflammatoire ontsteking die TB-
diabetes karakteriseert, zou het wijs zijn om ook anti-inflammatoire middelen in te gaan 
zetten. De TANDEM studie, waar deze thesis deel van uitmaakt, zal uiteindelijk inzicht 
bieden in biomarkers, geografische verschillen en de invloed van genetische verschillen 
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in het kader van TB-diabetes, en zo hopelijk bijdragen aan het voorkomen van TB-diabetes. 
Enkel met samenwerkingsverbanden zoals deze hebben wij als onderzoekers een kans om 
TB uiteindelijk te bestrijden. 
Deel 2: Tuberculose en metabolisme
De immuun respons tegen een indringend pathogeen kost veel energie. Recente 
technologische ontwikkelingen hebben geleid tot een explosie aan studies naar de 
cellulaire processen die zorgen voor deze energie. Deze metabole processen ondersteunen 
het activeren, de ontwikkeling en de functie van immuuncellen. Twee processen hebben 
hierbij de spotlight gehaald: de zogenaamde glycolyse en oxidatieve fosforylering (OXPHOS). 
Zowel de glycolyse als OXPHOS blijken een belangrijke rol te spelen in onze immuun 
respons, zoals cytokine productie in reactie op de stimulatie met microbiële antigenen 
(genaamd TLR liganden). In het tweede deel van mijn thesis heb ik de veranderingen in 
intracellulair metabolisme bestudeerd, en specifiek als gevolg van tuberculose infectie. 
In hoofdstuk 5 heb ik cellen bestudeerd van zowel gezonde mensen als tuberculose 
patiënten. Hier laat ik zien dat het proces van glycolyse belangrijk is voor de cytokine 
productie na M. tuberculosis infectie. Ook laat ik zien dat deze processen afhankelijk zijn 
van de AKT-mTOR route. In hoofdstuk 6 laat ik vervolgens zien dat LPS, een TLR4 ligand, 
als enige TLR ligand de OXPHOS platlegt. Vele andere TLR liganden, net zoals bijvoobeeld 
M. tuberculosis, activeren namelijk juist de OXPHOS. Ik laat zien dat de OXPHOS specifiek 
een rol speelt in de immuun respons waar fagocytose nodig is, om bijvoorbeeld bacteriën 
te klaren. In hoofdstuk 7 maak ik gebruik van systeembiologie en hiermee heb ik twee 
routes geïdentificeerd die belangrijk zijn in de immuunreactie tegen M. tuberculosis. 
Metabolisme van pyrimidine en de inositol fosfaat route blijken nieuwe en zelfs genetisch 
gezien belangrijke routes te zijn in de immuunreactie tegen M. tuberculosis. 
Deze studies leiden samen tot het laatste hoofdstuk van mijn thesis, waarin ik deze metabole 
routes bespreek als nieuwe potentiële therapieën tegen TB. In hoofdstuk 8 heb ik een 
klinische studie beschreven, waaruit blijkt dat metformine, een veelgebruikt medicijn tegen 
diabetes, een goede kandidaat is om metabole routes te beïnvloeden en zo eventueel 
tuberculose tegen te gaan. 
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TOEKOMSTPERSPECTIEF
De huidige behandeling van tuberculose varieert van een 9 maanden lange 
standaardbehandeling tot 24 maanden behandeling voor resistente TB. Dit maakt de 
behandeling van TB een van de langste behandelplannen van alle bacteriële infecties. Helaas 
werkt de behandeling niet altijd even goed. Er zijn bijwerkingen, medicatie intoxicatie, 
slechte naleving van instructies en een groeiende resistentie van TB tegen medicijnen. Sinds 
1970 zijn er eigenlijk geen goede nieuwe medicijnen tegen TB meer ontwikkeld. Men is niet 
in staat de behandeltijd of resistentie te verbeteren. Dit betekent dat er veel ruimte (en 
nood) is voor een nieuwe benadering van TB behandeling, bijvoorbeeld een behandeling 
die zowel de pathogeen als de patiënt beïnvloedt. 
Recente studies in deze thesis maar ook elders hebben een link gelegd tussen het cellulair 
metabolisme van de patiënt en de bijbehorende ontsteking en - in het geval van M. 
tuberculosis - bacteriële klaring. Medicijnen die het metabolisme beïnvloeden worden 
echter al lang gebruikt in de behandeling van vele andere ziekten. Daarom lijkt het alsof 
we nog nooit eerder zoveel nieuwe kandidaat medicijnen hebben gehad – die overigens 
al door de FDA zijn goedgekeurd – om tuberculose te bestrijden. De identificatie van 
goede kandidaten moet systematisch gebeuren. Het eerste doel van behandeling, wat het 
metabolisme als target heeft, moet de schade aan de weefsels en ontsteking verminderen, 
maar ook bacteriën opruimen. Ten tweede is het belangrijk dat wij als onderzoekers meer 
te weten komen over de immuun respons die belangrijk is voor TB, hoe deze metabool 
worden gecontroleerd en via welke routes. 
Er zijn momenteel drie kandidaten voor een behandeling die zowel op de patiënt als de 
pathogeen aangrijpen, gebaseerd op het veranderen van het metabolisme. Metformine, 
welke ook onderzocht is in deze thesis, staat voorop. Het is een FDA-goedgekeurd medicijn 
wat al veel gebruikt wordt in diabetes behandeling. Metformine verhoogt de glycolyse, 
maar remt mTOR. Dit resulteert in een vermindering van ontsteking en een verhoging 
van de processen die nodig zijn voor mycobacteriële klaring, zoals ROS productie, 
autofagie en fagocytose. Een tweede kanshebber is statine. Statines zijn cholesterol-
verlagende medicijnen die, zoals meerdere studies hebben laten zien, invloed hebben op 
mycobacteriële infectie in muizen. Ze verlagen hoge cholesterolwaarden maar vergroten 
ook de anti-mycobacteriële processen en verlagen ontsteking. Deze medicijnen worden 
tot nu toe alleen gebruikt in tuberculose behandeling als de patiënt ook last heeft van 
hoog cholesterol, zoals veel type 2 diabetes patiënten of patiënten met een verhoogd risico 
op cardiovasculaire ziekten. Hier is dus nog ruimte voor nieuw onderzoek. Ten derde zijn 
er nieuwe medicijnen die recentelijk meer aandacht hebben gekregen. Deze medicijnen 
moduleren het metabolisme van arachidonzuur, een aminozuur. Zileuton is een van deze 
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medicijnen en is al klinisch bewezen effectief voor de behandeling van asthma. Zileuton 
verandert de PGE2 productie, wat uiteindelijk muizen beschermt tegen ziekte. Het wordt 
een uitdaging om alle metabolisme-gerelateerde routes te behandelen, maar het is een 
belangrijk onderwerp voor toekomstig onderzoek. In figuur 2 (hoofdstuk 9) geef ik een 
illustratie van alle mogelijke behandelroutes. 
Ondanks jaren van strijd tegen tuberculose blijft het een wereldwijde bedreiging. Nieuwe 
en efficiëntere strategieën, zoals bijvoorbeeld het behandelen van zowel patiënt als 
pathogeen, en het nauw monitoren van risicogroepen zoals patiënten met diabetes, zijn 
nodig om als onderzoekers samen TB te hebben bestreden in 2050.
Translation by Siroon Bekkering.
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